| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Myriad Genetics, Inc.$5.45
-0.16 (-2.85%)
D 31Pipeline Score Diagnostics · Commercial
Market Cap
360.79 M
EPS
-4.32
P/E Ratio
-
Value Trade
8.64 M
SEC Financials
Q1 2026Dilution Risk
Revenue
200.40 M
R&D Expenses
27.10 M
Operating CF
-15.70 M
Total Assets
673.70 M
Total Liabilities
336.30 M
Equity
337.40 M
D/E Ratio
12,345
5.52 %
Week
-23.45 %
1 Month
-11.57 %
3 Month
-44.72 %
6 Month
-86.24 %
5 Year
-17.83 %
All Time
Cash Data
Cash Position
124.40 M
Monthly Burn
5.23 M
Runway
21.1 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
1.17 M
52 Week Range
3.53 - 8.59
% held by Insiders
6.98 %
% held by Institutions
92.29 %
Enterprise Value
447.89 M
Total Shares
94.49 M
Short %
8.81 %
Float Shares
90.90 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Myriad Genetics, Inc.
1343Total events
5Upcoming
294Tier-1 (high impact)
2009 – 2027Coverage
Upcoming catalysts 2
TBD
T2Quarterly Update
Subscribe to view catalyst details
TBD
T2Product Launch
Subscribe to view catalyst details
Event history 2
TBD
▲Product LaunchPost-Market
Subscribe to view catalyst details
TBD
▲Product LaunchPost-Market
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D31
Pipeline Score $85M
Pipeline ValueValuation Signal
3
Drugs Scored0.8x
rNPV / MCap Top 40%
Micro Cap (rank 549 of 913)
Percentile RankMyriad Genetics, Inc. faces pipeline headwinds (31/100), with $316M risk-adjusted pipeline value, led by SKB264 in Solid Tumor (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SKB264 Small molecule | Solid Tumor | Phase 2 | NCT05642780 | 10% | $246M | ACTIVE NOT_RECRUITING | 240 | VERY_FAST | C (42) | Dec 31, 2027 | ELEVATED_RISK | Oct 14, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Precise MRD | various cancer types | — | 2026-05-27 | 97% baseline detection rate; 16% of samples detected in the ultrasensitive range Read More | Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting Read More | |
Precise MRD | various cancer types | — | 2026-05-27 | 97% baseline detection rate; 16% of samples detected in the ultrasensitive range Read More | Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting Read More | |
Precise MRD | various cancer types | — | 2026-05-27 | 97% baseline detection rate; 16% of samples detected in the ultrasensitive range Read More | Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MYGN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MYGN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MYGNMyriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026
Myriad Genetics will release its second quarter 2026 financial results on July 30, 2026. The earnings conference call is scheduled for 4:30 pm ET, where management will discuss the company's performance. A live webcast will be available, and an archived version will be accessible afterward.
Read more →MYGNMyriad Genetics Launches FirstGene® Multiple Prenatal Screen
Myriad Genetics has launched the FirstGene Multiple Prenatal Screen, a comprehensive test that performs four prenatal genetic screens from a single blood draw as early as eight weeks gestation. This innovative test boasts high analytical sensitivity and specificity, providing clinicians with timely insights to support informed decision-making during pregnancy. The FirstGene screen aims to streamline the prenatal screening process, enhancing patient care.
Read more →MYGNMyriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
Myriad Genetics has announced the expanded availability of its Precise MRD test for breast, colorectal, and renal cancers, significantly increasing access for patients. The test utilizes whole-genome sequencing to provide detailed insights into disease status and treatment response. A recent publication from the MONITOR-Breast study further validates its effectiveness in monitoring ctDNA during therapy. This expansion aligns with Myriad's strategy to enhance precision oncology.
Read more →MYGNMyriad Genetics Names Raj Jampa as New Chief Technology Officer
Myriad Genetics has appointed Raj Jampa as the new Chief Technology Officer, effective June 1, 2026. Jampa, who has a strong background in technology leadership, will focus on enhancing the company's digital technology and AI capabilities to support its growth strategy. His experience includes roles at Agilent Technologies and Exact Sciences, where he led significant technology transformations.
Read more →MYGNMyriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
Myriad Genetics, Inc. showcased data regarding its Precise MRD assay at the 2026 ASCO Annual Meeting, presented through six posters highlighting its applications in various cancer types. Key findings from the MONSTAR-SCREEN-3 study revealed a 97% baseline detection rate and significant correlations between ctDNA positivity and disease-free survival. The presentations emphasized the prognostic capabilities of the assay, which can aid in earlier clinical decision-making and progression monitoring in cancer treatment. Experts from Myriad will provide additional insights during a session at the conference.
Read more →MYGNMyriad Genetics Launches Prolaris + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
Myriad Genetics has announced the launch of the Prolaris + AI Test, the first prostate cancer biomarker test that integrates clinical-pathological features with AI-powered digital pathology. This innovative approach aims to better identify patients eligible for active surveillance and personalize their treatment plans. The test is based on data from longitudinal studies and provides doctors with a single report that combines critical risk assessments. The Prolaris + AI Test is set to be available starting May 29, 2026, for U.S. samples, excluding New York State, with further approvals anticipated soon.
Read more →MYGNMyriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Myriad Genetics, a leader in molecular diagnostics, will participate in two upcoming healthcare conferences: the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. The investor meetings and presentations aim to enhance stakeholder engagement and demonstrate the company's commitment to advancing healthcare through genetic insights. Attendees can access the Goldman Sachs presentation via a live audio webcast on the company's website.
Read more →MYGN▼ -18.3%on this newsshared move
Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
Myriad Genetics reported its Q1 2026 financial results, highlighting strong performance in its Cancer Care Continuum business with revenues of $120.2 million. The company reaffirmed its financial guidance for 2026, indicating confidence in growth driven by new product launches, including the Precise MRD test for breast cancer. However, it also reported a cash outflow of $13.4 million, raising concerns about operational costs.
Read more →MYGNMyriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
A nationwide survey conducted by Myriad Genetics reveals strong patient support for personalized mental health care, with 88% of participants indicating greater confidence in treatment if tailored to their needs. The survey highlights significant dissatisfaction with current mental health care, where many feel treatments are overly standardized. Furthermore, a majority of respondents expressed a desire for more individualized treatment approaches and indicated low awareness of genetic testing options that could improve their medication management. The findings suggest a critical opportunity for enhanced patient care through personalized mental health strategies, as represented by the GeneSight Test.
Read more →MYGNMyriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026
Myriad Genetics, a leader in molecular diagnostics, will announce its first quarter 2026 financial results on May 5, 2026. The earnings call is scheduled for 4:30 PM ET, where management will discuss the company's performance. A live webcast will be available on their Investor Relations website.
Read more →MYGNMyriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026
Myriad Genetics announced it will present six abstracts, including two podium presentations, at the AACR Annual Meeting 2026. The focus will be on its Precise MRD assay and the results from the MONITOR-Breast study, which evaluates ctDNA dynamics during neoadjuvant therapy in breast cancer patients. These presentations aim to provide insights that could help personalize treatment decisions and address challenges in assessing patient responses to therapy.
Read more →MYGN▲ +7%on this newsshared move
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
Myriad Genetics has received approval from Japan's Ministry of Health for the MyChoice Test to be used as a companion diagnostic for prostate cancer patients. This allows clinicians to assess homologous recombination deficiency and BRCA1/2 status, broadening access to genomic insights. The approval is expected to enhance treatment options for patients, particularly those with castration-resistant prostate cancer.
Read more →MYGN▼ -6.9%on this newsshared move
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
Myriad Genetics will present new data at the SGO Annual Meeting, including findings on Precise MRD testing for ovarian cancer. The data suggest that monitoring ctDNA levels can predict recurrence risk. Additionally, three presentations will discuss genetic variant prevalence and hereditary cancer screening, emphasizing the company's commitment to cancer research.
Read more →MYGNMyriad Genetics, Inc. Investigated by the Portnoy Law Firm
Myriad Genetics, Inc. is facing an investigation by the Portnoy Law Firm over potential securities fraud, as the firm considers filing a class action for investors. This comes after a steep decline in Myriad's stock price by 41.3%, triggered by disappointing first quarter financial results. Specifically, the company reported a 20% drop in pharmacogenomics revenue due to reduced coverage from UnitedHealthcare for its GeneSight product. Consequently, the firm has adjusted its financial outlook for the remainder of 2025, reflecting a weaker business climate and leading to significant market volatility.
Read more →MYGNMyriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
Myriad Genetics has received FDA approval for the MyChoice CDx Test as a companion diagnostic for Zejula, a PARP inhibitor, in patients with advanced ovarian cancer. This test is designed to identify homologous recombination deficiency (HRD) status in patients, helping to improve treatment decisions based on genomic insights. The approval is rooted in data from the PRIMA trial and marks the test as the only FDA-approved option to determine HRD status for this specific treatment. The MyChoice CDx Test significantly enhances the identification of HRD-positive patients, vital for effective use of PARP inhibitors.
Read more →MYGN▲ +8.7%on this news
Myriad Commercially Launches Precise MRD with Select Community Oncologists
Myriad Genetics has launched the Precise MRD test for breast cancer patients as part of a limited release with select community oncologists. This molecular residual disease test is designed to detect ctDNA at extremely low levels, facilitating earlier intervention and personalized treatment decisions. The company plans a broader commercial launch across the U.S. later this year, aiming to improve patient monitoring and treatment outcomes. Experts in oncology highlight the test's potential to enhance cancer detection and monitoring beyond traditional methods.
Read more →MYGNSix presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests
Myriad Genetics is set to present new data at the 2026 ASCO-GU conference, showcasing the effectiveness of its Precise MRD, Prolaris, and MyRisk tests in cancer care. The findings indicate high sensitivity in molecular residual disease detection and significant prognostic capabilities for prostate cancer. These advancements may enhance patient outcomes and treatment strategies across various cancer types.
Read more →MYGNMyriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution
Myriad Genetics reported its fourth quarter and full-year 2025 financial results, highlighting positive growth in hereditary cancer testing and mental health services. The company reaffirmed its financial guidance for 2026, which includes the launch of three new tests, indicating a strong outlook. However, prenatal testing has faced challenges, impacting overall performance.
Read more →MYGNMyriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
Myriad Genetics, Inc. is set to release its fourth quarter and full year 2025 financial results on February 23, 2026. The earnings conference call will take place at 4:30 pm ET, with an overview of the company's performance provided by management. Additionally, the executives will participate in several upcoming investor healthcare conferences throughout March 2026, promoting continued engagement with stakeholders.
Read more →MYGNMyriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
Myriad Genetics announced a commercialization roadmap for its Precise MRD assay, set for a limited clinical launch in March 2026, starting with breast cancer. The assay demonstrates high sensitivity in detecting circulating tumor DNA (ctDNA) and may expand to additional cancer types in the coming years. The initiative aims to improve patient outcomes through earlier insights and informed treatment decisions.
Read more →MYGN▼ -5.6%on this news
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
Myriad Genetics announced preliminary financial results for the fourth quarter and full year 2025, along with guidance for 2026. The results are unaudited and may change upon finalization. The company highlighted its leadership in molecular diagnostics while acknowledging various risks that could impact future performance.
Read more →MYGN▲ +6.2%on this news
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
Myriad Genetics, a leader in molecular diagnostics, announced that its CEO, Sam Raha, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14. The presentation will be available via live webcast, showcasing the company's advancements in precision medicine and diagnostic testing. This event underscores Myriad's commitment to improving patient care.
Read more →MYGNMyriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance SALT LAKE CITY, Januar y 12, 2 026 - Myriad Genetics, Inc. (NASDAQ MYGN),
Myriad Genetics has announced select preliminary financial results for the fourth quarter and full year 2025, projecting revenues between $207 million and $209 million for Q4 and $822 million to $824 million for the entire year. The company also introduced financial guidance for 2026, estimating revenue between $860 million and $880 million, indicating a potential growth of 6% compared to 2025. However, these preliminary results are subject to revision and do not reflect final audited figures. Additionally, Myriad noted various risks that could impact future financial performance.
Read more →MYGNMyriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
Myriad Genetics announced it will present eight abstracts at the 2025 San Antonio Breast Cancer Symposium, showcasing advances in breast cancer diagnostics and treatment. Key presentations will include data on the MyRisk Hereditary Cancer Test and the Precise Molecular Residual Disease (MRD) Test, which has high sensitivity and specificity for low-tumor-shedding cancers. The company emphasizes its commitment to improving patient care through innovative genetic testing and risk assessment methods. Myriad will also sponsor a session discussing the role of genomic and germline testing in breast cancer management.
Read more →MYGNMyriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
Myriad Genetics has expanded its MyRisk® Hereditary Cancer Test to include 15 new clinically actionable genes, now totaling 63 genes. This update aligns with NCCN and ASCO guidelines, enhancing the test's clinical utility across various cancer types. The company aims to support clinicians in making informed treatment decisions and improving patient care.
Read more →MYGNMyriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference
Myriad Genetics will present 11 new research studies at the NSGC 44th Annual Conference, focusing on advancements in oncology and reproductive genetic testing. The company emphasizes its commitment to improving patient outcomes through innovative genetic testing solutions. Myriad's latest products will be showcased, and the conference will feature multiple presentations from the company.
Read more →MYGN▼ -21%on this newsshared move
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
Myriad Genetics reported solid third quarter 2025 results, with stable revenue and a 13% increase in volume for its MyRisk hereditary cancer test. The company reaffirmed its financial guidance for the year, highlighting strong cash flow and positive adjusted EBITDA. Additionally, Myriad is focusing on the Cancer Care Continuum and has partnered with SOPHiA GENETICS to enhance its offerings.
Read more →MYGNNew Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner
Myriad Genetics announced a post-hoc analysis of the PRIME study, revealing that patients with Major Depressive Disorder (MDD) whose clinicians accessed GeneSight results experienced quicker remission and response to treatment. This benefit was sustained for at least six months. The analysis included 1,764 veterans and highlighted the effectiveness of pharmacogenomic-guided treatment.
Read more →MYGNMyriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025
Myriad Genetics, Inc. will announce its financial results for the third quarter of 2025 on November 3, 2025. The announcement will be followed by an earnings conference call at 4:30 PM ET, where management will discuss the company's performance and business updates. These financial results reflect the continued operations of a leading molecular diagnostics company committed to improving patient care.
Read more →MYGNMyriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
Myriad Genetics has expanded its Foresight Carrier Screen Universal Plus Panel by adding the F8 and FXN genes. These additions enhance the panel's capability to detect genetic conditions such as hemophilia A and Friedreich's ataxia. The screening is now fully compliant with ACMG guidelines, providing valuable insights for family planning. Myriad's technology boasts a high detection rate for inherited conditions.
Read more →MYGNMyriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
Myriad Genetics and SOPHiA GENETICS have announced a collaboration to develop a global liquid biopsy companion diagnostic test. This partnership aims to enhance cancer care by utilizing Myriad's laboratory capabilities and SOPHiA's extensive network. The initial focus will be on the MSK-ACCESS® test, which analyzes ctDNA from blood samples. Both companies will pursue regulatory submissions to facilitate market access.
Read more →MYGNMyriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
Myriad Genetics announced the publication of a study in The Lancet Oncology regarding its Precise MRD test for oligometastatic clear-cell renal cell carcinoma. The study found that the test can detect circulating tumor DNA levels, potentially allowing patients to delay systemic treatments. This could lead to reduced side effects and better treatment outcomes. The findings suggest that ctDNA may serve as a valuable biomarker in cancer therapy.
Read more →MYGNNew Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression
Myriad Genetics announced a new meta-analysis showing that the GeneSight Psychotropic test significantly improves response and remission rates in patients with major depressive disorder (MDD). The analysis included data from 3,532 adults and demonstrated the test's superiority over standard treatment approaches. Myriad plans to use these findings to enhance patient access to the GeneSight test.
Read more →MYGNMyriad Genetics Appoints Ben Wheeler Chief Financial Officer
Myriad Genetics has appointed Ben Wheeler as Chief Financial Officer, effective August 16, 2025. Wheeler, who has been with the company for over 13 years, previously held the role of Chief Financial Officer of operations. His promotion is viewed positively by the company's leadership, who believe his expertise will aid in executing the company's profitable growth strategy. Myriad Genetics is also reaffirming its financial guidance for the full year 2025.
Read more →MYGNMyriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum
Myriad Genetics reported its second quarter 2025 financial results, showing a revenue increase of 1% year-over-year, with a notable 5% rise when excluding certain headwinds. The company experienced strong growth in hereditary cancer testing, particularly in Oncology, and raised its 2025 revenue guidance. Despite a significant net loss largely due to impairment charges, Myriad announced a new $200 million credit facility to support future growth initiatives. The company is also focusing on strategic investments and restructuring to enhance profitability and accelerate growth across its portfolio.
Read more →MYGN▼ -5.2%on this newsshared move
Myriad Genetics Announces New $200 Million Credit Facility
Myriad Genetics has announced the closure of a new five-year senior secured term loan credit facility totaling $200 million with OrbiMed. This facility provides $125 million in funded capital and an option to borrow an additional $75 million until June 30, 2027. The company aims to leverage this financial support to further its growth strategy. The facility replaces Myriad's previous asset-based lending (ABL) facility and is secured by a substantial majority of the company's assets.
Read more →MYGN▼ -5.2%on this newsshared move
Myriad Genetics Reports Second Quarter 2025 Financial Results Raises 2025 Revenue Guidance Following Positive Business Momentum Highlights Second quarter 2025 revenue of $213.1 million increased by 1% year-over-year. Exc
Myriad Genetics reported its second quarter 2025 financial results, achieving revenue of $213.1 million, a 1% increase year-over-year. The company raised its revenue guidance for 2025 following strong growth in hereditary cancer testing, particularly in Oncology. However, net losses were substantial due to non-cash impairment charges. Overall, Myriad is focusing on strategic growth pillars to enhance its market position while managing increased operational costs.
Read more →MYGN▼ -6.4%on this newsshared move
Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025
Myriad Genetics, Inc. will announce its second quarter 2025 financial results on August 5, 2025, followed by a conference call at 4:30 PM ET. The company aims to provide an overview of its financial performance and business updates. Interested participants can access the call via telephone or through a live webcast. An archived version of the call will be made available on their Investor Relations website after the live event.
Read more →MYGNMyriad Genetics Earns 2025 Great Place To Work Certification™
Myriad Genetics announced it has earned the Great Place to Work Certification for the third year in a row, with 84% of employees affirming the company's positive work environment. This certification is based on employee feedback about their workplace experience, emphasizing the company's commitment to inclusivity and support. The recognition illustrates Myriad's dedication to creating a high-trust workplace culture that empowers employees to make a difference.
Read more →MYGN▲ +9.4%on this news
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
Myriad Genetics has announced early access to the FirstGene Multiple Prenatal Screen, a new prenatal genetic test that assesses risks for common genetic conditions from a single blood sample. The FirstGene screen simplifies risk assessment by combining multiple tests into one assay, allowing for a comprehensive evaluation without paternal testing. A large-scale clinical study will be conducted to establish the screen's validity and utility, with over 5,000 patients participating across various clinical sites. This new offering represents a significant advancement in prenatal genetic testing and expands Myriad's existing portfolio.
Read more →MYGN▲ +6.4%on this news· ran to +17% by day 3shared move
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types
Myriad Genetics announced promising interim results from the MONSTAR-SCREEN 3 study, showcasing the effectiveness of its Precise MRD test in detecting ctDNA across various cancer types. The study demonstrated a remarkable 100% detection rate of ctDNA and the ability to identify extremely low levels of ctDNA, providing significant insights for patient treatment. Key findings suggest that ctDNA monitoring can enhance personalized medicine by predicting responses to therapies, particularly in challenging cancers. The ongoing study aims to validate the broad application of Precise MRD in detecting residual disease across cancer types.
Read more →MYGN▲ +6.1%on this news
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
Myriad Genetics will present data from seven new research studies at the 2025 ASCO Annual Meeting, underscoring significant advancements in precision oncology. Among the highlights is the MONSTAR-SCREEN-3 study, which achieved 100% baseline detection of ctDNA across multiple tumor types. The company is also set to introduce new products, including the Precise MRD Test and the Prolaris Prostate Cancer Prognostic Test, showcasing its commitment to enhancing cancer care through innovative genetic and genomic testing solutions.
Read more →MYGN▼ -41.3%on this news
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
Myriad Genetics has announced the publication of a study in JCO Precision Oncology, demonstrating that its RiskScore tool significantly influences breast cancer screening recommendations based on individual patient risk. The study, which revealed that nearly 20% of patients received varied risk assessments compared to the traditional Tyrer-Cuzick model, showed that those identified with a greater than 20% lifetime risk were more likely to engage in recommended screening practices. The findings underline the importance of integrating polygenic risk scores in clinical settings to improve patient outcomes.
Read more →MYGN▼ -5.6%on this news· ran to -49% by day 3shared move
Myriad Genetics Reports First Quarter 2025 Financial Results Updates 2025 Financial Guidance Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds 1 of $16 million, reve
Myriad Genetics (NASDAQ: MYGN) reported its financial results for the first quarter of 2025, showing a revenue decline of 3% year-over-year to $196 million. The company's Prenatal segment experienced an 11% growth, while Pharmacogenomics saw a significant 20% drop. Despite an increase in gross margin, overall financial guidance for 2025 has been lowered due to performance challenges with certain tests. Myriad's leadership emphasizes a strategic focus on both reducing expenditures and investing in new product development.
Read more →MYGNMyriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025
Myriad Genetics, Inc. (NASDAQ: MYGN) will announce its first quarter 2025 financial results on May 6, 2025, followed by a conference call at 4:30 pm EDT. The call will provide insights into the company's financial performance and business updates. Additionally, Myriad will participate in upcoming investor healthcare conferences in May and June, signaling its commitment to investor relations and market engagement.
Read more →MYGNMyriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting
Myriad Genetics is set to present new clinical data on its Precise MRD test at the AACR Annual Meeting, showcasing its effectiveness for patients with oligometastatic clear-cell renal cell carcinoma. Dr. Chad Tang will discuss the advantages of metastasis-directed radiation therapy, along with the promising role of circulating tumor DNA as a personalized biomarker. The data reveals favorable survival rates, highlighting the potential for broader application and utility of the Precise MRD test in cancer treatment. The presentation is considered significant within the medical community, especially given the challenges previously faced in detecting MRD.
Read more →MYGNMyriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing
Myriad Genetics has announced a study published in the Journal of Clinical Psychopharmacology showing that patients with major depressive disorder experienced fewer psychiatric hospitalizations after utilizing the GeneSight Psychotropic Test. The study reported up to a 39% reduction in psychiatric-related hospitalizations and noted that the test aids healthcare providers in selecting more effective mental health medications. The findings suggest GeneSight testing can significantly influence treatment decisions, improving patient outcomes by personalizing medication use. However, the study did not include a control group to measure the exact impact of the GeneSight test on these outcomes.
Read more →MYGNMyriad Genetics Announces Inducement Awards
Myriad Genetics, Inc. has announced the grant of inducement awards to its new chief commercial officer, Mr. Donnelly, totaling $3.75 million. This includes $2 million in time-based restricted stock units (RSUs) and $1.75 million in performance-based restricted stock units (PSUs), effective from the start of his employment. The equity awards are designed to attract high-level talent while aligning with Nasdaq Listing Rule 5635(c)(4). The company aims to support its future growth and strategic initiatives with these leadership enhancements.
Read more →MYGNMyriad Genetics Names Brian Donnelly as New Chief Commercial Officer
Myriad Genetics announced the appointment of Brian Donnelly as its new Chief Commercial Officer effective May 1, 2025. Donnelly brings over 20 years of experience in the healthcare and diagnostics sectors, with a strong track record in building high-performing teams and driving growth. He expressed enthusiasm about joining Myriad and emphasized the company's commitment to advancing genetic insights. His role is expected to be crucial in scaling the business and enhancing product adoption.
Read more →MYGNMyriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools
Myriad Genetics has announced a collaboration with Gabbi to enhance access to hereditary cancer risk assessment tools. This partnership will integrate Gabbi's telehealth services and Myriad’s MyRisk test, allowing women at risk of breast cancer to receive comprehensive evaluations. The initiative aims to improve early detection and personalized care plans, helping patients manage their cancer risk. The combined resources of both companies will provide logistical support and a seamless experience for women seeking guidance on breast cancer risk.
Read more →MYGNKate Schraml Investor Contact Matt Scalo (224) 875-4493 (801) 584-3532 PR myriad.com matt.scalo myriad.com Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results Full-year
Myriad Genetics reported its fourth quarter and full-year financial results for 2024, highlighting an 11% year-over-year revenue growth. The company showed strong sales in both Pharmacogenomics and Prenatal testing, while maintaining a gross margin of 71.7%. However, it also reported a GAAP net loss of $43 million in the quarter. Myriad's collaboration with PATHOMIQ aims to enhance its oncology portfolio with AI technology, indicating a continued focus on innovation and growth into 2025.
Read more →MYGNMyriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth
Myriad Genetics reported financial results for Q4 and full-year 2024, showing an 11% year-over-year revenue growth. The company benefited from strong demand for its Pharmacogenomics and Prenatal testing services, achieving a Q4 revenue of $211 million. Despite its growth, Myriad reported a net loss of $43 million in Q4, along with rising operational expenses. Looking forward, the company reaffirmed its guidance for 2025 and highlighted its strategic collaboration with PATHOMIQ to enhance its Oncology offerings through AI technology.
Read more →MYGNMyriad Genetics Announces Senior Leadership Transition
Myriad Genetics, Inc. announced the appointment of Sam Raha as President and CEO, effective April 30, 2025. Raha, currently the COO, is replacing Paul J. Diaz, who will transition to a consultant role at the company. The Board expressed confidence in Raha's ability to lead and drive growth, highlighting his experience in the diagnostics field. Additionally, Mark S. Verratti will be promoted to COO as part of this leadership transition, with a search for a new CCO already underway.
Read more →MYGNMyriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio
Myriad Genetics has announced a strategic partnership with PATHOMIQ to exclusively license the PATHOMIQ_PRAD AI technology for prostate cancer. This collaboration will enhance Myriad's oncology offerings by adding AI-powered testing solutions, enabling better treatment decisions. The AI platform is designed to decode complex cancer pathology information, improving prognostic and predictive capabilities in prostate cancer management. Myriad plans to commercially launch its first AI-driven prostate cancer test later this year, potentially advancing personalized medicine in this field.
Read more →MYGNMyriad Genetics Included in Forbes America’s Best Employers 2025 List
Myriad Genetics has been recognized on Forbes' America's Best Employers 2025 list, reflecting its commitment to employee satisfaction and workplace excellence. The selection was based on extensive evaluations from a large sample of over 217,000 U.S. employees. With 84% of its workforce citing it as a Great Place To Work, the company underscores its dedication to innovation and improving health outcomes through genetic testing.
Read more →MYGNMyriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025
Myriad Genetics, Inc. (NASDAQ: MYGN) will release its fourth quarter and full year 2024 financial results on February 24, 2025. An earnings conference call is scheduled for the same day at 4:30 pm ET, during which management will discuss the company’s performance. Additionally, Myriad will participate in several upcoming investor healthcare conferences addressing its operations and market strategies.
Read more →MYGNMyriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
Myriad Genetics has entered an agreement with CancerCARE for Life to enhance access to hereditary cancer testing through the MyRisk with RiskScore test. This partnership aims to reach over one million individuals in the CancerCARE network, allowing them to assess their eligibility for the test using an online screening tool. This initiative is expected to empower patients in making informed decisions about their health management. MyRisk is designed to provide personalized risk assessments by evaluating multiple genes linked to hereditary cancer.
Read more →MYGNMyriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
Myriad Genetics has been granted two new patents by the United States Patent and Trademark Office for its molecular residual disease (MRD) assay. The patents relate to automated methods of MRD analysis and patient journey aspects during cancer treatment. These patents build on Myriad's existing MRD technology, which aims to improve treatment monitoring and patient outcomes. Myriad's Precise MRD test is being evaluated in several studies, indicating a strong commitment to advancing cancer care.
Read more →MYGNMyriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
Myriad Genetics has partnered with Lumea Inc. to integrate its Prolaris and MyRisk cancer tests into Lumea's BxLink digital pathology platform. This collaboration aims to streamline the ordering and delivery processes of these molecular tests, allowing electronic orders and reducing manual errors. Clinicians can expect results in under 10 days, potentially improving patient outcomes by providing timely insights for treatment decisions. The partnership reflects a commitment to enhancing cancer care and improving efficiency in healthcare delivery.
Read more →MYGNMyriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
Myriad Genetics announced the unveiling of research demonstrating the effectiveness of its Prequel Prenatal Screen with AMPLIFY technology at just eight weeks of gestation. This breakthrough allows for reliable prenatal cell-free DNA screening earlier than the typical nine to ten weeks. The study aims to improve the assessment of risks for chromosomal abnormalities, enabling earlier diagnostic testing options for pregnant patients. The research received the Dru Carlson Memorial Award at the Society for Maternal-Fetal Medicine Conference.
Read more →MYGNMyriad Genetics Introduces Online Prenatal Genetic Testing Resource
Myriad Genetics has launched a new educational website named 'Know More Sooner' that provides comprehensive information about prenatal genetic testing. The site aims to improve awareness of the benefits of screening and offers resources for prospective parents, including patient stories. A significant survey indicates a demand for better education on genetic testing, as many women are not offered noninvasive prenatal testing. Myriad offers various genetic tests to aid parents in managing pregnancy-related genetic risks.
Read more →MYGNMyriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
Myriad Genetics announced a successful study revealing that the use of its MyGeneHistory online screening tool and patient education program significantly increased the completion rates of hereditary cancer testing. The study indicated a 30% rise in patients identified for testing and a doubling in the number of completed tests. With more than 10,000 patients involved, clinicians reported enhanced confidence in risk assessment practices and a commitment to continue utilizing the new tools to support genetic testing processes. The research was published in the journal Obstetrics & Gynecology, highlighting its significance in advancing cancer risk assessment.
Read more →MYGNMyriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance
Myriad Genetics, Inc. has announced select preliminary financial results for the fourth quarter and full year ended December 31, 2024. The company projects a total revenue increase of approximately 6% to 7% for Q4 2024 and about 11% for the entire year compared to 2023. Despite this growth, the company is still expecting significant GAAP losses per share. Additionally, it introduced a financial guidance range for 2025, highlighting expectations for continued revenue growth, though with inherent uncertainty due to the preliminary nature of the results.
Read more →MYGNMyriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
Myriad Genetics has entered into an agreement with sports broadcaster Hannah Storm to promote awareness about the importance of understanding family cancer history. Storm, a breast cancer survivor, will serve as an ambassador for Myriad’s Breast Cancer Risk Assessment Program, advocating for genetic testing and preventative measures. The program features the MyRisk with RiskScore Hereditary Cancer Test, aiming to improve early detection and treatment through a detailed family health history. The collaboration seeks to engage women in conversations about hereditary cancer risks and encourage proactive health measures.
Read more →MYGNMyriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Myriad Genetics, Inc. (NASDAQ: MYGN) will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2025. This presentation will showcase the company's advancements in genetic testing and precision medicine. Investors and attendees can access the presentation via a live webcast on Myriad's investor relations website, with an archived version available later the same day. This highlights Myriad's commitment to sharing advancements and insights in the healthcare domain.
Read more →MYGNMyriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report
Myriad Genetics, known for its work in genetic testing, has released its Quality, Innovation, and Corporate Responsibility Report. This report highlights the company's achievements over a 21-month period, emphasizing their commitment to operational excellence, innovation in genetic testing technologies, and strong corporate responsibility. Notable successes include high sample processing rates and favorable employee satisfaction scores. However, the report also contains forward-looking statements that acknowledge potential risks and uncertainties.
Read more →MYGNMyriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
Myriad Genetics announced that its MyRisk Hereditary Cancer Test with RiskScore study has been recognized as one of the top 10 significant advances in genomic medicine by the American Journal of Human Genetics. The study showcased the validation of RiskScore, demonstrating its superior predictive accuracy for breast cancer risk compared to traditional methods. Myriad aims to enhance health equity with a multi-ancestry approach. The recognition is expected to drive further adoption of RiskScore among healthcare providers and guideline societies.
Read more →MYGNMyriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
Myriad Genetics has provided an update on talks with UnitedHealthcare regarding its updated medical policy that limits access to pharmacogenetic tests, including the GeneSight test. In response to these changes, Myriad has presented additional clinical evidence to support the test's utility and has requested that access be maintained into 2025. CEO Paul J. Diaz expressed the company's hope for a swift resolution while acknowledging the tragic passing of UnitedHealthcare CEO Brian Thompson. Myriad continues to stand by the clinical validity of GeneSight as it navigates potential financial impacts from the policy change.
Read more →MYGNMyriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
Myriad Genetics has announced the election of Mark S. Davis to its Board of Directors, increasing the board size from eight to nine members. Davis brings significant experience from his career at Deloitte & Touche LLP and is expected to provide valuable insights in financial accounting and governance. Additionally, he has been appointed to the Audit and Finance Committee, reflecting a strategic enhancement in oversight. His commitment to advancing genetic solutions aligns with Myriad's mission in precision medicine.
Read more →MYGNMyriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
Myriad Genetics has praised the updated Prostate Cancer Guidelines from the National Comprehensive Cancer Network (NCCN), which emphasize the company's comprehensive offerings in genetic testing for prostate cancer. These guidelines endorse multigene germline testing and other diagnostic tools as essential for patient management. Myriad's products, such as the MyRisk Hereditary Cancer Test and Precise Tumor Molecular Profile Test, are now recognized as valuable resources in improving treatment decisions for prostate cancer patients. The company's ongoing investments in oncology solutions aim to enhance personalized patient care significantly.
Read more →MYGNMyriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
Myriad Genetics has announced it will present new data at the 2024 San Antonio Breast Cancer Symposium, focusing on a breast cancer risk assessment tool that integrates a polygenic score across all ancestries. Additionally, they will showcase their second-generation tumor-informed molecular residual disease (MRD) assay, which has demonstrated significant accuracy and sensitivity in detecting residual disease. The presentations are expected to provide valuable insights that can aid oncologists and breast surgeons in making informed decisions for breast cancer patients.
Read more →MYGNMyriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
Myriad Genetics has announced updates to its collaboration with Illumina, incorporating its proprietary Genomic Instability Score (GIS) into Illumina’s updated TruSight™ Oncology 500 v2 assay. This integration allows for HRD status reporting across a broader array of cancer types, expanding the potential for clinical research and CDx development. Myriad aims to strengthen its oncology product portfolio by enhancing the availability of detailed genomic profiling through this partnership.
Read more →MYGNMyriad Genetics Announces Prequel Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
Myriad Genetics has announced that its Prequel Prenatal Screen can now be performed as early as eight weeks into pregnancy, a significant advancement enabled by its AMPLIFY technology. This new capability allows for earlier access to genetic insights, helping expectant parents make informed decisions regarding their pregnancy. The gain in fetal DNA signal by 2.3-fold enhances the reliability of the screening results, providing information about potential chromosomal conditions. This is expected to streamline the prenatal care process for both healthcare providers and patients.
Read more →MYGNMyriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
Myriad Genetics has expanded access to its SneakPeek at-home early fetal sex DNA test by launching it in over 8,800 retail locations across the U.S., including Walmart, Walgreens, and CVS. This test, recommended by OBGYNs with over 99% accuracy, allows expectant parents to learn the gender of their baby as early as six weeks into pregnancy. The company emphasizes its commitment to providing affordable and accessible prenatal information. A product rebranding is also scheduled for 2025 as part of efforts to enhance customer engagement and experience.
Read more →MYGNMyriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
Myriad Genetics announced its financial results for the third quarter of 2024, revealing an 11% increase in revenue to $213 million and a significant reduction in net loss to $22.1 million. The company's adjusted EBITDA also saw a notable rise to $14.1 million compared to the previous year. However, they face challenges as UnitedHealthcare will discontinue coverage for the GeneSight test effective January 1, 2025, which may impact future revenue. Despite some setbacks, Myriad's diversified product offerings continue to support growth and the company has updated its financial guidance for 2024.
Read more →MYGNMyriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
Myriad Genetics announced that UnitedHealthcare is updating its medical policy to restrict access to the GeneSight pharmacogenetic test. The company disagrees with this change, arguing that there is substantial evidence supporting the test's efficacy. Myriad is actively engaging with UnitedHealthcare to reverse the policy shift, stating that GeneSight plays a critical role in helping healthcare providers find appropriate treatments for mental health conditions. The company believes that the updated policy will not affect GeneSight coverage under Medicare Advantage or managed Medicaid plans.
Read more →MYGN▼ -18.1%on this newsshared move
Megan Manzari Investor Contact Matt Scalo (385) 318-3718 (801) 584-3532 megan.manzari myriad.com matt.scalo myriad.com Myriad Genetics Reports Third Quarter 2024 Financial Result s Updates 2024
Myriad Genetics reported its third quarter 2024 financial results, highlighting an 11% revenue increase to $213 million, attributed mainly to growth in pharmacogenomics and prenatal testing. The company's net loss improved dramatically from the previous year, while adjusted EBITDA also rose significantly. However, Myriad faces potential revenue losses due to UnitedHealthcare's decision to discontinue coverage for its GeneSight testing. The company is actively working towards a resolution to maintain access for patients and has updated its 2024 financial guidance accordingly.
Read more →MYGNMyriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
Myriad Genetics, Inc. is set to announce its third quarter earnings results for 2024 on November 7, 2024, following the market close. The earnings call will provide an overview of the company's performance and future guidance. Additionally, Myriad management is scheduled to participate in notable healthcare investor conferences later in November. This ongoing engagement indicates the company's commitment to transparency with its investors.
Read more →MYGNMyriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
Myriad Genetics has announced a strategic partnership with jscreen to enhance access to preventative genetic testing for high-risk populations in the U.S. This collaboration combines Myriad's advanced hereditary cancer products with jscreen's educational outreach and genetic care navigation. The partnership aims to address the needs of individuals of Jewish descent and is expected to reach numerous high-risk adults through educational events and screenings. Myriad's commitment to quality genetic testing aligns with jscreen's mission to provide equitable care.
Read more →MYGNMyriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
Myriad Genetics has partnered with Flatiron Health to integrate its MyRisk Hereditary Cancer Test into Flatiron's OncoEMR platform. This integration enables over 4,200 providers across more than 800 cancer care locations to order and review genetic test results seamlessly within their existing systems. The initiative aims to enhance the accessibility and usability of genetic testing, promoting personalized patient care and improving overall treatment outcomes. The integration is available to all OncoEMR users immediately.
Read more →MYGNMyriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
Myriad Genetics has announced five new research collaborations aimed at exploring the use of molecular residual disease (MRD) testing in breast cancer. The studies focus on the potential of circulating tumor DNA (ctDNA) levels to predict treatment responses and guide surgical decisions. Hospitals across several institutions, including The University of Texas MD Anderson Cancer Center and The University of Rochester Medical Center, will participate in these initiatives, which may enhance the overall management of breast cancer. Myriad's Precise MRD test aims to address the challenges often faced in breast cancer monitoring by tracking numerous tumor-specific variants.
Read more →MYGNMyriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
Myriad Genetics, in partnership with Ultima Genomics, aims to enhance its clinical testing capabilities using the UG 100 sequencing platform. This collaboration focuses on leveraging the platform's low-cost and high-accuracy features to improve genetic tests like the Precise MRD and FirstGene Multiple Prenatal Screen. The installation of the UG 100 in Myriad's new Lab of the Future is expected to make cutting-edge genetic testing more accessible. Both companies express optimism about the platform's potential to transform genetic testing and patient care.
Read more →MYGNMyriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
Myriad Genetics has been granted a third patent for its molecular residual disease (MRD) assay by the U.S. Patent and Trademark Office. This patent strengthens the company's capability to deliver an ultra-sensitive test to detect tumor-specific mutations in circulating tumor DNA (ctDNA). The new technology is expected to enhance the power and specificity of current MRD assays and has already garnered collaborations with top cancer research institutions. Myriad anticipates that these advancements will enable profitable commercialization of their Precise MRD assay in a growing oncology market.
Read more →MYGNMyriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
Myriad Genetics announced its participation in the 2024 National Society of Genetic Counselors Annual Conference, where it will showcase 10 studies related to advancements in oncology and reproductive genetic testing. The research emphasizes the significance of genetic and genomic testing in enhancing patient care. Myriad aims to work closely with genetic counselors to make testing more accessible and easier for various patient populations. The conference will feature several poster presentations and a lunch symposium aimed at integrating breast cancer risk assessment into clinical practice.
Read more →MYGN▲ +9.1%on this news
Myriad Genetics to Host Investor Event on October 9, 2024
Myriad Genetics will host an Investor Event on October 9, 2024, at the Westin Grand Central Hotel in New York City. The event, lasting approximately two hours, will feature presentations from CEO Paul J. Diaz and other executives discussing the company’s growth strategy, operational initiatives, and product pipeline advancements. A live webcast of the event will also be available for those unable to attend in person, with a replay accessible for 30 days afterward.
Read more →MYGNMyriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
Myriad Genetics, Inc. (NASDAQ: MYGN) has announced its participation in two upcoming investor healthcare conferences. The CFO, Scott Leffler, will speak at the Wells Fargo Healthcare Conference on September 4, 2024, while the CEO, Paul J. Diaz, will present at the Morgan Stanley Healthcare Conference on September 5, 2024. Both presentations will be available via live and archived webcasts. This participation reflects Myriad's commitment to advancing genetic testing and precision medicine.
Read more →MYGNMyriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
Myriad Genetics reported a strong second quarter for 2024, achieving a 15% increase in revenue to $212 million compared to the same period in 2023. The company also improved its earnings per share and raised its financial guidance for the full-year revenue expectation to between $835 and $845 million. Significant growth was seen across various segments, particularly in prenatal and pharmacogenomics testing. Despite these positive developments, Myriad faced operational challenges, particularly in tumor profiling, which showed a decline in revenue year-over-year.
Read more →MYGNMyriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific
Myriad Genetics has effectively sold its EndoPredict business to Eurobio Scientific and licensed them to sell Prolaris diagnostic kits internationally. The company is also reorganizing its international operations to optimize resources and enhance growth opportunities in Europe and Asia. This strategic move is designed to simplify distribution and reduce risk while maintaining a focus on oncology and biopharma sectors. Myriad retains production rights for EndoPredict in the U.S. as part of its comprehensive oncology solutions.
Read more →MYGNMyriad Genetics Appoints Jennifer Fox as Chief Legal Officer
Myriad Genetics has appointed Jennifer Fox as its new Chief Legal Officer, effective September 3, 2024. Fox brings extensive legal experience in the life sciences sector, having held key roles at various prominent companies. Her responsibilities will include overseeing legal affairs, intellectual property, mergers and acquisitions, and compliance. The appointment has been well received by Myriad's President and CEO, who praised Fox's industry knowledge and leadership qualities.
Read more →MYGNMyriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024
Myriad Genetics, Inc. is set to release its second quarter financial results for 2024 on August 6, 2024, after the market closes. The company will host a conference call later that day at 4:30 PM ET to discuss its financial performance and provide a business update. Investors can participate via a live webcast or telephone after registering. An archived version of the call will be available on the company's Investor Relations website.
Read more →MYGNMyriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
Myriad Genetics and Personalis have announced a cross-licensing agreement for their patent estates, focusing on tumor-informed approaches for minimal residual disease (MRD) detection. This collaboration aims to enhance patient access to MRD testing, which is gaining popularity as a diagnostic tool for monitoring cancer treatment effectiveness. The market for MRD testing is projected to grow significantly, with both companies committed to advancing these technologies. However, the announcement also includes forward-looking statements that highlight potential risks related to adoption and patent defenses.
Read more →MYGNMyriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
Myriad Genetics has announced the granting of a second foundational patent by the United States Patent and Trademark Office for its molecular residual disease (MRD) technology. This patent, coupled with an earlier one, boosts Myriad's ability to provide a high-definition MRD assay capable of detecting tumor DNA in various patient fluid samples. The company aims to commercialize its Precise MRD assay while conducting several high-impact studies in collaboration with leading research institutions. Preliminary results from these collaborations are expected to be released in the fall of 2024.
Read more →MYGNMyriad Genetics Earns 2024 Great Place To Work Certification™
Myriad Genetics has been awarded the Great Place To Work Certification for 2024, marking its second consecutive year of recognition. The certification is based on employee feedback, with 84% of staff affirming the company's positive workplace environment, substantially exceeding the national average. This accolade highlights Myriad's commitment to fostering an inclusive work culture that supports employee growth and work/life balance.
Read more →MYGNMyriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
Myriad Genetics has announced a collaboration with GSK to enhance access to homologous recombination deficiency (HRD) testing for high-grade serous ovarian cancer patients across nine countries. This initiative involves leveraging Myriad's MyChoice HRD Plus and MyChoice CDx Plus Tests to facilitate genetic testing, which is essential for personalized treatment approaches. Leaders from both companies emphasize their shared commitment to addressing healthcare disparities and improving outcomes for advanced ovarian cancer patients through better access to diagnostic solutions.
Read more →MYGNMyriad Genetics Launches New Universal Plus Panel for Foresight Carrier Screen
Myriad Genetics has announced the launch of a new Universal Plus Panel for its Foresight Carrier Screen, which screens for 39 inherited conditions and up to 272 associated genes. This addition aims to advance equitable prenatal care and is aligned with recommendations from the American College of Medical Genetics. The panel utilizes next-generation sequencing to identify pathogenic variants across diverse ancestry, enhancing the decision-making process for family planning. The updated screening also includes resources for genetic counseling to help families navigate their results.
Read more →MYGNIN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE MYRIAD GENETICS, INC. STOCKHOLDER DERIVATIVE LITIGATION ) ) C.A. No. 2021-0686-SG NOTICE OF PENDENCY OF SETTLEMENT OF DERIVATIVE LITIGATION TO ALL CURRENT STOCKHOLD
Myriad Genetics, Inc. is currently involved in derivative litigation regarding allegations of fiduciary duty breaches by its Directors and Officers. A proposed settlement has been suggested to resolve the litigation, with a hearing scheduled for August 6, 2024. The resolution of this case could lead to enhancements in corporate governance. However, the court has not determined the merits of the claims, which could affect Myriad's reputation in the market.
Read more →MYGNMyriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO Annual Meeting
Myriad Genetics is set to present groundbreaking research and product innovations at the 2024 ASCO Annual Meeting. The company will unveil data from seven studies focused on breast cancer and provide insights into its advanced genetic tests, including the Precise MRD Test and the MyChoice CDx HRD Companion Diagnostic Test. Furthermore, the firm plans to discuss upcoming expansions in liquid biopsy testing aimed at improving cancer care. This initiative underscores Myriad's commitment to enhancing the precision of cancer treatment through genetic insights.
Read more →MYGNMyriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
Myriad Genetics reported strong first quarter 2024 financial results, achieving a 12% increase in revenue year-over-year, amounting to $202 million. The company significantly reduced its net loss to $26 million and reported positive adjusted EBITDA of $4 million, indicative of improving financial health. Key areas driving growth include prenatal testing and pharmacogenomics. Despite some challenges, such as a decline in tumor profiling revenue, the company remains optimistic about market share gains and future product developments.
Read more →MYGNMyriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
Myriad Genetics has announced a reorganization of its European operations, including the sale of its EndoPredict business to Eurobio Scientific. This strategic shift is designed to align resources more effectively with domestic opportunities while continuing support for international biopharma partners. As part of the agreement, Myriad will retain rights to produce EndoPredict in the U.S. and expects the transaction to close in the second or third quarter of 2024. The move aims to enhance growth prospects and improve operational efficiency.
Read more →MYGNMyriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
Myriad Genetics, Inc. will release its first quarter 2024 financial results on May 7, 2024, followed by a conference call to discuss the company's performance. The earnings report will be accessible on Myriad's Investor Relations website. In addition to the earnings call, management will participate in multiple investor conferences throughout May and June, showcasing the company's efforts in the genetic testing market. Myriad Genetics continues to position itself as a leader in precision medicine.
Read more →MYGNMyriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
Myriad Genetics announced encouraging findings from a multi-year study involving nearly 21,000 patients with major depressive disorder. The research demonstrated a significant reduction in hospitalizations following GeneSight testing, including a 39% relative decrease in psychiatric-related admissions. Additionally, the study indicated that the use of medications with significant gene-drug interactions declined, while prescriptions for medications without such interactions increased. Further analysis of the data is anticipated to assess the financial impact of medication selection guided by pharmacogenomic testing.
Read more →MYGNMyriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
Myriad Genetics, Inc. has announced that it has received a patent for a molecular residual disease (MRD) assay that improves the detection of circulating tumor DNA (ctDNA) through a novel method of preparing cell-free DNA. This patent, granted by the U.S. Patent Office, supports Myriad's position as a leader in precision medicine. The company is actively developing its Precise MRD assay in a state-of-the-art lab and has ongoing collaborations with prestigious cancer research centers. Myriad aims to launch the assay commercially in late 2025, pending further validation and studies.
Read more →MYGNMyriad Genetics Announces Patent Granted for SneakPeek Snap Device
Myriad Genetics announced the granting of a U.S. patent for its SneakPeek Snap device, which allows for convenient blood collection for fetal sex determination. The new patent protects the technology until 2040 and promises enhanced accuracy by minimizing external DNA contamination. This innovation supports Myriad's position in the genetic testing market and opens avenues for potential licensing agreements with other device suppliers. The company views this as a recognition of its innovative contributions to PCR-based fetal testing.
Read more →MYGNMyriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance
Myriad Genetics reported a strong financial performance for the fourth quarter and full-year 2023, with revenue growth driven by its genetic testing services. The company achieved a 11% increase in revenue compared to the previous year, totaling $753 million, and raised its revenue guidance for 2024. However, despite positive adjusted earnings per share, Myriad posted a GAAP loss per share and negative cash flow from operations in the fourth quarter. The acquisition of assets from Intermountain Precision Genomics is expected to enhance its precision oncology offerings.
Read more →MYGNMyriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
Myriad Genetics has announced a collaboration with the National Cancer Center Hospital East in Japan to conduct the SCRUM-MONSTAR-SCREEN-3 clinical trial. The trial will utilize Myriad's Precise MRD test to monitor circulating tumor DNA in patients with various solid and hematological cancers. Led by Dr. Takayuki Yoshino, the study aims to generate evidence supporting the broad application of MRD testing across different cancer types and varying stages of disease severity. The partnership highlights the potential of personalized treatment strategies using multi-omic profiling in oncology.
Read more →MYGNMyriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Myriad Genetics, Inc. will hold its fourth-quarter earnings conference call on February 27, 2024, to discuss its financial results for 2023. The call will include a financial overview and an update on company performance, along with revenue and earnings guidance for 2024. Additionally, Myriad's management will participate in several investor conferences in March, reflecting ongoing investor engagement.
Read more →MYGNMyriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
Myriad Genetics has appointed Dr. Dallas Reed as Principal Medical Advisor for its women's health unit. Dr. Reed brings nearly 15 years of experience in genetics and obstetrics/gynecology and aims to enhance access to genetic testing in various aspects of women's health. The company emphasizes its commitment to equity in patient care and anticipates significant developments in the field under Dr. Reed's guidance.
Read more →MYGNMyriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
Myriad Genetics has announced the completion of its acquisition of several assets from Intermountain Precision Genomics, which includes the Precise Tumor Test and the upcoming Precise Liquid Test. This acquisition is strategic for Myriad as it aims to enhance its oncology portfolio by providing advanced tumor profiling services. The company has completed validation studies required for Medicare reimbursement for its new liquid biopsy test, set to launch later this year. However, the success of this initiative remains dependent on reimbursement approvals.
Read more →MYGNMyriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
Myriad Genetics announced the appointment of Dr. George Daneker Jr. as President and Chief Clinical Officer of Oncology, effective March 18, 2024. Dr. Daneker has over 30 years of experience in oncology and precision medicine and will lead Myriad's commercial and clinical strategies. His role will include overseeing the company's oncology portfolio, which offers a range of genetic testing services. The announcement was met with optimism regarding the future innovation and expansion of Myriad's oncology offerings.
Read more →MYGNMyriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
Myriad Genetics has announced its intention to acquire select assets from Intermountain Precision Genomics, which includes the Precise Tumor and Precise Liquid tests, along with a CLIA-certified laboratory. The deal, expected to finalize on February 1, 2024, aims to bolster Myriad's oncology offerings and improve operational efficiencies. The acquisition is also anticipated to provide new opportunities for clinical development and enhance patient care for those requiring tumor profiling and liquid biopsy tests.
Read more →MYGNMyriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
Myriad Genetics, Inc. has expressed support for the recently published ASCO-SSO guidelines that promote germline testing for patients with breast cancer. The new guidelines recommend BRCA1/2 testing for all patients diagnosed with invasive breast cancer under 65, and those over 65 should be tested if there is a relevant personal or family history. Additionally, the guidelines aim to enhance patient access to genetic information, which could lead to more personalized treatment strategies. This move aligns with Myriad's commitment to advancing genetic testing in cancer care.
Read more →MYGNMyriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
Myriad Genetics, Inc. will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024, at 4:30 PM PST. The event underscores Myriad's commitment to sharing advancements in genetic testing and precision medicine. The presentation will be accessible via a live webcast, with an archived version available later the same day. This engagement reflects Myriad's efforts to enhance patient care and reduce healthcare costs through innovative solutions.
Read more →MYGNMyriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance
Myriad Genetics announced the retirement of Chief Financial Officer Bryan Riggsbee and the appointment of Scott Leffler as his successor, effective January 29, 2024. Riggsbee will remain as a strategic advisor until March 31, 2024, to ensure a smooth transition. Leffler brings nearly 20 years of finance experience in healthcare and is expected to lead the company towards enhanced profitability and growth. Additionally, Myriad reiterated its financial guidance for 2023 and introduced projections for 2024.
Read more →MYGNMyriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
Myriad Genetics has announced the launch of the Myriad Collaborative Research Registry (MCRR), a large pan-cancer registry providing access to genomic and clinical data from over one million patients. This platform aims to enhance precision cancer research by enabling researchers to analyze a wide range of genetic information. The MCRR, built on the DNAnexus platform, allows for secure and comprehensive data sharing, supporting significant advancements in cancer treatment and prevention. The registry continues to expand and is open for research concept submissions from various institutions.
Read more →MYGNMyriad Genetics Celebrates One Million SneakPeek Results Shared with Expectant Parents
Myriad Genetics has announced that its SneakPeek Early Gender DNA Test has reached a milestone of one million results delivered to expectant parents. This test, which boasts a 99% accuracy rate, allows parents to determine their baby's sex as early as six weeks into pregnancy through an at-home testing kit or a local clinic sample. The company emphasizes that the SneakPeek test contributes to expanding access to fetal sex testing, complementing its other reproductive health solutions. Myriad's acquisition of Gateway Genomics has bolstered its offerings in genetic testing and precision medicine.
Read more →MYGNMyriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
Myriad Genetics has announced a collaboration with Personalis to market the ImmunoID NeXT biomarker discovery platform to pharmaceutical customers. This partnership will enhance Myriad’s offerings in precision medicine, particularly for those utilizing its cancer tests. The agreement reflects the growing demand from pharmaceutical partners for comprehensive genomic testing solutions to support drug development.
Read more →MYGN▼ -8.9%on this news
Myriad Genetics to Participate in Stephens Annual Investment Conference
Myriad Genetics, Inc. will participate in the Stephens Annual Investment Conference on November 15, 2023, in Nashville, TN. The event will feature a fireside chat with company management, aimed at discussing the firm's contributions to genetic testing and precision medicine. Interested parties can watch a live and archived webcast of the presentation on Myriad's investor relations website.
Read more →MYGN▼ -8.9%on this news
Myriad Genetics Announces Pricing of Upsized Offering of Common Stock
Myriad Genetics, a leader in genetic testing, has announced the pricing of an upsized public offering of 6,470,588 shares of common stock at $17.00 per share, aiming to raise around $110 million. The proceeds will be utilized primarily for debt repayment and to settle a class action lawsuit. This financing initiative indicates Myriad's strategic move toward improving its financial position as the closing date is slated for November 13, 2023, pending customary conditions.
Read more →MYGNMyriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock
Myriad Genetics, a leader in genetic testing, has announced a proposed public offering of $100 million worth of shares of common stock, with an additional option for underwriters to purchase up to $15 million more. The company plans to use a significant portion of the proceeds to pay off outstanding loans and settle a class action lawsuit. While the offering presents an opportunity for raising capital, it also faces uncertainties related to market conditions and specific terms.
Read more →MYGNMyriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance
Myriad Genetics reported a strong third quarter for 2023, achieving an 18% increase in testing volumes and a 23% rise in revenue year-over-year. The company has improved its revenue guidance for 2023 to between $747 million and $753 million, while also introducing guidance for 2024 at $815 million to $835 million. Despite the financial gains, Myriad Genetics recorded a GAAP operating loss of $60.1 million due to legal settlements and increasing operating expenses. The expansion of their credit facility and a new long-term agreement with UnitedHealthcare are expected to support future growth.
Read more →MYGNMyriad Genetics Appoints Sam Raha as Chief Operating Officer
Myriad Genetics has appointed Sam Raha as Chief Operating Officer, effective December 11, 2023. With over 25 years of experience in life sciences and molecular diagnostics, Raha will oversee lab operations, customer service initiatives, and product development. His previous roles include leadership positions at Agilent and Illumina. The company anticipates his contributions will enhance its long-term growth strategy and operational performance.
Read more →MYGN▲ +7.6%on this newsshared move
Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023
Myriad Genetics, Inc. (NASDAQ: MYGN) will release its third quarter financial results on November 6, 2023, followed by an earnings conference call at 4:30 p.m. EDT. The company aims to offer a financial overview and business update during the call. Participants can access the conference through several dial-in and webcast options, fostering investor communication.
Read more →MYGNBREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOOD A new national survey from Myriad Genetics Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, revealed that breast density and...
Myriad Genetics conducted a national survey revealing that many women misunderstand key breast cancer risk factors, particularly breast density and family health history. The survey found that nearly half of the respondents were unaware of breast density's implications for cancer risk. Additionally, communication about family medical history was notably low, which may hinder women's understanding of their own risk.
Read more →MYGNMyriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
Myriad Genetics has reported two significant milestones in its collaboration with Illumina to support clinical research for targeted therapies. The partnership aims to advance comprehensive genomic profiling and HRD testing using the Illumina TruSight Oncology 500 assay. Myriad has qualified for prospective clinical trial testing with an investigational test based on Illumina’s TSO Comp solution and has also begun a reproducibility test project to facilitate future regulatory filings. Both companies express enthusiasm for the potential advancements in cancer care resulting from this partnership.
Read more →MYGNMyriad Genetics Issues 2022 Environmental, Social and Governance Report
Myriad Genetics, Inc. has released its 2022 Environmental, Social and Governance (ESG) report, showcasing its commitment to responsible and sustainable operations within the healthcare sector. Key highlights from the report include advancements in scientific research, providing financial assistance for genetic testing to uninsured patients, and efforts towards increasing diversity within the workplace. The company also emphasized its commitment to reducing its environmental footprint, recycling significant amounts of plastic waste. However, the report includes forward-looking statements that are subject to various risks and uncertainties.
Read more →MYGNMyriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
Myriad Genetics has announced a collaboration with Memorial Sloan Kettering Cancer Center to explore the use of minimal residual disease (MRD) testing in breast cancer. This research aims to evaluate the predictive benefits of Myriad's MRD testing platform in two patient cohorts: one receiving CDK4/6 inhibitors and another in the neoadjuvant setting. The collaboration seeks to enhance treatment strategies by more precisely identifying which patients will respond to specific therapies, leveraging advanced whole-genome sequencing for better sensitivity and specificity. This study is among the first to assess MRD testing's predictive capability in relation to certain breast cancer treatments.
Read more →MYGNMyriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work
Myriad Genetics, a leader in genetic testing and precision medicine, has been recognized in 2023 by Great Place To Work and Fortune magazine as one of the Best Workplaces in Health Care. This accolade is based on extensive survey data from over 208,000 employees in the health care sector. Myriad achieved Great Place To Work certification, with 86% of its employees affirming that the company is a great workplace. The recognition underscores the company's dedication to fostering a supportive and growth-oriented work environment.
Read more →MYGNMyriad Genetics to Participate in Morgan Stanley Global Healthcare Conference
Myriad Genetics, Inc. (NASDAQ: MYGN) is set to participate in the Morgan Stanley 21st Annual Global Healthcare Conference with a fireside chat scheduled for September 13, 2023. Additionally, the company will hold an in-person Investor Day on September 19 at the Dr. Walter Gilbert Innovation Center in South San Francisco, where executives will outline strategies for commercialization, clinical advancements, and future products. The events underscore Myriad's commitment to advancing genetic testing and precision medicine.
Read more →MYGNMyriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk
Myriad Genetics has announced a collaboration with Onsite Women’s Health to launch a new breast cancer risk assessment program. This partnership aims to provide personalized insights and improve clinical care for women, particularly those considered at higher risk for breast cancer. The program will initially be offered through a portion of Onsite's OBGYN and primary care partnerships and plans for further expansion in 2024. It emphasizes the importance of early screening and genetic testing in managing breast cancer risk effectively.
Read more →MYGNMyriad Genetics to Host Investor Day on September 19, 2023
Myriad Genetics is set to host an Investor Day on September 19, 2023, at the Dr. Walter Gilbert Innovation Center in South San Francisco. The event will include a tour of the facility, followed by presentations from President and CEO Paul J. Diaz and the executive leadership team. Topics will cover company strategies, advancements in clinical research, and future products. A live webcast will be available for remote attendees, with a replay accessible for 30 days post-event.
Read more →MYGNMyriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris
Myriad Genetics has integrated Absolute Risk Reduction (ARR) into its Prolaris Prostate Cancer Prognostic Test, aiding personalized treatment decisions regarding hormone therapy. The updated test quantifies benefits of adding androgen deprivation therapy (ADT) to radiation therapy (RT), providing insights on patient-specific risks of metastasis. Studies presented at the 2023 ASCO Annual Meeting show varied benefits of ADT based on Prolaris results, allowing for more informed decision-making in prostate cancer care. This advancement aims to balance effective treatment with potential side effects of ADT.
Read more →MYGNMyriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment
Myriad Genetics and Intermountain Health have announced their participation in ComboMATCH, a national clinical trial organized by the National Cancer Institute to explore new cancer treatment combinations. This initiative aims to improve outcomes for patients with locally advanced or metastatic solid tumors by utilizing genetic testing to identify effective therapy combinations. Patients may gain access to these promising treatment options through the trials, enhancing precision oncology care. The collaboration is poised to offer better genomic profiling and treatment strategies for cancer patients.
Read more →MYGN▼ -9.5%on this newsshared move
Myriad Genetics Announces Enhancements to the GeneSight Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status
Myriad Genetics has announced enhancements to the GeneSight Psychotropic test, now incorporating patients' smoking status to provide more accurate genetic insights into medication metabolism for mental health treatments. This update focuses on how smoking can influence the activity of the CYP1A2 gene, affecting around 91% of patients with the highly inducible variant. By considering smoking status, the test aims to improve clinicians’ ability to tailor treatment plans effectively, ensuring better outcomes for patients. The updated test is now available for prescribing clinicians.
Read more →MYGNMyriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth
Myriad Genetics reported second quarter financial results showing a 17% increase in testing volume year-over-year and reaffirmed its guidance for 2023. Revenue grew 2% to $183.5 million, increasing to 10% when excluding changes in estimates from the prior year. The company successfully secured a new $90 million asset-based credit facility to improve financial flexibility. However, Myriad faced a GAAP operating loss due to litigation costs and ongoing challenges with payor dynamics affecting revenue.
Read more →MYGNMyriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023
Myriad Genetics, a prominent player in genetic testing, will announce its second quarter financial results on August 3, 2023. The earnings call will provide a financial overview and a business update for the period ending June 30, 2023. Interested parties can join the call via dial-in or live webcast, with options for international callers. This event highlights the company's ongoing commitment to transparency and stakeholder engagement.
Read more →MYGNMyriad Genetics Announces Inclusion of Breast Density to MyRisk with RiskScore Breast Cancer Risk Assessment
Myriad Genetics has announced the inclusion of breast density in its MyRisk® Hereditary Cancer Test with RiskScore®. This first-of-its-kind risk model integrates breast density along with family history and genetic markers to provide a comprehensive assessment of breast cancer risk. The aim is to enhance early detection and personalize patient care strategies, particularly for individuals with dense breast tissue. This innovation aligns with recent FDA regulations mandating mammography facilities to report breast density to patients.
Read more →MYGNMyriad Genetics Announces New $90 Million Asset-Based Credit Facility
Myriad Genetics, Inc. has announced a new asset-based credit facility worth $90 million, administered by JPMorgan Chase Bank. This facility provides the company with enhanced financial flexibility to support its growth strategy, with a potential increase in borrowing capacity to $115 million. The new credit line replaces the previous facility and will mature on June 30, 2026. It is secured by the company's assets and highlights the ongoing financial commitment to advancing precision medicine.
Read more →MYGNMyriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
Myriad Genetics has announced a research collaboration with The University of Texas MD Anderson Cancer Center to enhance treatment selection for metastatic renal cell carcinoma (RCC) using its minimal residual disease (MRD) testing platform. This innovative platform is designed to detect circulating tumor DNA (ctDNA) and is expected to be more sensitive compared to existing MRD tests. The collaboration aims to explore a comprehensive genome-wide approach to assess treatment response and surveillance in RCC patients. This initiative addresses a significant need for non-invasive diagnostic tools in the management of RCC.
Read more →MYGNMyriad Genetics to Participate in Goldman Sachs Healthcare Conference
Myriad Genetics, a leader in genetic testing and precision medicine, will participate in the 44th Annual Goldman Sachs Global Healthcare Conference. CEO Paul J. Diaz is scheduled to take part in a fireside chat on June 13, 2023, at 2:00 p.m. PT. The conversation will be available for replay on Myriad's investor relations website, which aims to enhance communication with investors and stakeholders. This event underscores Myriad's commitment to advancing health and well-being through genetic insights.
Read more →MYGNMyriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023
Myriad Genetics is set to showcase advancements in its oncology portfolio at the 2023 ASCO Annual Meeting. Key highlights include the addition of the Folate Receptor Alpha biomarker and the presentation of significant studies related to breast cancer and prostate cancer. The company aims to enhance personalized patient care through improved genetic insights and has recently strengthened its leadership team with oncology experts. Additionally, Myriad emphasizes its commitment to increasing access to genetic testing for all patients.
Read more →MYGNMyriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer
Myriad Genetics has announced the addition of Folate Receptor Alpha (FRα) to its Precise™ Oncology Solutions portfolio, providing an important companion diagnostic option for ovarian cancer treatment. The FRα biomarker helps identify patients eligible for the FDA-approved drug ELAHERE® (mirvetuximab soravtansine-gynx), especially those resistant to platinum-based chemotherapy. This addition is recognized in the National Comprehensive Cancer Network guidelines and could benefit a significant proportion of patients based on the SORAYA study results. Healthcare providers can now receive comprehensive testing results through a single laboratory for better treatment decision-making.
Read more →MYGN▼ -5%on this news
Myriad Genetics Earns 2023 Great Place to Work Certification™
Myriad Genetics has been awarded the 2023 Great Place to Work certification, with 86% of employees rating the company positively. This certification reflects Myriad's focus on fostering an inclusive and collaborative workplace. CEO Paul J. Diaz expressed gratitude to the staff for their contributions towards advancing the company's mission. The recognition reinforces Myriad's status as a desirable employer based on the experiences shared by its employees.
Read more →MYGNMyriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range
Myriad Genetics reported a strong financial performance for the first quarter of 2023, achieving a 10% year-over-year revenue growth, attributed to solid execution across its various business segments. Testing volumes showed significant growth, particularly in hereditary cancer testing within Women's Health, which rose by 32%. Despite these positive outcomes, the company still experienced an increased GAAP operating loss and a decline in gross margins. Myriad also updated its 2023 financial guidance, raising the lower end of its revenue projection, reflecting confidence in continued growth.
Read more →MYGNMyriad Genetics to Participate in BofA Securities Healthcare Conference
Myriad Genetics, Inc. will participate in the BofA Securities Healthcare Conference in Las Vegas, scheduled for May 9, 2023. The event will include a fireside chat featuring Myriad's management, which will be accessible via a live and archived webcast. This participation underscores the company's role in genetic testing and precision medicine, reflecting its commitment to advancing healthcare.
Read more →MYGNMyriad Genetics to Release First Quarter Financial Results on May 3, 2023
Myriad Genetics, Inc. will report its first quarter earnings for 2023 on May 3, 2023, with a conference call scheduled for 4:30 p.m. ET. The financial results will be made available after market close on the same day. During the call, Myriad's management will present an overview of the company’s performance up to March 31, 2023, providing insights into both financial data and business developments.
Read more →MYGNMyriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification
Myriad Genetics and Intermountain Precision Genomics have received certification from the New York State Department of Health, allowing them to offer solid tumor testing across all 50 U.S. states. This certification enhances accessibility to genetic testing for cancer patients, aiding in more targeted treatment decisions. The companies emphasize the importance of laboratory safety and quality in providing these services. The collaboration reflects their commitment to improving patient outcomes in precision medicine.
Read more →MYGNMyriad Genetics and SimonMed Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program
Myriad Genetics and SimonMed Imaging have announced a collaboration to launch a new hereditary cancer assessment program that integrates genetic testing and diagnostic imaging. This program seeks to enhance patient access to affordable genetic testing and provide personalized health insights. Set to begin in early May 2023, the initiative will gradually expand to all of SimonMed's 86 women's imaging sites by the end of the year. The partnership aims to improve early cancer diagnosis and management in high-risk patients, aligning with recent clinical guidelines.
Read more →MYGN▲ +13.2%on this news
Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC
Myriad Genetics has expressed support for the new expanded carrier screening guidelines established by the National Society of Genetic Counselors (NSGC). These guidelines advocate for equitable access to genetic testing for all individuals contemplating reproduction and for pregnant couples. The move aims to enhance reproductive risk assessments and improve patient care through informed decision-making. Myriad's leadership has shared insights on the impact of these guidelines, emphasizing the importance of genetic testing in enhancing family health.
Read more →MYGNMyriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight Volumes
Myriad Genetics reported its fourth quarter financial results, revealing a revenue of $177.8 million, representing an 11% growth year-over-year. The company attributed this performance to strong increases in hereditary cancer and pharmacogenomics testing volumes, which grew by 16% and 23%, respectively. Despite a growing revenue stream, the company experienced an increase in operating losses and a decline in cash reserves due to recent acquisitions. Myriad Genetics is optimistic about 2023, with plans for new product releases and a focus on sustainable growth.
Read more →MYGNMyriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023
Myriad Genetics, a key player in genetic testing and precision medicine, is scheduled to announce its fourth-quarter financial results on February 28, 2023. The earnings conference call will occur at 4:30 p.m. ET, providing a financial overview and business updates for the period ending December 31, 2022. The company aims to highlight its performance and ongoing commitment to improving patient care through genetic insights.
Read more →MYGNMyriad Genetics to Participate in Upcoming Healthcare Conferences
Myriad Genetics, Inc. (NASDAQ: MYGN) announced its participation in upcoming healthcare conferences, including the BTIG MedTech Conference on February 14, 2023, and the 44th Annual Raymond James & Associates Institutional Investors Conference on March 6, 2023. Additionally, the company will present at the 43rd Annual Cowen Health Care Conference on March 7, 2023. These conferences will highlight Myriad's advancements in genetic testing and precision medicine. Live webcasts of the presentations will be available on the company's website.
Read more →MYGNMyriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing
Myriad Genetics has reported several breakthroughs from its 2022 research focused on making genetic testing more accessible across diverse patient populations. Key innovations include the introduction of RiskScore, which provides equitable risk assessments for breast cancer among women of all ancestries, and the GeneSight Psychotropic test, which enhances medication selection for patients with major depressive disorder. The studies also emphasize the ability of MyChoice assays to be run in decentralized settings, improving access for ovarian cancer diagnostics. Overall, these advancements represent significant strides towards equity in healthcare and improved patient outcomes.
Read more →MYGNMyriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities
Myriad Genetics has welcomed new guidelines from the American College of Medical Genetics and Genomics, which endorse non-invasive prenatal screening (NIPS) for chromosomal abnormalities. The company emphasizes its advancements in NIPS technology with the existing Prequel test and is set to launch a new FirstGene test by Q3 2023. This innovation combines various screening modalities into one test using proprietary AMPLIFY technology, significantly improving detection accuracy for conditions like 22q microdeletion syndrome. Myriad also plans to present growing evidence of the test's effectiveness at upcoming conferences.
Read more →MYGNMyriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference
Myriad Genetics, Inc. announced that its CEO Paul J. Diaz and Chief Scientific Officer Dale Muzzey will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023. The presentation will be available via a live webcast on their Investor Relations website. Additionally, COO Nicole Lambert will participate in a panel discussion at the Goodwin + KPMG 4th Annual Symposium on January 11, discussing global precision medicine.
Read more →MYGNMyriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans
New leaders to elevate product portfolio, customer-centric commercial capabilities, and sales and marketing execution SALT LAKE CITY, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the
Read more →MYGNMyriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model
SALT LAKE CITY, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study validating RiskScore as a well-calibrated and more accurate predictor of breast cancer ris
Read more →MYGNMyriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment
Spotlight discussion highlights how combined risk score may lead to improved breast cancer prevention and screening strategies. SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today anno
Read more →MYGNMyriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will spotlight efforts to expand access to prenatal and hereditary cancer genetic insights at the 41st Annual National Society of Genetic C
Read more →MYGN▲ +11.9%on this newsshared move
Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information
UroSuite helps healthcare providers personalize treatment with easier access to biomarker, germline and somatic testing from a single source. SALT LAKE CITY, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medici
Read more →MYGN▼ -15.6%on this news
Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek Early Gender DNA Test
$67.5 million tuck-in acquisition strengthens Myriad’s Women’s Health portfolio of prenatal products Fast-growing SneakPeek test has helped 750,000 parents learn baby’s gender from home – earliest method to date at 6 weeks into pregnancy SALT LAKE CITY, Nov. 01, 2022 (GLOBE NEW
Read more →MYGN▼ -15.6%on this news
Myriad Genetics Reports Third Quarter Financial Results
Revenue of $156.4 million for the quarter ended September 30, 2022. Third quarter revenue, excluding divested businesses, was impacted by currency translations ($3.3 million), change of estimates1 ($5.3 million). Third quarter testing volumes, excluding divested businesses, grew
Read more →MYGNMyriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member
SALT LAKE CITY, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today the election of Paul M. Bisaro to its Board of Directors, effective immediately. Bisaro had an extensive career in the pha
Read more →MYGNMyriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022
SALT LAKE CITY, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third-quarter earnings conference call on Tuesday, Nov. 1, 2022 at 4:30 p.m. ET. The company’s quarterly earnings will be rel
Read more →MYGNMyriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis Diagnostic System as a Companion Diagnostic for Lynparza in Early-Stage Breast Cancer
SALT LAKE CITY, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted expanded coverage for the use of Myriad’s BRACAnalysis® D
Read more →MYGN▲ +5.7%on this news
Myriad Genetics Reports Second Quarter Financial Results
Revenue of $179.3 million for the quarter ended June 30, 2022 Excluding revenue from divested businesses, revenue increased 7% year-over-year and 9% sequentially from the first quarter of 2022 Diluted GAAP earnings per share (EPS) of $(0.18) and adjusted EPS of $0.04 in the seco
Read more →MYGNMyriad Genetics to Release 2022 Second-Quarter Financial Results on Aug. 4, 2022
SALT LAKE CITY, July 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second-quarter earnings conference call on Thursday, Aug. 4, 2022 at 4:30 p.m. EDT. The company’s quarterly earnings will be
Read more →MYGN▲ +5.7%on this news· ran to +18% by day 1
Myriad Genetics to Share Update on Business Transformation, Research and Development Pipeline, and Growth Plans at Investor Day on Aug. 11, 2022
SALT LAKE CITY, July 19, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will host an Investor Day on Aug. 11, 2022, providing a strategic business update and overview of the company’s growth opportunities, resea
Read more →MYGNMyriad Genetics Issues Inaugural Environmental, Social and Governance Report
2021 report demonstrates focus on ESG initiatives supporting health equity, social justice, and sustainability SALT LAKE CITY, June 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its first en
Read more →MYGN▲ +7.5%on this newsshared move
Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration
Healthcare providers can easily order Myriad’s genetic tests for the more than 250 million patients within Epic’s network Partnership bolsters Myriad’s growth plan to scale customer-centric, tech-enabled commercial capabilities with over 600 EHR integrations this year SALT LAKE
Read more →MYGN▼ -5%on this news
Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference
SALT LAKE CITY, June 09, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the company’s transformation and growth plan during a fireside chat at the Goldman Sachs 43
Read more →MYGNMyriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022
SALT LAKE CITY, May 26, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will present multiple studies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the value of genetic ins
Read more →MYGNMyriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022
Revenue of $164.9 million for the quarter ended March 31, 2022 Excluding revenue from divested businesses, revenue increased 11% year-over-year Diluted GAAP earnings per share (EPS) of $(0.26) and adjusted EPS of $(0.03) in the first quarter of 2022 improved by $0.26 and $0.03 y
Read more →MYGNMyriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference
SALT LAKE CITY, May 04, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be discussing the company’s transformation and growth plan during a fireside chat at the Bank of Ame
Read more →MYGNMyriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology Solutions
Precise™ Liquid Biopsy will provide insights on circulating tumor DNA in the blood to help guide cancer treatment decisions SALT LAKE CITY, May 03, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced
Read more →MYGNMyriad Genetics to Release First-Quarter 2022 Financial Results on May 5, 2022
SALT LAKE CITY, April 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first-quarter 2022 earnings conference call on Thursday, May 5, 2022 at 4:30 p.m. EDT. The company’s quarterly earnings will
Read more →MYGN▼ -6.4%on this news
Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care
SALT LAKE CITY, March 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of Precise™ Oncology Solutions, a comprehensive offering designed to help oncologists determine effective and p
Read more →MYGN▼ -6.4%on this newsshared move
Myriad Genetics Receives FDA Approval of BRACAnalysis CDx as a Companion Diagnostic for Lynparza in Early Breast Cancer
SALT LAKE CITY, March 11, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the U.S. Food and Drug Administration (FDA) has approved Myriad’s BRACAnalysis® CDx test for use as a companion diagnostic
Read more →MYGN▲ +6.5%on this news· ran to +19% by day 1
Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies
Myriad to establish new Walter Gilbert Research and Innovation Center Company also cited among 2022 Top Workplaces USA National List by Energage SALT LAKE CITY, March 08, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision m
Read more →MYGNMyriad Genetics CEO Paul Diaz to Speak at 42nd Annual Cowen Health Care Conference
SALT LAKE CITY, March 02, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be participating in a fireside chat at the 42nd Annual Cowen Health Care Conference on March 8, 20
Read more →MYGN▲ +7%on this news
Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives
Strong business performance despite COVID-19 headwinds Revenue of $160.8 million in the fourth quarter and $690.6 million for the year ended Dec. 31, 2021, up 4% and 24%, respectively Excluding revenue from divested businesses, revenue increased 19% for the fourth quarter and 34
Read more →MYGNMyriad Genetics to Release Fourth-Quarter 2021 Financial Results on February 24, 2022
SALT LAKE CITY, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its 2021 fourth-quarter earnings conference call on Thursday, February 24, 2022 at 4:30 p.m. ET. The company’s quarterly earnings
Read more →MYGNMyriad Genetics to Present at Two Upcoming Healthcare Conferences
SALT LAKE CITY, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be presenting at two upcoming healthcare conferences. On Feb. 17, 2022, R. Bryan Riggsbee, chief financial officer, will participate
Read more →MYGNMyriad Genetics CEO Paul Diaz to Speak at 40th Annual J.P. Morgan Health Care Conference
SALT LAKE CITY, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will provide an update on the execution of the company’s strategic transformation and growth plans at the 40th
Read more →MYGNMyriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service
SALT LAKE CITY, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the retirement of Jerry Lanchbury Ph.D. as chief scientific officer (CSO), after more than 19 years of distinguished servic
Read more →MYGNMyriad Genetics Promotes Nicole Lambert to Chief Operating Officer
SALT LAKE CITY, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the promotion of Nicole Lambert to chief operating officer (COO). In her new role, she will continue to report directly to
Read more →MYGNlambertcoo Myriad Genetics Promotes Nicole Lambert to Chief Operating Officer
Myriad Genetics Promotes Nicole Lambert to Chief Operating Officer SALT LAKE CITY, Dec. 14, 2021 - Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the promotion of Nicole Lambert to chief operating officer (COO). In her n
Read more →MYGNMyriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Value of Genetic Testing in Breast Cancer Risk Assessment and Treatment
SALT LAKE CITY, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two upcoming poster presentations at the 2021 San Antonio Breast Cancer Symposium (SABCS) that showcase the importance of g
Read more →MYGNMyriad Genetics Reports Third Quarter 2021 Results, Continues Strong Execution of Strategic Growth & Transformation Plans
Revenue of $167.3 million up 15% year-over-year. Excluding revenue from divested businesses, revenue increased 27% year-over-year Diluted GAAP earnings per share (EPS) of $0.30 and adjusted EPS of $(0.02) SALT LAKE CITY, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (
Read more →MYGNMyriad Genetics to Release Third Quarter Financial Results on November 2, 2021
SALT LAKE CITY, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it will hold its quarterly earnings conference call for the quarter ended September 30, 2021, at 4:30 p.m. EDT on Tuesd
Read more →MYGNMyriad Genetics Names Pamela Wong as Chief Legal Officer
SALT LAKE CITY, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Pamela Wong as its new Chief Legal Officer. In her role, she is responsible for leading the company’s leg
Read more →MYGNMyriad Genetics Completes Sale of Myriad Autoimmune’s Vectra Testing Business to LabCorp
SALT LAKE CITY, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has completed the sale of select operating assets and intellectual property (IP), including the Vectra® test, from
Read more →MYGN▲ +14.2%on this news
Myriad Genetics Delivers Strong Revenue and Earnings Growth in June 2021 Quarter, Continues to Execute on Strategic Growth & Transformation Plans
SALT LAKE CITY, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its second quarter ended June 30, 2021 and provided an update on recent business performance and strat
Read more →MYGNMyriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries
Myriad’s MyRisk® Hereditary Cancer test with RiskScore® provides a breast cancer risk assessment for all women not previously diagnosed with breast cancer, regardless of ancestry MyRisk with RiskScore is an important step to help address racial and ethnic disparities in the heal
Read more →MYGNMyriad Genetics to Release Second Quarter Financial Results on August 3, 2021
SALT LAKE CITY, July 28, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it will hold its quarterly earnings conference call for the quarter ended June 30, 2021, at 4:30 p.m. EDT on Tuesday, A
Read more →MYGNMyriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities
SALT LAKE CITY, July 21, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for a new recommendation statement by the American College of Medical Genetics and Genomics (ACMG), advising tha
Read more →MYGNMyriad Genetics Completes Sale of Myriad RBM to IQVIA’s Q2 Solutions
SALT LAKE CITY, July 01, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has completed the sale of its wholly-owned subsidiary, Myriad RBM, Inc. to Q2 Solutions, a leading global clinical t
Read more →MYGNMyriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare Conference
SALT LAKE CITY, June 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the company’s transformation plan and growth initiatives during a fireside chat at the Goldman Sac
Read more →MYGNMyriad Genetics Completes the Sale of Myriad myPath Melanoma, LLC, Laboratory to Castle Biosciences
SALT LAKE CITY, June 01, 2021 (GLOBE NEWSWIRE) -- On May 28, 2021, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, completed the sale of its wholly-owned subsidiary, Myriad myPath, LLC, which owns the laboratory that offers the myPath Mel
Read more →MYGNJared Maxwell Investor Contact Nathan Smith (801) 505-5027 (801) 505-5067 jmaxwell myriad.com nathan.smith myriad.com Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutio
Media Contact Jared Maxwell Investor Contact Nathan Smith (801) 505-5027 (801) 505-5067 jmaxwell myriad.com nathan.smith myriad.com Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions SALT LAKE CITY, May 24, 2021 - Myriad Genetics, Inc. (NASDAQ MYGN
Read more →MYGNMyriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions
SALT LAKE CITY, May 24, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has signed a definitive agreement to sell Myriad RBM, Inc. to Q2 Solutions, a leading global clinical trial laboratory ser
Read more →MYGNMyriad Genetics Appoints Melissa Gonzales to Lead Women’s Health Business
SALT LAKE CITY, May 20, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Melissa Gonzales has been named president of its Women’s Health business. Gonzales has more than 20 years of women’s he
Read more →MYGNMyriad Genetics to Share New Data at 2021 ASCO Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries
SALT LAKE CITY, May 19, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it will present results from a study with more than 275,000 women validating the use of a new method for polygenic breas
Read more →MYGNMyriad Genetics CEO Paul J. Diaz to Present at Bank of America Securities 2021 Virtual Health Care Conference
SALT LAKE CITY, May 05, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the company’s transformation plan and growth initiatives during a fireside chat at the Bank o
Read more →MYGNMyriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives
Revenue of $173.1 million increases 12% sequentially GAAP earnings per share of ($0.52), adjusted EPS of ($0.06) improves $0.06 sequentially Total test volumes increase 5% sequentially despite typical seasonality, with average revenue per test also increasing relative to the De
Read more →MYGNMyriad Genetics to Update Progress on Transformation Plan and Growth Initiatives, Share Long-Term Financial Outlook at 2021 Investor Day
SALT LAKE CITY, May 03, 2021 (GLOBE NEWSWIRE) -- At its 2021 Investor Day, Myriad Genetics, Inc. (NASDAQ: MYGN), today will provide a strategic business update, including an overview of initiatives to expand its reach and solidify its position as a leading partner in genetic test
Read more →MYGNMyriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmune’s Vectra Testing Business to Labcorp
SALT LAKE CITY, May 03, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it has entered into a definitive agreement to sell select operating assets and intellectual property (IP), including the Vectr
Read more →MYGNMyriad Genetics to Release March 2021 Quarterly Financial Results on May 3, 2021, Host Investor Day on May 4, 2021
SALT LAKE CITY, April 27, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it will release its financial results for the quarter ended March 31, 2021 at 4:05 pm EDT on May 3, 2021. The company will n
Read more →MYGNMyriad Genetics Signs Definitive Agreement to Sell Myriad myPath Melanoma, LLC, Laboratory to Castle Biosciences
SALT LAKE CITY, April 27, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it has signed a definitive agreement to sell the Myriad myPath Melanoma, LLC, Laboratory, which is the laboratory that offer
Read more →MYGNMyriad Genetics Announces Eric Santa as Chief Growth Officer, Names New Diversity and Marketing Leaders
SALT LAKE CITY, March 29, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Eric Santa as its new Chief Growth Officer. In this role, he will be responsible for accelerating growth initiatives and bu
Read more →MYGNMyriad Genetics Receives Additional Reimbursement for myChoice Diagnostic System in Japan
SALT LAKE CITY, March 25, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it has received additional reimbursement for its myChoice® Diagnostic System in Japan. The Myriad myChoice test is the most
Read more →MYGNMyriad Genetics Joins Forces with Intermountain Precision Genomics for a Comprehensive Offering of Germline and Somatic Tumor Testing Services
SALT LAKE CITY, March 02, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a new strategic precision oncology collaboration with Intermountain Precision Genomics, a service of Intermountain Healthca
Read more →MYGNMyriad Genetics Delivers 6% Sequential Revenue Growth; Company Continues to Execute Strategic Transformation Plan
Revenue of $154.6 million up 6% sequentially in quarter ended Dec. 31, 2020 GAAP Earnings per share (EPS) of ($0.59) and adjusted EPS of ($0.12) Despite COVID-19 headwinds, total test volumes increase 7% sequentially with stable pricing Signed in-network agreement with the maj
Read more →MYGNMyriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021
SALT LAKE CITY, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it will hold its quarterly earnings conference call for the period ending December 30, 2020 with investors and analysts at 4:
Read more →MYGNMyriad Genetics to Participate in Multiple Upcoming Health and Technology Conferences
SALT LAKE CITY, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it will participate at multiple upcoming health and technology conferences, sharing insights on how the company is inte
Read more →MYGNMyriad Genetics Launches New Vectra Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis
SALT LAKE CITY, Feb. 02, 2021 (GLOBE NEWSWIRE) -- To help more patients with rheumatoid arthritis (RA), Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today launched the new Vectra® Cardiovascular Risk assessment that can predict the ris
Read more →MYGNMyriad Genetics Receives Reimbursement for BRACAnalysis Diagnostic System in Japan
Patients with Prostate or Pancreatic Cancer to Benefit from Treatment with Lynparza More Than 20,000 Patients in Japan Now Qualify for Genetic Testing SALT LAKE CITY, Jan. 19, 2021 (GLOBE NEWSWIRE) -- In an announcement that will help more people with advanced prostate and panc
Read more →MYGNMyriad Genetics Forms Strategic Partnership with Illumina in Oncology
Note: Paul Diaz, President & CEO of Myriad Genetics will speak today at the 39th Annual JP Morgan Healthcare Conference at 2:50 p.m. EST accessible via a live audio webcast at the following direct link or through the investor section of Myriad’s website at www.myriad.com. SALT L
Read more →MYGNMyriad Genetics Receives First Reimbursement Decision for myChoice Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula
SALT LAKE CITY, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimbursement decision for the Myriad myChoice® Diagnostic System, which helps determine if women
Read more →MYGNMyriad Genetics Provides Transformation Update, Pursues Strategic Alternatives for Autoimmune Business, Realigns International Operations
SALT LAKE CITY, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the substantial completion of its strategic business unit and products review which will enable the company to better serve
Read more →MYGNMyriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in precision medicine and molecular diagnostics, will discuss the company’s transformation and growth initiatives at the 39th Annual J.P. Morgan Hea
Read more →MYGNMyriad Genetics Announces Global Expansion of Myriad myChoice Tumor Testing in Europe and China
SALT LAKE CITY, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today the expansion of Myriad myChoice® tumor testing in several European markets and China. Myriad myChoice CDx is
Read more →MYGNMyriad Genetics Delivers 56% Sequential Increase in Quarterly Revenue; Test Volumes Reach 90% of Pre-COVID-19 Level at End of Quarter
Revenue of $145.2 million up 56% sequentially in quarter ended Sept. 30, 2020 GAAP operating income increased $28.7 million sequentially; non-GAAP operating income increased $30.2 million sequentially GAAP EPS of ($0.20) and adjusted EPS of ($0.15) improved sequentially $40 mi
Read more →MYGNMyriad Genetics to Announce Quarterly Financial Results on November 9, 2020
SALT LAKE CITY, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its quarterly earnings conference call for the period ending September 30, 2020 with investors and analyst
Read more →MYGNJared Maxwell Investor Contact: Scott Gleason (801) 505-5027 (801) 584-1143 jmaxwell@myriad.com sgleason@myriad.com Myriad Genetics Files Fiscal Year 2020 Proxy Statement, Implements Corporate
Media Contact: Jared Maxwell Investor Contact: Scott Gleason (801) 505-5027 (801) 584-1143 jmaxwell@myriad.com sgleason@myriad.com Myriad Genetics Files Fiscal Year 2020 Proxy Statement, Implements Corporate Governance Changes In Support of Stakeholder Interests SALT
Read more →MYGNMyriad Genetics Files Fiscal Year 2020 Proxy Statement, Implements Corporate Governance Changes In Support of Stakeholder Interests
SALT LAKE CITY, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today that the company has filed its fiscal year 2020 proxy statement and made significant changes to its board struc
Read more →MYGNJared Maxwell (801) 505-5027 jmaxwell@myriad.com Investor Contact: Scott Gleason (801) 584-1143 sgleason@myriad.com Myriad Genetics Expands Board of Directors with New Member Rashmi Kumar Elec
Myriad Genetics Expands Board of Directors with New Member Rashmi Kumar Elected to Myriad s Board of Directors. SALT LAKE CITY, Sept. 10, 2020 Myriad Genetics, Inc. (NASDAQ: MYGN, Myriad or the Company ), a global leader in molecular diagnostics and precision medicine, today a
Read more →MYGNMyriad Genetics Expands Board of Directors with New Member
SALT LAKE CITY, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced the election of Rashmi Kumar, age 51, to its Board of Directors, effective immediat
Read more →MYGNJared Maxwell Investor Contact: Scott Gleason (801) 505-5027 (801) 584-1143 jmaxwell@myriad.com sgleason@myriad.com Myriad Genetics Announces Inducement Awards
Media Contact: Jared Maxwell Investor Contact: Scott Gleason (801) 505-5027 (801) 584-1143 jmaxwell@myriad.com sgleason@myriad.com Myriad Genetics Announces Inducement Awards SALT LAKE CITY, August 14, 2020 Myriad Genetics, Inc. (NASDAQ: MYGN, Myriad or the Company
Read more →MYGNMyriad Genetics Appoints Paul J. Diaz as President and Chief Executive Officer and a Member of the Board of Directors
SALT LAKE CITY, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced the appointment of Paul J. Diaz as President and Chief Executive Officer, effective
Read more →MYGNMyriad Genetics Reports Fiscal Fourth-Quarter 2020 Financial Results
Test Volumes Improved Meaningfully By the End of the Fourth Quarter Following Substantial Declines in March and April Due to the Initiation of Social Distancing Policies Total Fourth-Quarter Revenues of $93.2 Million Fourth-Quarter Diluted EPS of ($0.74) and Adjusted EPS of ($0
Read more →MYGNMyriad to Announce Fiscal Fourth-Quarter and Full Fiscal Year 2020 Financial Results on August 13, 2020
SALT LAKE CITY, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal fourth-quarter 2020 sales and earnings conference call with investors and analysts at 4:30 p.m.
Read more →MYGNMyriad Launches Proprietary AMPLIFY™ Technology, Further Increasing the Performance of its Prequel™ NIPS Test
SALT LAKE CITY, July 29, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has launched its proprietary AMPLIFY™ technology, which further increases the performance of its Preq
Read more →MYGNMyriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra
SALT LAKE CITY, July 28, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has launched a new enhancement that is now available on its Vectra® test report. The new test report
Read more →MYGNJared Maxwell Investor Contact: Scott Gleason (801) 505-5027 (801) 584-1143 jmaxwell@myriad.com sgleason@myriad.com Myriad Genetics Expands Board of Directors with New Member and Announces Upc
Media Contact: Jared MaxwellInvestor Contact: Scott Gleason (801) 505-5027 (801) 584-1143 jmaxwell@myriad.com sgleason@myriad.com Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D. Daniel M. Skovronsky
Read more →MYGNMyriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D.
Daniel M. Skovronsky, M.D., Ph.D. Elected to Myriad’s Board of Directors. Walter (Wally) Gilbert, Ph.D., announces upcoming retirement from the Board of Directors SALT LAKE CITY, July 22, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”),
Read more →MYGNMyriad Announces New Studies Validating the Ability of Myriad’s riskScore Test to Modify Breast Cancer Risk Prediction
SALT LAKE CITY, July 07, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today two recent publications validating the polygenic risk score (PRS) component of Myriad’s breast cancer risk stratificat
Read more →MYGNMyriad Announces Partnership with OptraHEALTH to Deliver “Gene™” a New AI Based Information Tool for Hereditary Cancer Patients
SALT LAKE CITY, July 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced a new collaboration with OptraHEALTH® to implement a cognitive ChatBOT named Gene™ to provide genetic and financial a
Read more →MYGNMyriad Launches New GeneSight Psychotropic Patient Collection Kit
SALT LAKE CITY, July 01, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced the launch of a new patient home collection kit for the GeneSight® Psychotropic test. The kit allows the DNA sample co
Read more →MYGNMyriad Announces New Favorable Coverage Policies for Prolaris from Three New Commercial Health Plans Including Major National Provider
SALT LAKE CITY, June 15, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has received favorable coverage decisions for Prolaris® from three new commercial health plans includ
Read more →MYGNMyriad Genetics Announces Publication of a Prospective Clinical Study of the EndoPredict Test in Women with Early-Stage Breast Cancer
SALT LAKE CITY, June 04, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced the publication of a prospective study demonstrating that the EndoPredict® test pred
Read more →MYGNMyriad Presents New Data at ASCO Validating the Ability of riskScore to Provide Personalized Breast Cancer Risk Information to Patients
SALT LAKE CITY, May 29, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced the presentation of two new studies at the 2020 American Society of Clinical Oncology (ASCO) annual meeting demonstrati
Read more →MYGNMyriad Genetics Appoints Daniel K. Spiegelman to the Board of Directors and Announces Upcoming Retirement of John T. Henderson, M.D.
SALT LAKE CITY, May 28, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, today announced the election of Daniel K. Spiegelman, age 61, to its Board of Directors, effective immediately, expanding the Bo
Read more →MYGNJared Maxwell Investor Contact: Scott Gleason (801) 505-5027 (801) 584-1143 jmaxwell@myriad.com sgleason@myriad.com Myriad Genetics Appoints Daniel K. Spiegelman to the Board of Directors and
Media Contact: Jared MaxwellInvestor Contact: Scott Gleason (801) 505-5027(801) 584-1143 jmaxwell@myriad.comsgleason@myriad.com Myriad Genetics Appoints Daniel K. Spiegelman to the Board of Directors and Announces Upcoming Retirement of John T. Henderson, M.D. SALT LAKE CITY,
Read more →MYGNMyriad Receives FDA Approval of BRACAnalysis CDx as a Companion Diagnostic for Lynparza in HRR-mutated Metastatic Castration-Resistant Prostate Cancer
SALT LAKE CITY, May 20, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) approved the BRACAnalysis CDx® test for use as a companion diagnostic
Read more →MYGNMyriad Receives FDA Approval of myChoice CDx as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer
SALT LAKE CITY, May 11, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) approved the myChoice CDx® test for use as a companion diagnostic by h
Read more →MYGNMyriad Genetics Reports Fiscal Third-Quarter 2020 Financial Results
Total Third-Quarter Revenues of $164.0 Million Third-Quarter Diluted EPS of ($1.55) and Adjusted EPS of ($0.08) SALT LAKE CITY, May 05, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precisi
Read more →MYGNRon RogersInvestor Contact:Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Third-Quarter 2020 Financial Results • Total
Media Contact:Ron RogersInvestor Contact:Scott Gleason (801) 584-3065(801) 584-1143 rrogers@myriad.comsgleason@myriad.com Myriad Genetics Reports Fiscal Third-Quarter 2020 Financial Results SALT LAKE CITY, May 5, 2020 - Myriad Genetics, Inc. (NASDAQ: MYGN, "Myriad" or the "Co
Read more →MYGNMyriad to Announce Fiscal Third-Quarter 2020 Financial Results on May 5, 2020
SALT LAKE CITY, April 28, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal third-quarter 2020 sales and earnings conference call with investors and analysts at 4:30 p.m.
Read more →MYGNMyriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight Psychotropic Test in People with Major Depressive Disorder
SALT LAKE CITY, April 20, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced the publication of a meta-analysis of four clinical trials demonstrating that the G
Read more →MYGNMyriad Withdrawing Financial Guidance for FY2020 Due to Business Impact from Coronavirus Pandemic
SALT LAKE CITY, April 08, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, announced today that due to the impact of the global COVID-19 pandemic, the company is withdrawing its fiscal year 2020 financial guidance. “Prior t
Read more →MYGNRon RogersInvestor Contact:Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Withdrawing Financial Guidance for FY2020 Due to Business Impact from Coron
Media Contact:Ron RogersInvestor Contact:Scott Gleason (801) 584-3065(801) 584-1143 rrogers@myriad.comsgleason@myriad.com Myriad Withdrawing Financial Guidance for FY2020 Due to Business Impact from Coronavirus Pandemic SALT LAKE CITY, April 8, 2020 - Myriad Genetics, Inc. (N
Read more →MYGNMyriad Receives Reimbursement for the BRACAnalysis Diagnostic System in Japan for Patients with Breast or Ovarian Cancer Associated with HBOC
SALT LAKE CITY, April 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has received reimbursement and launched the BRACAnalysis® Diagnostic System (i.e., “BRACAnalysis”) in Japan to help
Read more →MYGNMyriad Seeks Japanese Regulatory Approval for its BRACAnalysis Diagnostic System in People with Advanced Pancreatic and Prostate Cancer
SALT LAKE CITY, March 30, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced it has submitted a supplementary application with the Japanese Ministry of Health Labour and Welfare for its BRACAnalysis®
Read more →MYGNMyriad Announces Board of Directors Leadership Transition
S. Louise Phanstiel Appointed Chair of the Board of Directors; John T. Henderson, M.D., to Remain on the Board SALT LAKE CITY, March 23, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced tod
Read more →MYGNRon RogersInvestor Contact:Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Announces Board of Directors Leadership Transition S. Louise Phanstiel Appo
Media Contact:Ron RogersInvestor Contact:Scott Gleason (801) 584-3065(801) 584-1143 rrogers@myriad.comsgleason@myriad.com Myriad Announces Board of Directors Leadership Transition S. Louise Phanstiel Appointed Chair of the Board of Directors; John T. Henderson, M.D., to Rema
Read more →MYGNMyriad Genetics to Present at the SVB Leerink Global Healthcare Conference
SALT LAKE CITY, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that R. Bryan Riggsbee, president and CEO, is scheduled to present at the SVB Leerink Global Healthcare Conference at 10:
Read more →MYGNMyriad Submits sPMA for myChoice CDx with Lynparza in First-Line Maintenance Therapy in Advanced Ovarian Cancer
SALT LAKE CITY, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug Administration (FDA) f
Read more →MYGNRon Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Announces Leadership Transition R. Bryan Riggsbee, Chief Financial Office
Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Announces Leadership Transition R. Bryan Riggsbee, Chief Financial Officer Appointed Interim President and CEO Mark C. Capon
Read more →MYGNRon RogersInvestor Contact:Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Second-Quarter 2020 Financial Results • Tota
Media Contact:Ron RogersInvestor Contact:Scott Gleason (801) 584-3065(801) 584-1143 rrogers@myriad.comsgleason@myriad.com Myriad Genetics Reports Fiscal Second-Quarter 2020 Financial Results SALT LAKE CITY, Feb. 6, 2020 - Myriad Genetics, Inc. (NASDAQ: MYGN, "Myriad" or the "
Read more →MYGNMyriad Announces Leadership Transition
R. Bryan Riggsbee, Chief Financial Officer Appointed Interim President and CEO Mark C. Capone Resigns, Effective Immediately SALT LAKE CITY, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN), a leader in molecular diagnostics and
Read more →MYGNMyriad Genetics Reports Fiscal Second-Quarter 2020 Financial Results
Total Second-Quarter Revenues of $195.1 Million Second-Quarter Diluted EPS of ($0.11) and Adjusted EPS of $0.23 SALT LAKE CITY, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precis
Read more →MYGNMyriad to Announce Fiscal Second-Quarter 2020 Financial Results on February 6, 2020
SALT LAKE CITY, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal second-quarter 2020 sales and earnings conference call with investors and analysts at 4:30 p.m.
Read more →MYGNMyriad Submits sPMA for myChoice CDx with Zejula in First-Line Platinum Responsive Advanced Ovarian Cancer
SALT LAKE CITY, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug Administration (FDA) f
Read more →MYGNMyriad Submits sPMA for BRACAnalysis CDx as a Companion Diagnostic for Lynparza in Metastatic Castration-resistant Prostate Cancer
SALT LAKE CITY, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug Administration (
Read more →MYGNMyriad Genetics to Present at the J.P. Morgan 2020 Healthcare Conference
SALT LAKE CITY, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that Mark C. Capone, president and CEO, is scheduled to present at the J.P. Morgan 2020 Healthcare Conference at 3:00 p.m
Read more →MYGNMyriad Receives FDA Approval of BRACAnalysis CDx as Companion Diagnostic for Lynparza (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreatic Cancer
SALT LAKE CITY, Dec. 30, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® for use as a companion diagnostic test
Read more →MYGNMyriad Genetics’ Board Member, S. Louise Phanstiel, Recognized by WomenInc. Magazine in 2019 List of Most Influential Corporate Directors
SALT LAKE CITY, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and precision medicine, announced that board member S. Louise Phanstiel has been named to WomenInc. Magazine’s 2019 Most Influential Corporate Board Directors
Read more →MYGNMyriad’s Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer Genes
SALT LAKE CITY, Dec. 14, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that results of a new validation study of the company’s polygenic risk score (PRS) for breast cancer were presented at the 2
Read more →MYGNMyriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening
SALT LAKE CITY, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new study of the Prequel™ Prenatal Screen was published online in the journal Prena
Read more →MYGNMyriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
SALT LAKE CITY, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that multiple studies will be presented at the 2019 San Antonio Breast Cancer Symposium (SABCS) being held Dec. 10-14,
Read more →MYGNMyriad Genetics Announces Regulatory Approval of the BRACAnalysis Diagnostic System in Japan for Breast Cancer Patients
SALT LAKE CITY, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the BRACAnalysis® Diagnostic System (i.e., “BRACAnal
Read more →MYGNMyriad Genetics, Inc. (MYGN), Overstock.com, Inc. (OSTK) & Waitr Holdings Inc. (WTRH) - Bronstein, Gewirtz & Grossman, LLC Class Action Announcement
NEW YORK, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below
Read more →MYGNMyriad’s Prequel™ Prenatal Screen Demonstrates High Performance Across All Fetal-Fraction Levels in Women Undergoing Noninvasive Prenatal Screening
SALT LAKE CITY, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced that a new study of the Prequel™ Prenatal Screen was published online in the journal
Read more →MYGNMyriad Genetics, Inc. (MYGN), Overstock.com, Inc. (OSTK) & Waitr Holdings Inc. (WTRH) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action
NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below
Read more →MYGNMyriad Genetics to Present at the 2019 Stephens Nashville Investment Conference
SALT LAKE CITY, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that Bryan Riggsbee, CFO, is scheduled to present at the Stephens Nashville Investment Conference at 12:15 p.m. EST on
Read more →MYGNRon RogersInvestor Contact:Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal First-Quarter 2020 Financial Results • Total
Media Contact:Ron RogersInvestor Contact:Scott Gleason (801) 584-3065(801) 584-1143 rrogers@myriad.comsgleason@myriad.com Myriad Genetics Reports Fiscal First-Quarter 2020 Financial Results SALT LAKE CITY, Nov.4, 2019 - Myriad Genetics, Inc. (NASDAQ: MYGN, "Myriad" or the "Co
Read more →MYGNMyriad Genetics Reports Fiscal First-Quarter 2020 Financial Results
Total First-Quarter Revenues of $186.3 Million Excluding Out-of-Period Adjustments Revenue Would Have Been $197.5 Million First-Quarter Diluted EPS of ($0.28) and Adjusted EPS of $0.08 SALT LAKE CITY, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myri
Read more →MYGNMyriad Genetics, Inc. (MYGN), Overstock.com, Inc. (OSTK) & Waitr Holdings Inc. (WTRH) - Bronstein, Gewirtz & Grossman, LLC Alerts Investors of Class Action
NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below
Read more →MYGNMyriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting
SALT LAKE CITY, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that three studies on Vectra® will be featured at the 2019 American College of Rheumatology (ACR) Annual Meeting being
Read more →MYGNMyriad to Announce Fiscal First-Quarter 2020 Financial Results on November 4, 2019
SALT LAKE CITY, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal first-quarter 2020 sales and earnings conference call with investors and analysts at 4:30 p.m.
Read more →MYGNMyriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting
SALT LAKE CITY, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that it will present results from seven studies at the 2019 National Society of Genetic Counselors (NSGC) annual meeti
Read more →MYGNMyriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting
SALT LAKE CITY, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that it will present results from five studies at the 2019 American Society of Human Genetics (ASHG) annual meeting be
Read more →MYGNRon Rogers Investor Contact:Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Expands Board of Directors with Two Additional Members Colleen F.
Media Contact: Ron RogersInvestor Contact:Scott Gleason (801) 584-3065(801) 584-1143 rrogers@myriad.comsgleason@myriad.com Myriad Genetics Expands Board of Directors with Two Additional Members Colleen F. Reitan and Lee N. Newcomer, M.D., Elected to Myriad's Board of Director
Read more →MYGNMyriad Genetics Expands Board of Directors with Two Additional Members
SALT LAKE CITY, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced the election of Colleen F. Reitan, age 60, and Lee N. Newcomer, M.D., age 67, to it
Read more →MYGNMyriad Announces Research Collaboration with University of Leeds
SALT LAKE CITY, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced it will collaborate with the Leeds Centre for Personalised Medicine and Health to evaluate the clinical utility of th
Read more →MYGNMyriad Genetics to Present at the 2019 Morgan Stanley Global Healthcare Conference
SALT LAKE CITY, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the Morgan Stanley Global Healthcare Conference
Read more →MYGNMyriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention
SALT LAKE CITY, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, today announced its support of the U.S. Preventive Services Task Force (USPSTF) recommendation on expanded hereditary cancer ri
Read more →MYGNMyriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2019 Financial Results
Total Fourth-Quarter Revenues of $215.4 Million Fourth-Quarter Diluted EPS of ($0.06) and Adjusted EPS of $0.41 SALT LAKE CITY, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precis
Read more →MYGNRon RogersInvestor Contact:Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2019 Financial Results
Media Contact:Ron RogersInvestor Contact:Scott Gleason (801) 584-3065(801) 584-1143 rrogers@myriad.comsgleason@myriad.com Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2019 Financial Results SALT LAKE CITY, Aug. 13, 2019 - Myriad Genetics, Inc. (NASDAQ: MYGN, "M
Read more →MYGNMyriad Will Seek FDA Approval of BRACAnalysis CDx As a Companion Diagnostic for Lynparza (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer
SALT LAKE CITY, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, today announced that the AstraZeneca/Merck Phase III PROfound study (NCT02987543) demonstrated that men with metastatic castrat
Read more →MYGNMyriad to Announce Fiscal Fourth-Quarter 2019 Financial Results on August 13, 2019
SALT LAKE CITY, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will hold its fiscal fourth-quarter 2019 sales and earnings conference call with investors and analysts at 4:30 p.m. EDT on Tuesday,
Read more →MYGNMyriad Announces Publication of First Comprehensive Economic Study Demonstrating Cost Effectiveness of EndoPredict for Breast Cancer
SALT LAKE CITY, June 25, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that The Pharmacogenomics Journal published the results of the first comprehensive cost-effectiveness analysis of the EndoPredict® tes
Read more →MYGNMyriad Genetics Receives Second Insurance Reimbursement Decision for its BRACAnalysis Diagnostic System in Japan
SALT LAKE CITY, June 19, 2019 (GLOBE NEWSWIRE) -- Myriad Genetic Laboratories, Inc., a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced the Japanese Ministry of Health, Labour, and Welfare has granted a second manufacturing and marketing approval f
Read more →MYGNMyriad Genetics to Present at the 2019 Goldman Sachs Global Healthcare Conference
SALT LAKE CITY, June 05, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the Goldman Sachs Global Healthcare Conference a
Read more →MYGNMyriad Genetics Announces New Results from Two Large Studies of Its myRisk Hereditary Cancer Test at American Society of Clinical Oncology
SALT LAKE CITY, June 03, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that results from two studies of the myRisk® Hereditary Cancer test will be featured today in presentations at the
Read more →MYGNMyriad Genetics to Present Multiple Studies at the 2019 American Society of Clinical Oncology Annual Meeting
SALT LAKE CITY, May 14, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will present results from multiple studies at the 2019 American Society of Clinical Oncology (ASCO) annual meeting to be held May 31 t
Read more →MYGNMyriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results
Total Third-Quarter Revenues of $216.6 Million, Up 18 Percent Third-Quarter Diluted EPS of $0.09 and Adjusted EPS of $0.46, Up 35 Percent SALT LAKE CITY, May 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in persona
Read more →MYGNRon RogersInvestor Contact:Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results • Total
Media Contact:Ron RogersInvestor Contact:Scott Gleason (801) 584-3065(801) 584-1143 rrogers@myriad.comsgleason@myriad.com Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results SALT LAKE CITY, May 7, 2019 - Myriad Genetics, Inc. (NASDAQ: MYGN, "Myriad" or the "Co
Read more →MYGNMyriad Announces Coverage Decision by Kroger Prescription Plans for GeneSight
SALT LAKE CITY, May 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a worldwide leader in personalized medicine, today announced that Kroger Prescription Plans, will provide GeneSight® as an benefit option for Kroger Prescription Plan employer group clients. A
Read more →MYGNMyriad to Announce Fiscal Third-Quarter 2019 Financial Results on May 7, 2019
SALT LAKE CITY, April 23, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will hold its fiscal third-quarter 2019 sales and earnings conference call with investors and analysts at 4:30 p.m. EDT on Tuesday,
Read more →MYGNMyriad to Present Multiple Women’s Health Studies at the 2019 American College of Obstetricians and Gynecologists Annual Meeting
SALT LAKE CITY, April 23, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that its Myriad Women’s Health business unit will present data from several studies at the 2019 Annual Clinical and Scientific meeting of Th
Read more →MYGNMyriad Genetics Named to Forbes 2019 List of America's Best Midsize Employers and the Women Tech Council’s 2019 Shatter List
SALT LAKE CITY, April 17, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced today announced that the company was named to Forbes 2019 list of America's Best Midsize Employers for the third year in a row. And l
Read more →MYGNMyriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice HRD CDx Test
SALT LAKE CITY, April 09, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it has submitted the first module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its my
Read more →MYGNMyriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership
SALT LAKE CITY, April 04, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it has expanded its companion diagnostic collaboration with AstraZeneca and Merck (known as MSD outside the US and Canada). Under the
Read more →MYGNMyriad Women’s Health to Highlight New Studies Demonstrating the Superior Clinical Performance of the Foresight and Prequel™ Prenatal Tests
SALT LAKE CITY, April 02, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that its Myriad Women’s Health business unit will present results from two important studies at the 2019 American College of Medical
Read more →MYGNMyriad to Present 18 Studies at the 2019 Annual Clinical Genetics Meeting
SALT LAKE CITY, March 21, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that its Myriad Women’s Health business unit will present data from 18 studies at the 2019 Annual Clinical Genetics Meeting (ACMG) being hel
Read more →MYGNRon RogersInvestor Contact:Scott Gleason (801) 584-3065(801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad's myPath Melanoma Test Receives Medicare Coverage Test Will Help Patients Re
Media Contact:Ron RogersInvestor Contact:Scott Gleason (801) 584-3065(801) 584-1143 rrogers@myriad.comsgleason@myriad.com Myriad's myPath Melanoma Test Receives Medicare Coverage Test Will Help Patients Receive a Definitive Diagnosis for a Suspicious Skin Lesion Biopsy SALT
Read more →MYGNMyriad’s myPath Melanoma Test Receives Medicare Coverage
SALT LAKE CITY, March 14, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the Medicare Administrative Contractor Palmetto GBA MolDx has issued a final local coverage determination (LCD) for the myPath®
Read more →MYGNMyriad Announces Publication of Expanded Carrier Screen Study in Genetics in Medicine
SALT LAKE CITY, March 06, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that its Myriad Women’s Health business unit has published the first data-driven evaluation of commonly stated recommendations of pan
Read more →MYGNMyriad’s BRACAnalysis CDx Test Successfully Identified Patients with Metastatic Pancreatic Cancer Who Benefitted from Treatment with Olaparib
Myriad Will Seek FDA Approval of BRACAnalysis CDx as a Companion Diagnostic for Olaparib in this Patient Population SALT LAKE CITY, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that the Phase III POLO
Read more →MYGNMyriad Applauds the American Society of Breast Surgeons New Guidelines Recommending Genetic Testing for All People with Breast Cancer
SALT LAKE CITY, Feb. 15, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced its support of the American Society of Breast Surgeons (ASBrS) new guidelines that recommend all people diagnosed with breast cancer u
Read more →MYGNMyriad Genetics to Present at Multiple Upcoming Healthcare Conferences
SALT LAKE CITY, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that it will be presenting at multiple upcoming healthcare conferences. R. Bryan Riggsbee, chief financial officer at My
Read more →MYGNMyriad Announces Prequel™ Prenatal Screen with Expanded Aneuploidy Analysis for all 23 Chromosome Pairs
SALT LAKE CITY, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that its Myriad Women’s Health subsidiary has enhanced the PrequelTM Prenatal Screen to include all 23 chromosome pairs rather than ju
Read more →MYGNMyriad to Present New Data for Its Expanded Carrier and Noninvasive Prenatal Screens at the 2019 Society for Maternal-Fetal Medicine Annual Meeting
SALT LAKE CITY, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and personalized medicine, today announced that its Myriad Women’s Health business unit will present new data from eight studies at the 2019 Society fo
Read more →MYGNRon RogersInvestor Contact:Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Second-Quarter 2019 Financial Results • Tota
Media Contact:Ron RogersInvestor Contact:Scott Gleason (801) 584-3065(801) 584-1143 rrogers@myriad.comsgleason@myriad.com Myriad Genetics Reports Fiscal Second-Quarter 2019 Financial Results SALT LAKE CITY, Feb. 5, 2019 - Myriad Genetics, Inc. (NASDAQ: MYGN, "Myriad" or the "
Read more →MYGNMyriad Genetics Reports Fiscal Second-Quarter 2019 Financial Results
Total Second-Quarter Revenues of $216.8 Million, Up 15 Percent Second-Quarter Diluted EPS of $0.03 and Adjusted EPS of $0.38, Up 6 Percent SALT LAKE CITY, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molec
Read more →MYGNMyriad to Announce Fiscal Second-Quarter 2019 Financial Results on February 5, 2019
SALT LAKE CITY, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will hold its fiscal second-quarter 2019 sales and earnings conference call with investors and analysts at
Read more →MYGNForward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statem
Review of GeneSight Supporting Clinical Data January 4, 2019 Exhibit 99.1 Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Compan
Read more →MYGNMyriad Genetics to Present at the 37th Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 37th annual J.P. Morgan Healthcare Conference at 4:00 p.m. PT (7:00 pm ET) on January 7,
Read more →MYGNMyriad Announces Publication of Vectra Study in Journal Rheumatology
SALT LAKE CITY, Dec. 26, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced the results from a large commercial cohort and several clinical studies on development of the adjusted Vectra® score that were publish
Read more →MYGNMyriad Announces Important New Data for Its EndoPredict Breast Cancer Test Will Be Presented at the 2018 San Antonio Breast Cancer Symposium
SALT LAKE CITY, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that new data on its EndoPredict® test will be presented by academic collaborators at the San Antonio Breast Cancer Symposium. The ke
Read more →MYGNMyriad Validates Polygenic Score to Predict Breast Cancer Risk in Women of Hispanic Ancestry Who Test Negative for Hereditary Cancer Mutations
SALT LAKE CITY, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced results from an important study to validate the polygenic component of a forthcoming riskScore™ test for Hispanic w
Read more →MYGNRon Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Announces $50 Million Accelerated Share Repurchase Program
Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Announces $50 Million Accelerated Share Repurchase Program SALT LAKE CITY, Nov. 19, 2018 Myriad Genetics, Inc. (NASDAQ: MYGN)
Read more →MYGNMyriad Announces $50 Million Accelerated Share Repurchase Program
SALT LAKE CITY, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the company has entered into an accelerated share repurchase (“ASR”) agreement with Bank of America, N.A. under which the company
Read more →MYGNMyriad to Present New Data from Its Industry-Leading Portfolio of Genetic Tests for Breast Cancer at the 2018 San Antonio Breast Cancer Symposium
SALT LAKE CITY, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that 10 studies will be featured at the San Antonio Breast Cancer Symposium (SABCS) being held Dec. 4-8, 2018 in San Antonio, Tx. Dat
Read more →MYGNRon RogersInvestor Contact:Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal First-Quarter 2019 Financial Results • Total
Media Contact:Ron RogersInvestor Contact:Scott Gleason (801) 584-3065(801) 584-1143 rrogers@myriad.comsgleason@myriad.com Myriad Genetics Reports Fiscal First-Quarter 2019 Financial Results SALT LAKE CITY, Nov. 6, 2018 - Myriad Genetics, Inc. (NASDAQ: MYGN, "Myriad" or the "C
Read more →MYGNMyriad Genetics Reports Fiscal First-Quarter 2019 Financial Results
Total First-Quarter Revenues of $202.3 Million, Up 13 Percent First-Quarter Diluted EPS of ($0.01) and Adjusted EPS of $0.43, Up 48 Percent Revised Full-Year Revenue Guidance to $855 to $865 Million; Maintained Diluted EPS Guidance of $0.40 to $0.45 and Adjusted EPS Guidance of
Read more →MYGNMyriad Receives the Prestigious 2018 Utah Top Workplaces Award
SALT LAKE CITY, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced its recognition as a 2018 recipient of the Utah Top Workplaces Award. This prestigious award is based on employee-
Read more →MYGNMyriad Presents Two New Studies at the Western Section of the American Urological Association
New Data Demonstrate the Clinical Performance of the Prolaris® and myRisk® Hereditary Cancer Genetic Tests in Men with Prostate Cancer SALT LAKE CITY, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announce
Read more →MYGNMyriad Genetics to Present at the Stephens New York Investment Conference
SALT LAKE CITY, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that R. Bryan Riggsbee, CFO, is scheduled to present at the Stephens New York Investor Conference at 9:00 a.m. EDT
Read more →MYGNMyriad to Announce Fiscal First-Quarter 2019 Financial Results on November 6, 2018
SALT LAKE CITY, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will hold its fiscal first-quarter 2018 sales and earnings conference call with investors and analysts at 4
Read more →MYGNMyriad Announces Publication of Foresight™ Carrier Screen Clinical Utility Study in Genetics in Medicine
Large Study Demonstrates that Expanded Carrier Screening Informs Couples’ Reproductive Choices and Pregnancy Management SALT LAKE CITY, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that results
Read more →MYGNMyriad’s BRACAnalysis CDx Test Identifies Patients with Newly Diagnosed Advanced Ovarian Cancer Who May Benefit from Maintenance Treatment with Lynparza
SALT LAKE CITY, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that its BRACAnalysis CDx® test accurately identified patients with newly-diagnosed, advanced-stage, BRCA-mutated (
Read more →MYGNMyriad Receives FDA Approval of BRACAnalysis CDx as Companion Diagnostic for Pfizer’s TALZENNA (talazoparib)
SALT LAKE CITY, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® to be used by healthcare profession
Read more →MYGNMyriad Announces New Laboratory Agreement with Pfizer
SALT LAKE CITY, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, announced today that it has signed a new laboratory services agreement with Pfizer Inc. Under the terms of the agreement, Myriad will provide BRACAna
Read more →MYGNMyriad and Pfizer Build Upon a Previously Announced Companion Diagnostic Agreement
SALT LAKE CITY, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that it has signed a commercialization plan with Pfizer Inc. The plan is under an existing companion diagnostic agreement, in which M
Read more →MYGNMyriad Genetics Announces Four Presentations at the 2018 American College of Rheumatology Annual Meeting
SALT LAKE CITY, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that four studies on Vectra® will be featured at the American College of Rheumatology (ACR) meeting being held Oct. 19-24, 2018 in Chi
Read more →MYGNMyriad Announces New GeneSight Study Published in Personalized Medicine
SALT LAKE CITY, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a worldwide leader in personalized medicine, today announced that a health economic study to evaluate the financial impact of the GeneSight® combinatorial pharmacogenomic (CPGx) test on major
Read more →MYGNMyriad Announces Publication of Variant Reclassification Study in the Journal of the American Medical Association
SALT LAKE CITY, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a worldwide leader in personalized medicine, today announced that results from a landmark study of variant classifications following hereditary cancer genetic testing were published in the Jo
Read more →MYGNMyriad Genetics to Present at the 2018 Morgan Stanley Global Healthcare Conference
SALT LAKE CITY, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the Morgan Stanley Global Healthcare Conference
Read more →MYGNRon RogersInvestor Contact:Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2018 Financial Results
Media Contact:Ron RogersInvestor Contact:Scott Gleason (801) 584-3065(801) 584-1143 rrogers@myriad.comsgleason@myriad.com Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2018 Financial Results SALT LAKE CITY, Aug. 21, 2018 - Myriad Genetics, Inc. (NASDAQ: MYGN, "M
Read more →MYGNMyriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2018 Financial Results
Total Fourth-Quarter Revenues of $200.9 Million Fourth-Quarter Diluted EPS of $0.18 and Adjusted EPS of $0.38, Up 31 Percent SALT LAKE CITY, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnosti
Read more →MYGNMyriad Reschedules Release of Fiscal Fourth-Quarter 2018 Financial Results
SALT LAKE CITY, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it is moving its fiscal fourth-quarter 2018 sales and earnings conference call with investors and analysts to
Read more →MYGNMyriad to Announce Fiscal Fourth-Quarter 2018 Financial Results on August 14, 2018
SALT LAKE CITY, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will hold its fiscal fourth-quarter 2018 sales and earnings conference call with investors and analysts at
Read more →MYGNRon Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Announces Closing of Counsyl Acquisition Transformational Acquisition Enh
Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Announces Closing of Counsyl Acquisition Transformational Acquisition Enhances Myriad s Leadership Position in Women s Health
Read more →MYGNMyriad Announces Closing of Counsyl Acquisition
SALT LAKE CITY, July 31, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, announced today that it has completed the acquisition of Counsyl, Inc. a leader in reproductive genetic testing based in South San Francisco, Calif.
Read more →MYGNMyriad Announces Publication of IMPACT Study in Journal of Psychiatric Research
SALT LAKE CITY, July 25, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, today announced that results from the Individualized Medicine: Pharmacogenetics Assessment and Clinical Treatment (IMPACT) study were published in t
Read more →MYGNMyriad Announces Coverage Decision by Kroger Prescription Plans for Vectra DA
SALT LAKE CITY, July 18, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, today announced that Kroger Prescription Plans, will provide Vectra® DA as a benefit option for Kroger Prescription Plan employer group clients. “
Read more →MYGNMyriad’s BRACAnalysis CDx Supplementary PMA Accepted by FDA for Review as a Companion Diagnostic for Talazoparib in Metastatic Breast Cancer
SALT LAKE CITY, June 18, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplementary premarket approval (sPMA) applicatio
Read more →MYGNMYRIAD GENETICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Myriad Genetics, Inc. - MYGN
NEW ORLEANS, June 08, 2018 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 19, 2018 to file lead plaintiff applications in a securities class action lawsuit against Myriad Genetics, Inc. (NasdaqGS:MYGN), if they
Read more →MYGNMYRIAD GENETICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Myriad Genetics, Inc. - MYGN
NEW ORLEANS, June 01, 2018 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 19, 2018 to file lead plaintiff applications in a securities class action lawsuit
Read more →MYGNMyriad Genetics Presents Second Pivotal Validation Study for riskScore™ Test at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
SALT LAKE CITY, June 01, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that results from a second major clinical validation study of its polygenic riskScore™ test will be featured in an o
Read more →MYGNMyriad Genetics to Present at Two Upcoming Investor Conferences
SALT LAKE CITY, May 31, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced that it will be presenting at two upcoming investor conferences. On June 12, 2018, Mark C. Capone, president and CEO, will
Read more →MYGNMyriad Genetics Signs Definitive Agreement to Acquire Counsyl, Inc.
SALT LAKE CITY, May 28, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has signed a definitive agreement to acquire Counsyl, a pioneer in expanded carrier screening and non-invasiv
Read more →MYGNRon Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Signs Definitive Agreement to Acquire Counsyl, Inc. Creates Prem
Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Signs Definitive Agreement to Acquire Counsyl, Inc. Creates Premier Women s Health Business Unit in High Growth Genetic Te
Read more →MYGNMyriad Announces Seven New Payer Coverage Decisions for Prolaris
SALT LAKE CITY, May 23, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, today announced seven new commercial coverage decisions for Prolaris®, the company’s market leading prognostic test for patients with prostate cancer
Read more →MYGNMyriad Genetics to Present Eight Studies at the 2018 American Society of Clinical Oncology Annual Meeting
SALT LAKE CITY, May 15, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present results from eight studies at the 2018 American Society of Clinical Oncology (ASCO) annual meeti
Read more →MYGNMYRIAD GENETICS, INC. INVESTOR UPDATE: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of Utah on behalf of shareholders of Myriad Genetics, Inc.
NEW YORK, May 10, 2018 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Utah on behalf of investors that purchased or otherwise acquired securities of Myria
Read more →MYGNRon Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Third-Quarter 2018 Financial Results • Tot
News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Third-Quarter 2018 Financial Results SALT LAKE CITY, May 8, 2018 - Myriad Genetics, I
Read more →MYGNMyriad Genetics Reports Fiscal Third-Quarter 2018 Financial Results
Total Revenues of $193.5 Million GAAP Diluted EPS of $0.16 and Adjusted EPS of $0.31 Up 15 Percent Company Raises Both Revenue and Adjusted EPS Guidance for Fiscal Year 2018 Company Announces Commercial Coverage Decision for GeneSight® SALT LAKE CITY, May 08, 2018 (GLOBE NEWS
Read more →MYGNMyriad Genetics to Present Five Studies at the Seventh International Symposium on Hereditary Breast and Ovarian Cancer
SALT LAKE CITY, May 04, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present results from five studies at the Seventh International Symposium on Hereditary Breast and Ovaria
Read more →MYGNMyriad Lawsuit: Bernstein Liebhard LLP Reminds Investors of Important Deadline in Class Action Against Myriad Genetics, Inc. - MYGN
NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP reminds investors of the important June 19, 2018 lead plaintiff deadline in the class action lawsuit against Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”). The lawsuit seeks to recover damages on behal
Read more →MYGNMyriad Genetics Named to Forbes 2018 List of America’s Best Midsize Employers
SALT LAKE CITY, May 02, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the company was named to Forbes 2018 list of America’s Best Midsize Employers. “We are excited and honored to b
Read more →MYGNMYRIAD GENETICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of Utah on behalf of shareholders of Myriad Genetics, Inc.
NEW YORK, April 25, 2018 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Utah on behalf of investors that purchased or otherwise acquired securities of Myria
Read more →MYGNMyriad Announces Launch of "Go Green" Sustainability Initiative In Support of Earth Day
SALT LAKE CITY, April 19, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, today announced the launch of its new Go Green sustainability initiative. As part of the initiative, Myriad is initially focused on promoting incre
Read more →MYGNMyriad to Announce Fiscal Third-Quarter 2018 Financial Results on May 8, 2018
SALT LAKE CITY, April 17, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will hold its fiscal third-quarter 2018 sales and earnings conference call with investors and analysts at 7
Read more →MYGNMyriad Receives Pre-Market Approval for its BRACAnalysis Diagnostic System in Japan
SALT LAKE CITY, April 02, 2018 (GLOBE NEWSWIRE) -- Myriad Genetic Laboratories, Inc., a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), announced today that the Japanese Ministry of Health, Labour, and Welfare has granted manufacturing and marketing approval for M
Read more →MYGNMyriad Applauds AACU Position Statement on Molecular Testing for Risk Stratification in Prostate Cancer
SALT LAKE CITY, March 06, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, announced today that the American Association of Clinical Urologists (AACU) have issued a position statement supporting molecular testing for prost
Read more →MYGNMyriad Genetics Demonstrates Strong Commitment to Preventing Hereditary Colon Cancer as Part of National Colorectal Cancer Awareness Month
SALT LAKE CITY, March 01, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, continues to demonstrate an unmatched commitment to hereditary cancer risk assessment and genetic testing during National Colorecta
Read more →MYGNMyriad’s myRisk Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic Mutation
SALT LAKE CITY, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that results from a large 1,162 patient study of the Myriad myRisk® Hereditary Cancer test will be featured during
Read more →MYGNMyriad Genetics Reports Fiscal Second-Quarter 2018 Financial Results
Total Revenues of $194.0 Million GAAP Diluted EPS of $0.45 and Adjusted EPS of $0.31 Up 19 Percent Company Raises Financial Guidance for Fiscal Year 2018 SALT LAKE CITY, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in molecular diagnos
Read more →MYGNRon Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Second-Quarter 2018 Financial Results • To
News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Second-Quarter 2018 Financial Results SALT LAKE CITY, Feb. 6, 2018 - Myriad Genetics,
Read more →MYGNMyriad to Announce Fiscal Second-Quarter 2018 Financial Results on February 6, 2018
SALT LAKE CITY, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal second-quarter 2018 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, February 6, 2018. During the call, Ma
Read more →MYGNMyriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations for Hereditary Prostate Cancer
SALT LAKE CITY, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that the company is applauding a new consensus statement from a team of international experts with screening recomme
Read more →MYGNMyriad Receives FDA Approval of BRACAnalysis CDx as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Metastatic Breast Cancer
SALT LAKE CITY, Jan. 12, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) approved BRACAnalysis CDx® for use as a companion diagnostic by hea
Read more →MYGNMyriad Genetics Announces Expanded Research Collaboration with AstraZeneca
SALT LAKE CITY, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that AstraZeneca will use the Company’s myChoice® HRD Plus in an exploratory analysis to identify women with advance
Read more →MYGNMyriad Genetics to Present at the 36th Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the JP Morgan Annual Healthcare Conference at 2:
Read more →MYGNMyriad’s BRACAnalysis CDx Test Effectively Identified Metastatic Breast Cancer Patients with Improved Outcomes from Pfizer's PARP Inhibitor, Talazoparib
SALT LAKE CITY, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that data from the EMBRACA trial showed Myriad’s BRACAnalysis CDx® test successfully identified patients with metas
Read more →MYGNMyriad Genetics Presents Results From Two Important EndoPredict Studies at the 2017 San Antonio Breast Cancer Symposium
SALT LAKE CITY, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new results from two studies with EndoPredict® are being featured at the 2017 San Antonio Breast Cancer Symposium (S
Read more →MYGNMyriad Genetics Presents Pivotal Validation Study for New riskScore™ Test at the 2017 San Antonio Breast Cancer Symposium
SALT LAKE CITY, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced results from a ground-breaking validation study to better define the risk of breast cancer in women of European ance
Read more →MYGNMyriad Collaborates with Department of Veterans Affairs in Large Trial Evaluating the GeneSight Test to Improve Mental Health Outcomes for Veterans
SALT LAKE CITY, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that the Department of Veterans Affairs (VA) recently initiated a national, multi-center trial to evaluate the company's GeneSight®
Read more →MYGNMyriad Genetics to Present at the 2017 Jefferies London Healthcare Conference
SALT LAKE CITY, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the Jefferies Healthcare Conference at 8:40 a.m.
Read more →MYGNRon RogersInvestor Contact:Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal First-Quarter 2018 Financial Results • Total
Media Contact:Ron RogersInvestor Contact:Scott Gleason (801) 584-3065(801) 584-1143 rrogers@myriad.comsgleason@myriad.com Myriad Genetics Reports Fiscal First-Quarter 2018 Financial Results SALT LAKE CITY, Nov. 7, 2017 - Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader i
Read more →MYGNMyriad Genetics Reports Fiscal First-Quarter 2018 Financial Results
Total Revenues of $190.2 Million Up 7 Percent GAAP Diluted EPS of $1.15 and Adjusted EPS of $0.26 Up 13 Percent GeneSight® Demonstrates Statistical Significance for Response and Remission in Prospective Study SALT LAKE CITY, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, I
Read more →MYGNMyriad Genetics Collaborates with CareFirst BlueCross BlueShield on Coverage with Evidence Development (CED) Study for the Vectra DA Test
BALTIMORE and SALT LAKE CITY, Nov. 06, 2017 (GLOBE NEWSWIRE) -- CareFirst BlueCross BlueShield (CareFirst) and Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in molecular diagnostics and personalized medicine, today announced that they have signed an agreement to collaborat
Read more →MYGNRon RogersInvestor Contact:Scott Gleason (801) 584-3065(801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Announces GeneSight Psychotropic Results from a Large Prospective Trial in P
Media Contact:Ron RogersInvestor Contact:Scott Gleason (801) 584-3065(801) 584-1143 rrogers@myriad.comsgleason@myriad.com Myriad Announces GeneSight Psychotropic Results from a Large Prospective Trial in Patients with Major Depressive Disorder GeneSight Demonstrated Statisti
Read more →MYGNMyriad Announces GeneSight Psychotropic Results from a Large Prospective Trial in Patients with Major Depressive Disorder
SALT LAKE CITY, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced positive results from a double-blind, multi-center, randomized controlled trial assessing the impact of the GeneSight® Psychotropic
Read more →MYGNMyriad to Announce Fiscal First-Quarter 2018 Financial Results on November 7, 2017
SALT LAKE CITY, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced that it will hold its fiscal first-quarter 2018 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, November 7, 2017. During the call, Ma
Read more →MYGNMyriad Submits BRACAnalysis CDx Application for Regulatory Approval in Japan for HER2- Metastatic Breast Cancer
SALT LAKE CITY, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that it has submitted BRACAnalysis® CDx in Japan for review by the Pharmaceutical Medical Devices Agency (PMDA) and
Read more →MYGNMyriad’s BRACAnalysis CDx Supplementary PMA Accepted by FDA for Review as a Companion Diagnostic for Lynparza (olaparib) in Metastatic Breast Cancer
SALT LAKE CITY, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplementary premarket approval (sPMA) applicatio
Read more →MYGNMyriad Genetics Highlights Strong Commitment to Preventing and Fighting Breast Cancer as Part of Breast Cancer Awareness Month
SALT LAKE CITY, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, continues to demonstrate an unmatched commitment to hereditary cancer risk assessment and genetic testing during Breast Cancer Aware
Read more →MYGNMyriad Genetics Announces Positive Data Supporting New riskScore™ Test at the 36th Annual Conference of the National Society of Genetic Counselors
SALT LAKE CITY, Sept. 15, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that two important studies will be featured in podium presentations at the 36th annual conference of the National S
Read more →MYGNMyriad Genetics to Present Three Studies at the 2017 National Society of Genetic Counselors Annual Conference
SALT LAKE CITY, Sept. 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present results from three studies at the National Society of Genetic Counselors (NSGC) Annual Confere
Read more →MYGNMyriad Launches riskScore™ Beginning the Next Epoch in Hereditary Cancer Testing
SALT LAKE CITY, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that it has launched riskScore™, a new clinically validated precision medicine tool to enhance its myRisk® Heredita
Read more →MYGNmygn-ex991_53.pptx.htm 91% 87% Forward Looking Statements 15M Patient Preventive Care Market Some of the information presented here today may contain projections or other forward-looking statements regarding future event
91% 87% Forward Looking Statements 15M Patient Preventive Care Market Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on
Read more →MYGNMyriad Genetics to Present at the 2017 Morgan Stanley Global Healthcare Conference
SALT LAKE CITY, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the Morgan Stanley Global Healthcare Conference a
Read more →MYGNMyriad Genetics to Present at the 2017 Wells Fargo Healthcare Conference
SALT LAKE CITY, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the Wells Fargo Healthcare Conference at 8:50 a.
Read more →MYGNRon Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Fourth-Quarter 2017 and Fiscal Full-Year 2017 Fin
Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Fourth-Quarter 2017 and Fiscal Full-Year 2017 Financial Results SALT LAKE CITY, UTAH, August 8, 2017 - Myriad
Read more →MYGNMyriad Genetics Reports Fiscal Fourth-Quarter 2017 and Fiscal Full-Year 2017 Financial Results
Total Revenues of $200.5 Million Up 8 Percent GAAP Diluted EPS was $0.19 and Adjusted EPS of $0.30 Record Hereditary Cancer Demand and 86 Percent of Revenue Under Long-Term Contract Company Issues Fiscal Year 2018 and Fiscal First-Quarter 2018 Financial Guidance SALT LAKE CIT
Read more →MYGNMyriad to Announce Fiscal Fourth-Quarter 2017 Financial Results on August 8, 2017
SALT LAKE CITY, July 28, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal fourth-quarter 2017 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, August 8, 2017. During the call, Mark
Read more →MYGNMyriad’s BRACAnalysis CDx Test Identified Patients with Metastatic Breast Cancer Who Benefited from Treatment with Olaparib in Phase 3 OlympiAD Study
SALT LAKE CITY, June 04, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that its BRACAnalysis CDx® companion diagnostic test successfully identified BRCA-mutated patients with HER2- metast
Read more →MYGNMyriad Genetics Announces Results from a Large 2,000 Patient Clinical Utility Study of Its myRisk Hereditary Cancer Test at the 53rd Annual Meeting of ASCO
SALT LAKE CITY, June 02, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced results from Study 005, a large 2,000 patient prospective study of the Myriad myRisk® Hereditary Cancer test, which
Read more →MYGNMyriad Announces 17 Additional Health Insurance Plans Covering EndoPredict™
SALT LAKE CITY, June 02, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that multiple new insurance plans have announced positive coverage policies for EndoPredict. Recently, Blue Shield o
Read more →MYGNMyriad Genetics to Present at the 2017 William Blair Growth Stock Conference
SALT LAKE CITY, May 31, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the William Blair Growth Stock Conference at 12:40
Read more →MYGNMyriad Genetics to Present at the 2017 Goldman Sachs Global Healthcare Conference
SALT LAKE CITY, May 30, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the Goldman Sachs Global Healthcare Conference at
Read more →MYGNMyriad Genetics to Present Seven Studies at the 2017 American Society of Clinical Oncology Annual Meeting
SALT LAKE CITY, May 18, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present results from seven studies at the 2017 American Society of Clinical Oncology (ASCO) annual meeti
Read more →MYGNMyriad Genetics’ Prolaris Test Accurately Predicts the 10-Year Risk of Metastases in Men Treated for Prostate Cancer
SALT LAKE CITY, May 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new data demonstrating the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men
Read more →MYGNMyriad Genetics to Present Results from Four Studies at the American Urological Association 2017 Annual Meeting
SALT LAKE CITY, May 05, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present results from four separate prostate cancer studies at the American Urological Association (AUA)
Read more →MYGNMyriad Genetics Reports Fiscal Third-Quarter 2017 Financial Results
Third-Quarter 2017 Total Revenues of $196.9 Million Third-Quarter 2017 GAAP Diluted EPS of $0.06 and Adjusted EPS of $0.27 Company Increases Annual Revenue Guidance, Narrows Adjusted EPS Guidance SALT LAKE CITY, May 02, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MY
Read more →MYGNRon Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Third-Quarter 2017 Financial Results Third-Quarte
News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Third-Quarter 2017 Financial Results SALT LAKE CITY, UTAH, May 2, 2017 Myriad Genet
Read more →MYGNMyriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx Test to Identify Patients with Germline BRCA Mutations for Rubraca (rucaparib) Treatment
SALT LAKE CITY and BOULDER, Colo., April 27, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) and Clovis Oncology, Inc. (NASDAQ:CLVS) today announced a companion diagnostic collaboration to support a post-marketing regulatory commitment related to Clovis’ PARP inhibit
Read more →MYGNMyriad to Announce Fiscal Third-Quarter 2017 Financial Results on May 2, 2017
SALT LAKE CITY, April 18, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal third-quarter 2017 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, May 2, 2017. During the call, Mark C.
Read more →MYGNMyriad Genetics and BeiGene Sign Agreement to Develop Companion Diagnostics for Use with BeiGene’s Novel PARP Inhibitor, BGB-290
SALT LAKE CITY, April 06, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has entered into a companion diagnostic development collaboration with BeiGene, a clinical-stage biopharmac
Read more →MYGNMyriad Genetics Announces Five Scientific Presentations at the 2017 American College of Medical Genetics Annual Clinical Genetics Meeting
SALT LAKE CITY, March 20, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the company will present five scientific posters at the 2017 American College of Medical Genetics Annual Clini
Read more →MYGNMyriad Genetics Launches the EndoPredict Test in the United States for Patients with Breast Cancer
SALT LAKE CITY, March 13, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has launched the EndoPredict® test in the United States for patients with ER+ HER2- early-stage breast canc
Read more →MYGNMyriad’s BRACAnalysis CDx Test Successfully Identified Metastatic Breast Cancer Patients with Improved Outcomes from AstraZeneca's PARP Inhibitor, Olaparib
SALT LAKE CITY, Feb. 17, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new findings from the OlympiAD study that show its BRACAnalysis CDx® test successfully identified patients with HER2
Read more →MYGNMyriad’s Prolaris Test Significantly Improves the Risk Classification for One Third of Men Diagnosed with Localized Prostate Cancer
SALT LAKE CITY, Feb. 17, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in personalized medicine, today announced new data demonstrating the utility of the Prolaris® test to more accurately classify mortality risk and guide the management of newly d
Read more →MYGNRon Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results Second-Quar
News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results CITY, UTAH, Feb. 7, 2017 Myriad Genetics, Inc. (NA
Read more →MYGNMyriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results
Second-Quarter 2017 Total Revenues of $196.5 Million Second-Quarter 2017 GAAP Diluted EPS of $0.09 and Adjusted EPS of $0.26 Company Updates Fiscal Year 2017 Guidance and Issues Fiscal Third-Quarter 2017 Guidance SALT LAKE CITY, Feb. 07, 2017 (GLOBE NEWSWIRE) -- Myriad Genetic
Read more →MYGNMyriad to Announce Fiscal Second-Quarter 2017 Financial Results on February 7, 2017
SALT LAKE CITY, Jan. 24, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal second-quarter 2017 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, February 7, 2017. During the call, Mar
Read more →MYGNMyriad Genetics to Present at the 2017 JP Morgan Healthcare Conference
SALT LAKE CITY, Dec. 28, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 2017 JP Morgan Healthcare Conference at 6:00 p.m. ET on January 9, 2017, at the Westin St.
Read more →MYGNMyriad Genetics Will Present Results from Six Breast Cancer Studies at SABCS
SALT LAKE CITY, Nov. 28, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that the Company will present six breast cancer studies at the 2016 San Antonio Breast Cancer Symposium (SABCS) bein
Read more →MYGNMyriad Will Seek Japanese Regulatory Approval for BRACAnalysis CDx
SALT LAKE CITY, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will submit its BRACAnalysis CDx® test for approval by Japan’s Pharmaceuticals and Medical Devices Agency (P
Read more →MYGNRon Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal First-Quarter 2017 Financial Results Total Revenu
News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal First-Quarter 2017 Financial Results SALT LAKE CITY, UTAH, Nov. 1, 2016 Myriad Genetics,
Read more →MYGNMyriad Genetics Reports Fiscal First-Quarter 2017 Financial Results
Total Revenues of $177.5 Million Adjusted EPS of $0.23 and Diluted EPS of ($0.02) Company Maintains Fiscal Year 2017 Financial Guidance and Issues Fiscal Second-Quarter 2017 Financial Guidance SALT LAKE CITY, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN
Read more →MYGNMyriad’s BRACAnalysis CDx Test Identifies Patients with Ovarian Cancer Who Would Benefit from Second-Line Maintenance Treatment with Olaparib
SALT LAKE CITY, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that its BRACAnalysis CDx® test accurately identified patients who may benefit from treatment with olaparib. The BRA
Read more →MYGNMyriad RBM Announces an Agreement with Sanofi to Measure Predictive Cardiovascular Biomarkers in Patients with Diabetes
SALT LAKE CITY, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that it will work with Sanofi, a global and diversified healthcare leader, to perform a biomarker analysis of blood samples from the Eva
Read more →MYGNMyriad Genetics Inc. Forms Relationship with ION Solutions to Deliver Quality Hereditary Cancer Tests and Services to the Nation’s Largest Network of Community Oncologists
SALT LAKE CITY, Oct. 21, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in personalized medicine, and ION Solutions, a part of AmerisourceBergen, and the largest physician services organization specializing in the support of community oncology, anno
Read more →MYGNMyriad to Announce Fiscal First-Quarter 2017 Financial Results on November 1
SALT LAKE CITY, Oct. 20, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal first-quarter 2017 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, November 1, 2016. During the call, Mark
Read more →MYGNMyriad Genetics Teams Up with Project BioEYES to Advance STEM Education in Utah
SALT LAKE CITY, Oct. 18, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that more than 40 of its employees are volunteering to support Project BioEYES, which is a science, technology, engi
Read more →MYGNMyriad Will Present New Data on Its Variant Classification Program at the ASHG Annual Meeting
SALT LAKE CITY, Oct. 17, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced it will present four new studies at the American Society of Human Genetics Annual Meeting being held Oct. 18-22, 201
Read more →MYGNMyriad’s myChoice HRD Test Identifies Patients with Ovarian Cancer Who May Benefit from Treatment with Niraparib
SALT LAKE CITY, Oct. 08, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that its myChoice® HRD test identified more than double the number of patients who may benefit from treatment with n
Read more →MYGNMyriad Announces Four Poster Presentations at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting
SALT LAKE CITY, Oct. 07, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that four poster presentations will be featured at the 2016 European Society for Medical Oncology (ESMO) annual meet
Read more →MYGNMyriad Appoints Chip Parkinson as EVP for Reimbursement Strategy
SALT LAKE CITY, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Chip Parkinson will join the company in the newly created position of executive vice president (EVP) for Reimbursement Strategy. In this role, Mr. Parkinson will report to
Read more →MYGNMyriad to Present New myRisk Hereditary Cancer Data Further Demonstrating the Benefits of Gene Panel Testing
SALT LAKE CITY, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced it will present three new studies at the National Society of Genetic Counselors Annual Education Conference being h
Read more →MYGNMyriad RBM’s TruCulture and Gene Expression Profiling Characterizes Immune Responses in Landmark Study Led by Institut Pasteur
SALT LAKE CITY, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Myriad RBM, Inc., a wholly owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN) a global leader in personalized medicine, announced today that researchers from the Institut Pasteur have published new landmark research from the
Read more →MYGNRon Rogers Investor Contact: Scott Gleason (908) 285-0248 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Completes Acquisition of Assurex Health
Media Contact: Ron Rogers Investor Contact: Scott Gleason (908) 285-0248 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Completes Acquisition of Assurex Health SALT LAKE CITY, Utah, September 1, 2016 Myriad Genetics, Inc. (NASDAQ: MYGN)
Read more →MYGNMyriad Genetics Completes Acquisition of Assurex Health
SALT LAKE CITY, Sept. 01, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) a global leader in personalized medicine, announced today that it has completed its acquisition of Assurex Health effective August 31, 2016. Assurex Health, which is based in Mason, Ohio, is an
Read more →MYGNMyriad Genetics to Present at the 2016 Morgan Stanley Global Healthcare Conference
SALT LAKE CITY, Aug. 30, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 2016 Morgan Stanley Global Healthcare Conference at 9:20 a.m. ET on September 12, 2016, at
Read more →MYGNRon Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results Total Reven
Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results UTAH, August 9, 2016 Myriad Genetics, Inc. (NASDAQ: MYGN) today
Read more →MYGNMyriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results
Total Revenues of $186.5 Million Adjusted EPS of $0.36 and Diluted EPS of $0.32 Company Issues Fiscal First-Quarter 2017 and Fiscal Year 2017 Financial Guidance SALT LAKE CITY, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced financial resu
Read more →MYGNRon Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Signs Definitive Agreement to Acquire Assurex Health Allows Entr
Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Signs Definitive Agreement to Acquire Assurex Health Allows Entry Into Attractive High-Growth Neuroscience Market S
Read more →MYGNMyriad Genetics Signs Definitive Agreement to Acquire Assurex Health
SALT LAKE CITY, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has signed a definitive agreement to acquire Assurex Health, a global leader in genetic testing for psychotr
Read more →MYGNMyriad to Announce Fiscal Fourth-Quarter 2016 Financial Results on August 9
SALT LAKE CITY, July 26, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal fourth-quarter 2016 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, August 9, 2016. During the call, Mark
Read more →MYGNMyriad Announces Positive Results for an EndoPredict Clinical Study Published in the Journal of the National Cancer Institute
SALT LAKE CITY and COLOGNE, Germany, July 11, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), in collaboration with researchers from the Institute of Cancer Research in London, today announced positive results for EndoPredict®, a second-generation prognostic gene ex
Read more →MYGNRon Rogers (908) 285-0248 rrogers@myriad.com Investor Contact: Scott Gleason (801) 584-1143 sgleason@myriad.com Myriad s myChoice HRD Test Successfully Identifies Patients that Meet Primary Endpoint in TES
Myriad s myChoice HRD Test Successfully Identifies Patients that Meet Primary Endpoint in TESARO s Pivotal Phase 3 Ovarian Cancer Study with Niraparib myChoice HRD Increases Eligible Patients by Approximately Twofold SALT LAKE CITY, Utah, June 29, 2016 Myriad Genetics, Inc. (
Read more →MYGNMyriad’s myChoice HRD Test Successfully Identifies Patients that Meet Primary Endpoint in TESARO’s Pivotal Phase 3 Ovarian Cancer Study with Niraparib
SALT LAKE CITY, June 29, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that its myChoice® HRD test successfully identified an increased number of patients with ovarian cancer who may bene
Read more →MYGNRon Rogers Investor Contact: Scott Gleason (908) 285-0248 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Board Approves $200 Million Increase in Share Repurchase Program
Media Contact: Ron Rogers Investor Contact: Scott Gleason (908) 285-0248 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Board Approves $200 Million Increase in Share Repurchase Program SALT LAKE CITY, Utah, June 7, 2016 Myriad Genetics, Inc. (Nasdaq:
Read more →MYGNMyriad Board Approves $200 Million Increase in Share Repurchase Program
SALT LAKE CITY, June 07, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that its board of directors has approved an additional $200 million authorization for its share repurchase program. As of the end of the third quarter of fiscal year 2016, the Co
Read more →MYGNMyriad myRisk Hereditary Cancer Test Demonstrates the Magnitude of Breast and Ovarian Cancer Risk in Nearly 100,000 Patients
SALT LAKE CITY, June 06, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that two analyses demonstrating the utility of the Myriad myRisk® Hereditary Cancer test will be featured in oral pr
Read more →MYGNMyriad Genetics to Present at the 2016 Goldman Sachs Healthcare Conference
SALT LAKE CITY, June 06, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, is scheduled to present at the Goldman Sachs Healthcare Conference at 10:00 a.m. Pacific on June 8, 2016, at the Terranea Resort in Rancho
Read more →MYGNMyriad Will Present Three New Hereditary Cancer Studies at the ASCO Annual Meeting
SALT LAKE CITY, June 05, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that results from three studies with the Myriad myRisk® Hereditary Cancer test will be featured in podium presentati
Read more →MYGNRon Rogers Investor Contact: Scott Gleason (908) 285-0248 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Acquires Sividon Diagnostics Strengthens Market Leading Oncology Product
Media Contact: Ron Rogers Investor Contact: Scott Gleason (908) 285-0248 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Acquires Sividon Diagnostics Strengthens Market Leading Oncology Product Portfolio with Breast Cancer Prognostic Test EndoPredict
Read more →MYGNMyriad Acquires Sividon Diagnostics
SALT LAKE CITY, May 31, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has acquired Sividon Diagnostics, a leading breast cancer prognostic company, for €35 million upfront with th
Read more →MYGNMyriad Genetics’ Statement on HIPAA Complaint from Four Patients
SALT LAKE CITY, May 19, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced a complaint was filed against the Company with the Department of Health and Human Services on behalf of four individu
Read more →MYGNMyriad to Present New Research at the 2016 ASCO Annual Meeting
SALT LAKE CITY, May 18, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced it will present data from nine clinical studies with three different products at the 2016 American Society of Clinical Oncology annual meeting to be held June 3-7, 2016 in Chicago
Read more →MYGNMyriad Announces Plans to Launch a Web Portal for Patients that Will Provide Access to Test Results, Tools and Health Information
SALT LAKE CITY, May 18, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced plans to launch a new web portal on ms360.myriad.com that will allow patients to access their personal test results a
Read more →MYGNMyriad to Present Three New Studies at the AUA Annual Meeting
SALT LAKE CITY, May 06, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that results from three studies will be featured at the American Urological Association annual meeting, which will ta
Read more →MYGNMyriad Genetics Reports Fiscal Third-Quarter 2016 Financial Results
Total Revenues of $190.5 Million Adjusted EPS of $0.41 and Diluted EPS of $0.44 Company Issues Fiscal Fourth-Quarter and Updates Fiscal Year 2016 Financial Guidance SALT LAKE CITY, May 03, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced financial r
Read more →MYGNRon Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Third-Quarter 2016 Financial Results Total Revenu
News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Third-Quarter 2016 Financial Results CITY, UTAH, May 3, 2016 Myriad Genetics, Inc. (NASDAQ: MY
Read more →MYGNMyriad Genetics to Present at the Bank of America Health Care Conference
SALT LAKE CITY, May 02, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that R. Bryan Riggsbee, chief financial officer, Myriad Genetics, is scheduled to present at the 2016 Bank of America Healthcare Conference at 3:40 p.m. PDT (6:40 pm EDT) on May 1
Read more →MYGNMyriad to Announce Fiscal Third-Quarter 2016 Financial Results on May 3
SALT LAKE CITY, April 22, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal third-quarter 2016 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, May 3. During the call, Mark C. Capone
Read more →MYGNMyriad Genetics Announces Presentations at the 2016 American Association for Cancer Research Annual Meeting
SALT LAKE CITY, April 14, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the company and its scientific collaborators will present two studies at the American Association for Cancer R
Read more →MYGNMyriad myRisk Hereditary Cancer Article in Journal of Clinical Oncology Highlights Importance of Expanding Genetic Testing for Breast Cancer Patients
SALT LAKE CITY, March 30, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, working in collaboration with researchers from the Harvard Medical School, today announced that the Journal of Clinical Oncology ha
Read more →MYGNMyriad Genetics Teams Up with Access Health to Educate the Public about Hereditary Cancer and Genetic Testing
SALT LAKE CITY, March 21, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, and Access Health®, an educational program focused on health and wellness, today announced that they will air an educational progra
Read more →MYGNMyriad Presents Second Pivotal Validation Study for Its myPath Melanoma Test
SALT LAKE CITY, March 15, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced the results from the second pivotal clinical validation study for the myPath® Melanoma test at the 2016 USCAP Annua
Read more →MYGNMyriad Genetics to Present at the Barclays Capital 2016 Global Healthcare Conference
SALT LAKE CITY, March 08, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the Barclays Capital 2016 Globa
Read more →MYGNMyriad Advances Proprietary myVision Variant Classification Tools to a Broader Range of Cancer Risk Genes
SALT LAKE CITY, March 08, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced it will present new data on its proprietary variant classification program that is used to classify variants in can
Read more →MYGNMyriad Genetics Expands Strategic Research Collaboration With AbbVie
SALT LAKE CITY, Feb. 23, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced an expanded companion diagnostics (CDx) research collaboration with AbbVie, Inc. to support the development of AbbVi
Read more →MYGNMyriad Expands Diagnostic Research Collaboration With TESARO and Merck
SALT LAKE CITY, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced a strategic research collaboration with TESARO and Merck, known as MSD outside the U.S. and Canada, to help identify
Read more →MYGNMyriad Genetics Reports Fiscal Second-Quarter 2016 Financial Results
Total Revenues of $193.3 Million Adjusted Diluted EPS of $0.45 and Diluted EPS of $0.41 Company Maintains Fiscal Year 2016 Revenue Guidance, Raises Fiscal Year 2016 Earnings Guidance and Provides Fiscal Third-Quarter 2016 Financial Guidance SALT LAKE CITY, Feb. 02, 2016 (GLOBE
Read more →MYGNRon Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Second-Quarter 2016 Financial Results Total Reven
Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Second-Quarter 2016 Financial Results SALT LAKE CITY, UTAH, February 2, 2016 Myriad Genetics, Inc. (N
Read more →MYGNMyriad to Announce Fiscal Second-Quarter 2016 Financial Results on February 2
SALT LAKE CITY, Jan. 21, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal second-quarter 2016 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, Feb. 2. During the call, Mark C. Capon
Read more →MYGNMyriad Advances Prostate and Renal Cancer Molecular Diagnostic Tests at the 2016 ASCO Genitourinary Cancers Symposium
SALT LAKE CITY, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that new data will be highlighted on prostate and renal cancers at the 2016 ASCO Genitourinary Cancers Symposium, Ja
Read more →MYGNMyriad Genetics to Present at the 34th Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 34th annual J.P. Morgan Healthcare Conference at 9:30 a.m. PST (12:30 pm EST) on January 1
Read more →MYGNMyriad Will Present Eight Studies at the 2015 San Antonio Breast Cancer Symposium
New Data on the myChoice HRD and myRisk Hereditary Cancer Tests Will be Highlighted SALT LAKE CITY, Nov. 17, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that it will present eight post
Read more →MYGNMyriad RBM DiscoveryMAP(R) Technology Identifies Novel Biomarkers That May Predict Increased Risk of Cardiovascular Events in Patients With Diabetes
SALT LAKE CITY, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that its DiscoveryMAP platform successfully identified combinations of 15 protein biomarkers associated with cardiovascular (CV) events
Read more →MYGNRon Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal First-Quarter 2016 Financial Results Total Revenu
Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal First-Quarter 2016 Financial Results SALT LAKE CITY, UTAH, November 3, 2015 Myriad Genetics, Inc. (NA
Read more →MYGNMyriad Genetics Reports Fiscal First-Quarter 2016 Financial Results
Total Revenues of $183.5 Million Adjusted Diluted EPS of $0.41 and Diluted EPS of $0.37 Myriad Completes Conversion of Targeted Physicians to myRisk Hereditary Cancer Company Maintains Fiscal Year 2016 Financial Guidance and provides Fiscal Second-Quarter 2016 Financial Guidan
Read more →MYGNMyriad Genetics to Present at the 2015 Credit Suisse Healthcare Conference
SALT LAKE CITY, Oct. 28, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 24th Annual Credit Suisse Healthcare Conference at 5:00 pm EST on November 11, 2015, at th
Read more →MYGNMyriad Will Highlight New Data on Its myRisk(TM) Hereditary Cancer Test at the National Society of Genetic Counselors Annual Conference
SALT LAKE CITY, Oct. 21, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that new data on its myRisk Hereditary Cancer molecular diagnostic test will be featured in five presentations at th
Read more →MYGNMyriad to Announce Fiscal First Quarter 2016 Financial Results on November 3, 2015
SALT LAKE CITY, Oct. 20, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will issue financial results for the fiscal first-quarter 2016 and provide a business update following the close of market on Tuesday, November 3, 2015. The Company also
Read more →MYGNMyriad to Present New Data on Its myRisk(TM) Hereditary Cancer Test at the CGA-ICC Annual Meeting
SALT LAKE CITY, Oct. 9, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present new data on its myRisk Hereditary Cancer molecular diagnostic test at the 18th Annual Meeting of
Read more →MYGNMyriad Genetics to Highlight New Clinical Outcomes Data on myPath(R) Melanoma at the American Society of Dermatopathology Annual Meeting
SALT LAKE CITY, Oct. 8, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that new clinical outcomes and clinical utility data for myPath Melanoma will be featured at the American Society of
Read more →MYGNMyriad Genetics and Tufts Health Plan Sign Agreement to Cover Prolaris(R) for Members With Localized Prostate Cancer
SALT LAKE CITY, Oct. 7, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris for members diagnosed with localized prostate cancer. Prol
Read more →MYGNMyriad to Present Seven Studies at the ASHG Annual Meeting
SALT LAKE CITY, Oct. 5, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that there will be seven poster presentations featured at American Society for Human Genetics (ASHG) meeting being he
Read more →MYGNMyriad Appoints Jan Schluchter as Chief Commercial Officer for Europe
SALT LAKE CITY and ZURICH, Switzerland, Oct. 1, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in the personalized medicine industry with innovative, high-quality molecular diagnostics, today announced that Jan Schl chter, Ph.D., has joined the Company as
Read more →MYGNMyriad Genetics Presents New Data on Its Companion Diagnostic and Prostate Cancer Tests at the European Society for Medical Oncology Annual Meeting
SALT LAKE CITY, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced three poster presentations that will be featured at the 40th European Society for Medical Oncology (ESMO) meeting b
Read more →MYGNCopyright 2015 Myriad Genetics, Inc., all rights reserved. www.Myriad.com. Forward Looking Statements 2 Some of the information presented here today may contain projections or other forward looking statements regarding f
These statements are based on management s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specificall
Read more →MYGNMyriad Genetics to Present at the 2015 Morgan Stanley Healthcare Conference
SALT LAKE CITY, Sept. 14, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the Morgan Stanley Healthcare Conference at 9:20 a.m. EDT on September 18, 2015, at the Grand
Read more →MYGNMyriad Genetics, Inc. (Nasdaq: MYGN) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, Sept. 11, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN), a leader in the personalized medicine industry with innovative, high-quality molecular diagnostics, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Mark C. Capone, Pres
Read more →MYGNMyriad Adds to Scientific Evidence for the myPlan(R) Lung Cancer Prognostic Test
SALT LAKE CITY, Sept. 9, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today presented two posters on its myPlan Lung Cancer prognostic test at the International Association for the Study of Lung Cancer (IASLC) 16TH World Conference on Lung Cancer being held in Den
Read more →MYGNMyriad Genetics to Host 2015 Investor Day in New York City
SALT LAKE CITY, Sept. 2, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in the personalized medicine industry with innovative, high-quality molecular diagnostics, today announced that it will host an Investor Day in New York City on Sept. 14, 2015. At the
Read more →MYGNMyriad Receives Favorable Medicare Final Coverage Decision for the Prolaris(R) Test
SALT LAKE CITY, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Noridian, the Medicare Administrative Contractor (MAC) for Myriad, has issued a final local coverage determination (LCD) for Prolaris , Myriad's pioneering prognostic test f
Read more →MYGNMyriad Genetics Reports Fiscal Fourth-Quarter and Full Year 2015 Financial Results
Total Revenues of $189.9 Million Adjusted Diluted EPS of $0.41 and Diluted EPS of $0.26 myRisk Hereditary Cancer Panel Ended Fourth Quarter at 72 Percent Conversion Company Provides Fiscal Year 2016 and Fiscal First-Quarter 2016 Financial Guidance SALT LAKE CITY, Aug. 11, 201
Read more →MYGNRon Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Fourth-Quarter and Full Year 2015 Financial Resul
News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Fourth-Quarter and Full Year 2015 Financial Results UTAH, August 11, 2015 Myriad Genetics,
Read more →MYGNMyriad to Announce Fiscal Fourth Quarter 2015 Financial Results on August 11, 2015
SALT LAKE CITY, July 29, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will issue financial results for the fiscal fourth quarter and full year 2015 and provide a business update following the close of market on Tuesday, August 11, 2015. Th
Read more →MYGNMyriad Presents New myRisk(TM) Hereditary Cancer Data at 2015 ASCO Annual Meeting
SALT LAKE CITY, May 29, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will highlight several new clinical studies on its myRisk Hereditary Cancer molecular diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being hel
Read more →MYGNMyriad Significantly Advances the myChoice(R) HRD(TM) Companion Diagnostic Test
SALT LAKE CITY, May 29, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill. Myriad's myChoice
Read more →MYGNMyriad Genetics to Present at the 2015 Goldman Sachs Healthcare Conference
SALT LAKE CITY, May 28, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, president of Myriad Genetics Laboratories, is scheduled to present at the Goldman Sachs Healthcare Conference at 10:40 a.m. Pacific on June 9, 2015, at the Terra
Read more →MYGNMyriad Validates Active Surveillance Threshold With Prolaris(R) for Men With Prostate Cancer
SALT LAKE CITY, May 15, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented clinical data for its Prolaris test at the 2015 American Urological Association (AUA) Annual Meeting being held May 15 to 19 in New Orleans, La. The results highlighted and unders
Read more →MYGNMyriad Showcases Its Pioneering Research at the 2015 ASCO Annual Meeting
SALT LAKE CITY, May 13, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present data from 19 clinical studies at the 2015 American Society of Clinical Oncology annual meeting to be held May 29 to June 2, 2015 in Chicago, Ill. Key podium presen
Read more →MYGNMyriad to Present New Clinical Data on Prolaris(R) at the AUA 2015 Annual Meeting
SALT LAKE CITY, May 7, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present three studies that demonstrate the value of the Prolaris test for physicians and their patients at the 2015 American Urological Association (AUA) Annual Meeting bei
Read more →MYGNRon Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Third-Quarter 2015 Financial Results Total Revenu
Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Genetics Reports Fiscal Third-Quarter 2015 Financial Results SALT LAKE CITY, UTAH, May 5, 2015 Myriad Genetics, Inc. (NASDAQ
Read more →MYGNMyriad Genetics Reports Fiscal Third-Quarter 2015 Financial Results
Total Revenue of $180.0 Million Adjusted Diluted EPS of $0.40 and Diluted EPS of $0.29 myRisk Hereditary Cancer Panel Ended Third Quarter at 58 Percent Conversion Myriad Acquires MVZ Clinic to Facilitate Reimbursement in Germany Company Provides Fiscal Fourth-Quarter 2015 Fin
Read more →MYGNMyriad to Announce Fiscal Third Quarter 2015 Financial Results on May 5, 2015
SALT LAKE CITY, April 22, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the fiscal third quarter 2015 and provide a business update following the close of market on Tuesday, May 5, 2015. The Company also wil
Read more →MYGNMyriad and AstraZeneca Expand Research Collaboration on Lynparza
SALT LAKE CITY, April 1, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the expansion of its companion diagnostic collaboration with AstraZeneca. Under the terms of the expanded agreement, Myriad's BRACAnalysis CDx test will be used to prospectively
Read more →MYGNMyriad Announces Prolaris(R) Test Biopsy Results From EMPATHY-P Study at European Association of Urology Annual Meeting
SALT LAKE CITY and ZURICH, Switzerland, March 20, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30th Annual Congre
Read more →MYGNMyriad and BioMarin Expand Collaboration to Evaluate myChoice HRD(TM) as a Companion Diagnostic for Talazoparib
SALT LAKE CITY, March 17, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced an expansion of the Company's collaboration with BioMarin Pharmaceutical Inc. Under the expanded collaboration, BioMarin will use Myriad's myChoice HRD companion diagnostic test
Read more →MYGNMyriad RBM Launches New Immunoassay Services Based on the Ultrasensitive Simoa(TM) Platform
SALT LAKE CITY, March 5, 2015 (GLOBE NEWSWIRE) -- Myriad RBM, a wholly owned subsidiary of Myriad Genetics, Inc., (Nasdaq:MYGN) today announced the launch of immunoassay services based on the ultrasensitive Simoa (single molecule array) platform developed by Quanterix. The Simoa
Read more →MYGNMyriad Publishes myPath(TM) Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology
SALT LAKE CITY, March 4, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the Journal of Cutaneous Pathology published data from a pivotal clinical validation study that showed the myPath Melanoma test is highly effective at differentiating benign skin
Read more →MYGNMyriad Genetics to Present at the Barclays Global Healthcare Conference
SALT LAKE CITY, March 2, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, president of Myriad Genetic Laboratories, is scheduled to present at the Barclays Global Healthcare Conference at 11:15 a.m. Eastern on March 11, 2015, at Loews
Read more →MYGNRon Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Board Approves $200 Million Increase in Share Repurchase Program
Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Board Approves $200 Million Increase in Share Repurchase Program SALT LAKE CITY, Utah, Feb. 24, 2015 Myriad Genetics, Inc. (N
Read more →MYGNMyriad Genetics to Present at the 2015 Leerink Global Healthcare Conference
SALT LAKE CITY, Feb. 6, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad Genetics, is scheduled to present at the Leerink Global Healthcare Conference at 1:00 p.m. Eastern on February 12, 2015, at the
Read more →MYGNMyriad Genetics Reports Fiscal Second-Quarter 2015 Financial Results
Revenues of $184.4 Million Adjusted Diluted EPS of $0.40, and Diluted EPS of $0.32 myRisk Hereditary Cancer Revenues of $85.1 Million BRACAnalysis CDx Approved by the FDA Tumor BRACAnalysis CDx Granted European CE Marking Approval Company Revises Fiscal Year 2015 Financial G
Read more →MYGNRon Rogers (801) 584-3065 rrogers@myriad.com Investor Contact: Scott Gleason (801) 584-1143 sgleason@myriad.com Myriad Genetics Reports Fiscal Second-Quarter 2015 Financial Results Revenues of
Myriad Genetics Reports Fiscal Second-Quarter 2015 Financial Results LAKE CITY, UTAH, February 3, 2015 Myriad Genetics, Inc. (NASDAQ: MYGN) today announced financial results for its fiscal second-quarter and six months ended December 31, 2014, provided an update on recent busine
Read more →MYGNMyriad Announces Retirement of Peter D. Meldrum, President and CEO
SALT LAKE CITY, Feb. 3, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Peter D. Meldrum, president and chief executive officer, has notified the company of his decision to retire at the conclusion of the fiscal year on June 30, 2015. Pursuant to
Read more →MYGNMyriad Genetics Names Johnathan M. Lancaster as Vice President of Medical Affairs
SALT LAKE CITY, Jan. 22, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Johnathan M. Lancaster, M.D., Ph.D. has joined the Company as the vice president of Medical Affairs for Oncology, Myriad Genetic Laboratories, effective Feb. 9, 2015. In thi
Read more →MYGNMyriad Genetics to Announce 2Q15 Financial Results on February 3, 2015
SALT LAKE CITY, Jan. 21, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the fiscal second quarter 2015 and provide a business update following the close of market on Tuesday, February 3, 2015. The Company als
Read more →MYGNMyriad RBM Joins Institut Pasteur in the Global Fight Against Tuberculosis
SALT LAKE CITY, Jan. 20, 2015 (GLOBE NEWSWIRE) -- Myriad RBM, a wholly owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), today announced that it will assist the Institut Pasteur in a public-private research collaboration to fight the global tuberculosis (TB) epidemic. This
Read more →MYGNMyriad Obtains CE Mark for Tumor BRACAnalysis CDx(TM) and Launches Test in Europe as Companion Diagnostic for PARP Inhibitors
SALT LAKE CITY and ZURICH, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the Company has obtained CE Marking in Europe for its Tumor BRACAnalysis CDx test, which identifies tumors that have mutations in the BRCA1 or BRCA2 genes. Tumor BRACAn
Read more →MYGNMyriad Genetics to Present at the 2015 J.P. Morgan Annual Healthcare Conference
SALT LAKE CITY, Jan. 5, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad Genetics, is scheduled to present at the J.P. Morgan 33rd Annual Healthcare Conference at 9:30 a.m. Pacific on January 12, 2015,
Read more →MYGNMyriad Genetics Names Bernard Tobin as President of Crescendo Bioscience
SALT LAKE CITY, Dec. 22, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the appointment of Bernard F. Tobin as president of Crescendo Bioscience, effective January 5, 2015. Mr. Tobin will report to Peter D. Meldrum, president and CEO, Myriad Genetics
Read more →MYGNMyriad Receives FDA Approval of BRACAnalysis CDx(TM) as Companion Diagnostic for Lynparza(TM) (olaparib) in Ovarian Cancer Patients
SALT LAKE CITY, Dec. 19, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for BRACAnalysis CDx to be used as the only companion diagnostic in conjunction with AstraZeneca's
Read more →MYGNMyriad to Present Eight Studies at 2014 San Antonio Breast Cancer Symposium
SALT LAKE CITY, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the presentation of eight new studies evaluating the use of its molecular and companion diagnostics in patients with breast cancer at the 2014 San Antonio Breast Cancer Symposium
Read more →MYGNMyriad myPath(TM) Melanoma Improves Diagnosis and Treatment Plans
SALT LAKE CITY, Nov. 7, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented results from a prospective clinical utility study of its Myriad myPath Melanoma test at the 2014 American Society of Dermatopathology (ASDP) annual meeting in Chicago, Ill. Myriad
Read more →MYGNMyriad Genetics Reports Fiscal First Quarter 2015 Financial Results
Revenue of $168.8 million; diluted EPS of $0.21; adjusted EPS of $0.25 myRisk Hereditary Cancer revenue of $53.1 million, up 95 percent sequentially Draft Medicare decision covering Prolaris for low-risk prostate cancer patients CHMP recommends approval of olaparib in ovarian
Read more →MYGNMyriad and AbbVie Sign Expanded Agreement for Tumor BRACAnalysis CDx(TM)
SALT LAKE CITY, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has signed an expanded companion diagnostic agreement with AbbVie, Inc. (NYSE:ABBV), a leading global biopharmaceutical company to use Tumor BRACAnalysis CDx as a companio
Read more →MYGNMyriad Genetics to Present at the 2014 Credit Suisse Annual Healthcare Conference
SALT LAKE CITY, Oct. 29, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, president of Myriad Genetics Laboratories, is scheduled to present at the 2014 Credit Suisse Annual Healthcare Conference, at 3:00 p.m. Eastern on November 12,
Read more →MYGNMyriad Announces Inclusion of Prolaris(R) Test in NCCN Guidelines
SALT LAKE CITY, Oct. 27, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that its Prolaris test has been included in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) for all men with localized prosta
Read more →MYGNMyriad Establishes Tumor BRACAnalysis CDx(TM) Laboratory in Europe
SALT LAKE CITY and ZURICH, Oct. 24, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it has established a Tumor BRACAnalysis CDx laboratory in Europe. Myriad's next-generation Tumor BRACAnalysis CDx test is a companion diagnostic that will identify up
Read more →MYGNMyriad Genetics to Announce 1Q15 Financial Results on November 4, 2014
SALT LAKE CITY, Oct. 21, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the fiscal first quarter 2015 following the close of market on Tuesday, November 4, 2014. The Company also will host a conference call a
Read more →MYGNMyriad Receives Draft Medicare Coverage for Prolaris(R)
SALT LAKE CITY, Oct. 17, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued a draft local coverage determination (LCD) for Prolaris,
Read more →MYGNMyriad Appoints R. Bryan Riggsbee as Chief Financial Officer
SALT LAKE CITY, Oct. 8, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the appointment of R. Bryan Riggsbee as executive vice president, Chief Financial Officer, and Treasurer effective October 16, 2014. Jim Evans will continue in his role as Chief F
Read more →MYGNMyriad Presents Tumor BRACAnalysis CDx(TM) Study at ESMO
SALT LAKE CITY, Sept. 29, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that its Tumor BRACAnalysis CDx companion diagnostic test significantly improved the detection of cancer-causing BRCA 1/2 mutations by 44 percent in women with ovarian cancer. D
Read more →MYGNMyriad myPath(TM) Melanoma Test Reduced Indeterminate Cases by 76 Percent and Changed Treatment in 35 Percent of Cases
SALT LAKE CITY, Sept. 9, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented results from a pivotal clinical utility study of the Myriad myPath Melanoma test at the 2014 College of American Pathologists (CAP) annual meeting in Chicago, Ill. Myriad myPath
Read more →MYGNMyriad Publishes myRisk Hereditary Cancer Study in Cancer
SALT LAKE CITY, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN), today announced that the Myriad myRisk Hereditary Cancer test significantly improved the detection of cancer-causing mutations by 46 percent in patients with breast cancer in a new study publis
Read more →MYGNMyriad Genetics to Present at the Morgan Stanley Healthcare Conference
SALT LAKE CITY, Aug. 28, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, president of Myriad Genetics Laboratories, is scheduled to present at the Morgan Stanley Healthcare Conference at 9:45 a.m. Eastern time on September 10, 2014,
Read more →MYGNMyriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2014 Financial Results
SALT LAKE CITY, Aug. 12, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced financial results for its fiscal fourth quarter and fiscal year ended June 30, 2014, provided an update on recent business highlights, and provided financial guidance for its fis
Read more →MYGNMyriad Genetics to Announce Financial Results for the Fiscal Fourth Quarter and Full Year 2014 on August 12, 2014
SALT LAKE CITY, July 30, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the fiscal fourth quarter and full year 2014 as well as provide financial guidance for fiscal year 2015 following the close of market on
Read more →MYGNMyriad Announces Retirement of James Evans, Chief Financial Officer
SALT LAKE CITY, June 9, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that James Evans, chief financial officer of Myriad, has notified the Company of his intent to retire in order to attend to family health issues. To ensure a smooth transition, Ev
Read more →MYGNMyriad Genetics to Present at the Goldman Sachs Global Healthcare Conference
SALT LAKE CITY, June 3, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad, is scheduled to present at the 35th annual Goldman Sachs Global Healthcare Conference, at 10:40 a.m. Pacific on June 10, 2014,
Read more →MYGNMyriad Genetics Announces Participation in Innovative Collaboration to Accelerate Hereditary Cancer Research
SALT LAKE CITY, June 2, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) and leading cancer experts from the Memorial Sloan Kettering Cancer Center (MSKCC), Mayo Clinic, Abramson Cancer Center of the University of Pennsylvania and other laboratories are teaming up in
Read more →MYGNMyriad Presents Clinical Data on Myriad myRisk(TM) Hereditary Cancer Test at ASCO
SALT LAKE CITY, June 2, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented several clinical studies on the Myriad myRisk Hereditary Cancer test at the 2014 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois. Among the import
Read more →MYGNMyriad myPath(TM) Melanoma Test Improves the Reliability of Melanoma Diagnosis
SALT LAKE CITY, June 2, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented results from a pivotal clinical validation study of the Myriad myPath Melanoma test at the 2014 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Ill. The My
Read more →MYGNMyriad Presents Data on BRACAnalysis CDx(TM) and HRD(TM) at 2014 ASCO Meeting
SALT LAKE CITY, May 30, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN), a global leader in molecular diagnostics, announced the presentation of new data at the American Society of Clinical Oncology (ASCO) meeting this week that supports the clinical efficacy of its
Read more →MYGNMyriad Strengthens Commitment to Cancer Research at the ASCO 50th Annual Meeting
SALT LAKE CITY, May 15, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from 11 clinical studies with its molecular diagnostic tests will be featured at the 2014 American Society of Clinical Oncology annual meeting to be held May 30-June
Read more →MYGNMyriad Genetics to Present at the Bank of America 2014 Healthcare Conference
SALT LAKE CITY, May 9, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad, is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference, at 10:00 a.m. Pacific on May 13, 2014,
Read more →MYGNMyriad Genetics Reports Financial Results for Third Quarter of Fiscal Year 2014
SALT LAKE CITY, May 6, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced financial results for the fiscal third quarter and nine months ended March 31, 2014, increased its fiscal year 2014 guidance, and provided an update on recent business highlights.
Read more →MYGNMyriad and UnitedHealthcare Sign Three-Year Agreement Making myRisk(TM) Hereditary Cancer Test Available to United Members
SALT LAKE CITY, May 6, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has signed a three-year contract with UnitedHealthcare. The contract provides UnitedHealthcare with access for BRCA testing and the myRisk Hereditary Cancer test for patien
Read more →MYGNMyriad Genetics to Present Three Clinical Studies on Prolaris(R) at the 2014 American Urological Association Annual Meeting
SALT LAKE CITY, May 1, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced clinical data from three studies on Prolaris in prostate cancer patients will be featured at the 2014 American Urological Association (AUA) Annual Meeting, being held May 16-21, 20
Read more →MYGNMyriad Genetics to Announce Financial Results for the Third Quarter of Fiscal Year 2014 on Tuesday, May 6, 2014
SALT LAKE CITY, April 22, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the third fiscal quarter of 2014 following the close of market on Tuesday, May 6, 2014. The Company also will host a conference call on
Read more →MYGNMyriad Genetics Submits Premarket Approval to FDA for BRACAnalysis(R)
SALT LAKE CITY, April 7, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has submitted the first module of a premarket approval (PMA) application to the Food and Drug Administration (FDA) for the use of BRACAnalysis testing as a companion diag
Read more →MYGNMyriad to Present Seven Clinical Studies at the Annual Clinical Genetics Meeting
SALT LAKE CITY, March 25, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from seven clinical studies will be presented at the upcoming American College of Medical Genetics (ACMG) annual meeting, which will be held Mar. 25-Mar.29, 2013 in
Read more →MYGNMyriad Announces HRD Companion Diagnostic Collaboration With Tesaro
SALT LAKE CITY, March 24, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Tesaro, Inc. will use Myriad's novel HRD (homologous recombination deficiency) test to identify tumor types that may respond to its investigational poly-ADP ribose polymera
Read more →MYGNMyriad Publishes Clinical Utility Study for Prolaris(R)
SALT LAKE CITY, March 3, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has published data from the PROCEDE 500 study in the journal Current Medical Research and Opinion, demonstrating that 65 percent of physicians changed their original trea
Read more →MYGNMyriad Genetics Publishes Prolaris(R) Data in the Journal of Urology
SALT LAKE CITY, Feb. 18, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it has published data in the Journal of Urology demonstrating that its Prolaris test accurately predicted, based on biopsy specimens, which men would develop biochemical recurren
Read more →MYGNMyriad Genetics to Acquire Crescendo Bioscience(R)
SALT LAKE CITY, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has entered into a definitive agreement to acquire Crescendo Bioscience, Inc., a global leader in autoimmune diagnostics, for $270 million in cash which will be reduced by
Read more →MYGNMyriad Genetics Reports Financial Results for Second Quarter of Fiscal Year 2014
SALT LAKE CITY, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced financial results for its fiscal second quarter and six months ended December 31, 2013. Revenue for the second quarter was $204.1 million, a 37 percent increase over the same peri
Read more →MYGNMyriad's Prolaris(R) Test Significantly Modifies Treatment Decisions for Patients With Prostate Cancer
SALT LAKE CITY, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results from PROCEDE 500, a clinical utility study with its Prolaris test, at the 2014 ASCO Genitourinary Cancers Symposium in San Francisco, Calif. The study demonstrated the si
Read more →MYGNMyriad Publishes Data on Its Variant Classification Program in Clinical Genetics
SALT LAKE CITY, Jan. 28, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has published details of its myVision Myriad Variant Classification Program in the journal Clinical Genetics. myVision is the most advanced variant classification program
Read more →MYGNMyriad Genetics to Announce Financial Results for the Second Quarter of Fiscal Year 2014 on Tuesday February 4, 2014
SALT LAKE CITY, Jan. 23, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the second fiscal quarter 2014 following the close of market on Tuesday, February 4, 2014. The Company also will host a conference call
Read more →MYGNMyriad Genetics to Present Five Clinical Studies at 2014 ASCO GU Cancer Symposium
SALT LAKE CITY, Jan. 23, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from four studies in prostate cancer with Prolaris and one study in renal cancer will be presented at the 2014 ASCO Genitourinary Cancers Symposium, which will be he
Read more →MYGNMyriad Genetics to Present at the 32nd Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad, is scheduled to present at the 32nd Annual J.P. Morgan Healthcare Conference, at 9:30 a.m. Pacific on January 13, 2014, at the
Read more →MYGNMyriad's HRD(TM) Test Significantly Predicts Response to Cisplatin Treatment in Patients With Triple Negative Breast Cancer in Second Research Study
SALT LAKE CITY, Dec. 14, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented clinical data at the 2013 San Antonio Breast Cancer Symposium that showed the Myriad's HRD (homologous recombination deficiency) test was significantly associated with cisplatin
Read more →MYGNMyriad myRisk Hereditary Cancer(TM) Test Significantly Improves Detection of Women at Risk for Hereditary Cancer by 51 Percent
SALT LAKE CITY, Dec. 12, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented clinical data at the 2013 San Antonio Breast Cancer Symposium that showed the myRisk Hereditary Cancer test found 51 percent more patients with a higher risk of hereditary breast
Read more →MYGNMyriad Genetics Announces Cancer Research Collaboration With Janssen
BRACAnalysis Testing Will be Performed in Phase 3 Clinical Trial SALT LAKE CITY, Dec. 9, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Janssen Research & Development, LLC, will use Myriad's BRACAnalysis test in connection with its Phase 3 clin
Read more →MYGNMyriad Genetics Announces Upcoming Investor Event
SALT LAKE CITY, Dec. 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it will be hosting an investor event for research analysts and institutional investors on Thursday, December 12, 2013 at 8:30 p.m. EST in San Antonio, Texas. Mark Capone, pre
Read more →MYGNMyriad's Prolaris(R) Test Guides Treatment Decisions for Men with Prostate Cancer
SALT LAKE CITY, Dec. 4, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present data from four clinical studies with Prolaris at the 14th Annual Meeting of the Society for Urologic Oncology (SUO) in Bethesda, Md. Prolaris is a prognostic test
Read more →MYGNMyriad Genetics Announces Second HRD Collaboration
SALT LAKE CITY, Nov. 20, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced a research collaboration with BioMarin that will use Myriad's novel HRD (Homologous Recombination Deficiency) test to identify tumor types that may be sensitive to BioMarin's inv
Read more →MYGNMyriad Genetics Launches myPath(TM) Melanoma Diagnostic Test
SALT LAKE CITY, Nov. 12, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has launched Myriad myPath Melanoma, a new diagnostic test to effectively differentiate malignant melanoma from benign pigmented skin lesions. The myPath Melanoma test h
Read more →MYGNMyriad Genetics to Present at the 2013 Credit Suisse Annual Healthcare Conference
SALT LAKE CITY, Nov. 8, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that James Evans, Chief Financial Officer, is scheduled to present at the 2013 Credit Suisse Annual Healthcare Conference, at 10:30 a.m. Pacific on November 13, 2013, at the Phoen
Read more →MYGNMyriad Genetics Reports Financial Results for First Quarter of Fiscal Year 2014
SALT LAKE CITY, Nov. 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced financial results for its fiscal first quarter ended Sept. 30, 2013. Revenue for the fiscal first quarter increased 52 percent over the same period in the prior year to $202.5 mil
Read more →MYGNMyriad myPlan(TM) Lung Cancer Test Launched to Leading Oncologists
SALT LAKE CITY, Oct. 29, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has launched a new prognostic test, Myriad myPlan Lung Cancer, for patients diagnosed with early-stage lung adenocarcinoma. myPlan Lung Cancer is an RNA expression panel
Read more →MYGNMyriad myPlan(TM) Lung Cancer Test Meets Primary Endpoint in Validation Study
SALT LAKE CITY, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that validation data for the Myriad myPlan Lung Cancer test showed that it significantly predicted patients' risk of death from early-stage lung adenocarcinoma within five years
Read more →MYGNMyriad myRisk(TM) Hereditary Cancer Test Is Highly Accurate in Key Validation Study
SALT LAKE CITY, Oct. 24, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present data this week at the American Society of Human Genetics (ASHG) annual meeting in Boston showing that the Myriad myRisk Hereditary Cancer test meets rigorous qual
Read more →MYGNMyriad Genetics to Announce Fiscal First Quarter 2014 Financial Results on Tuesday November 5, 2013
SALT LAKE CITY, Oct. 23, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the first fiscal quarter 2014 following the close of market on Tuesday, Nov. 5, 2013. The Company also will host a conference call on Tu
Read more →MYGNMyriad's myPath(TM) Melanoma Test is Highly Effective in Verification Study
SALT LAKE CITY, Oct. 14, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from a verification study showed the Myriad myPath Melanoma test effectively differentiated malignant melanoma from benign skin lesions. The clinically-actionable in
Read more →MYGNMyriad Genetics Study Highlights Importance of myRisk(TM) Hereditary Cancer Testing
SALT LAKE CITY, Oct. 9, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present data showing the high prevalence and overlap between hereditary colon cancer and hereditary breast and ovarian cancer in patients previously diagnosed with endomet
Read more →MYGNMyriad's myRisk Hereditary Cancer(TM) Test Improves Colon Cancer Testing by 60 Percent
SALT LAKE CITY, Oct. 7, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced new clinical data from a study with myRisk Hereditary Cancer, a 25-gene hereditary cancer panel, that showed a 60 percent increase in mutations detected in cancer predisposition g
Read more →MYGNMyriad Genetics and BioMarin Advance PARP Collaboration Into Phase 3
SALT LAKE CITY, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that BioMarin Pharmaceutical Inc. will use Myriad's BRACAnalysis test in connection with its pivotal Phase 3 clinical studies for BMN 673. BMN 673 is a novel, orally-active PARP i
Read more →MYGNMyriad Genetics' myPlan(TM) Lung Cancer Test Meets Primary Clinical Endpoint
SALT LAKE CITY, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced new data published in Clinical Cancer Research that showed the myPlan Lung Cancer test is a significant predictor of lung cancer death in patients with early-stage, resectable l
Read more →MYGNMyriad Genetics Launches myRisk(TM) Hereditary Cancer Panel
SALT LAKE CITY, Sept. 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has launched myRisk Hereditary Cancer, a new multi-gene diagnostic test that will provide increased sensitivity by analyzing 25 genes associated with eight major cancers
Read more →MYGNMyriad Genetics to Present at the Morgan Stanley Global Healthcare Conference
SALT LAKE CITY, Sept. 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, President of Myriad Genetic Laboratories, Inc. is scheduled to present at the Morgan Stanley Global Healthcare Conference, at 2:55 p.m. Eastern on September 10,
Read more →MYGNMyriad Genetics Expands Collaboration with AstraZeneca on Olaparib Phase 3 Clinical Trials
SALT LAKE CITY, Sept. 4, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has entered into an expanded, nonexclusive global collaboration agreement with AstraZeneca to provide companion diagnostics for the olaparib Phase 3 clinical development
Read more →MYGNMyriad Genetics Reports Full-Year and Fiscal Fourth-Quarter 2013 Financial Results
SALT LAKE CITY, Aug. 13, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced financial results for its fiscal fourth quarter and full fiscal year ended June 30, 2013. Revenue for the fiscal fourth quarter increased 31 percent over the same period in the p
Read more →MYGNMyriad Genetics Announces Date of Full-Year and Fourth-Quarter Fiscal 2013 Financial Results Conference Call
SALT LAKE CITY, July 30, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will hold its fourth-quarter 2013 sales and earnings conference call with institutional investors and analysts at 4:30 p.m. ET on Tuesday, Aug. 13. During the call, Peter D. M
Read more →MYGNMyriad Expands Its Patient Financial Assistance Program
SALT LAKE CITY, July 15, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced a program to provide financial assistance to underinsured patients. Beginning July 22, Myriad will offer financial assistance to reduce qualified underinsured patients' out-of-po
Read more →MYGNMyriad and TESARO Enter Into Companion Diagnostic Agreement
SALT LAKE CITY, June 24, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has signed an agreement with TESARO, Inc. (Nasdaq:TSRO) to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in two separate Phase III clinical studies
Read more →MYGNMyriad Genetics to Present PROLARIS(R) Data at ASCO 2013, Continuing Its Commitment to Cancer Research
SALT LAKE CITY, May 30, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Jack Cuzick, Ph.D., of Queen Mary College University of London, will present data from five PROLARIS clinical studies in patients with prostate cancer at the American Society
Read more →MYGNMyriad Genetics to Present at the Bank of America Merrill Lynch Health Care Conference
SALT LAKE CITY, May 14, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO, is scheduled to present at the Bank Of America Merrill Lynch 2013 Health Care Conference, at 10:00 a.m. Pacific on May 16, 2013, at the E
Read more →MYGNMyriad Genetics Reports Third Quarter Fiscal Year 2013 Results
SALT LAKE CITY, May 7, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its third fiscal quarter and nine months ended March 31, 2013. Revenue for the third fiscal quarter increased 21 percent over the same period in the prior year to $156.
Read more →MYGNMyriad to Present New Molecular Data for Patients With Prostate Cancer at the American Urological Association 2013 Annual Meeting
SALT LAKE CITY, May 2, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today highlighted new clinical data on the PROLARIS 46-gene cell cycle progression (CCP) signature in patients with prostate cancer that will be presented at this year's American Urological Associ
Read more →MYGNMyriad Genetics Announces 2013 Analyst and Investor Day
SALT LAKE CITY, May 2, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that its Analyst and Investor Day for research analysts and institutional investors will take place on Thursday, May 9, 2013 at 9:00 a.m. EST in New York City. Peter D. Meldrum, pr
Read more →MYGNMyriad Genetics to Announce Third Fiscal Quarter 2013 Results on Tuesday, May 7, 2013
SALT LAKE CITY, April 18, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the third fiscal quarter 2013 following the close of market on Tuesday, May 7, 2013. The Company will also host a conference call on Tu
Read more →MYGNMyriad Adopts RainDance's Thunderstorm Platform for Next-Generation Sequencing Based Hereditary Cancer Panel
SALT LAKE CITY and LEXINGTON, Mass., April 17, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) and RainDance Technologies, Inc. today announced that they have entered into a commercial agreement whereby Myriad will adopt RainDance's ThunderStorm Target Enrichment Sys
Read more →MYGNMyriad and PharmaMar Announce First Commercial Partnership With Myriad's New HRD Test
SALT LAKE CITY, March 26, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has signed an agreement with PharmaMar, a leader in the development of marine-derived drugs. Under the terms of the agreement, Myriad will conduct homologous recombinati
Read more →MYGNMyriad's Prolaris(R) Test Predicts Risk of Prostate Cancer Recurrence in Fourth Peer Reviewed Study
SALT LAKE CITY, March 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a study published in the Journal of Clinical Oncology demonstrated that its Prolaris test, which analyzes the expression level of 46 cell cycle progression genes, accurately
Read more →MYGNMyriad Genetics Reports Second Quarter Fiscal Year 2013 Results
SALT LAKE CITY, Feb. 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its second fiscal quarter ended December 31, 2012. Revenue for the second fiscal quarter increased 21 percent over the same period in the prior year to $149.1 million.
Read more →MYGNMyriad Genetics to Announce Second Fiscal Quarter 2013 Results on Tuesday, February 5, 2013
SALT LAKE CITY, Jan. 15, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the second fiscal quarter 2013 following the close of market on Tuesday, February 5, 2013. The Company will also host a conference call
Read more →MYGNMyriad Genetics to Present at the 2013 J.P. Morgan Annual Healthcare Conference
SALT LAKE CITY, Dec. 17, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the 2013 J.P. Morgan Annual Healthcare Conference, at 9:30 a.m. Pacific Time on Monday, January 7, 2013. The
Read more →MYGNMyriad Announces Diabetes Collaboration With Sanofi
SALT LAKE CITY, Dec. 10, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics (Nasdaq:MYGN) announced today that Myriad RBM, a wholly owned subsidiary of Myriad Genetics, has entered into a research collaboration with Sanofi, a global and diversified healthcare leader, and Population Health
Read more →MYGNMyriad Genetics' HRD Test Predicts Response to Platinum Therapy in Triple-Negative Breast Cancer
SALT LAKE CITY, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled "Homologous recombination deficiency (HRD) score predicts pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA
Read more →MYGNMyriad Genetics' Prolaris Test Predicts Biochemical Recurrence in Prostate Cancer Patients Following Radiation Therapy
SALT LAKE CITY, Nov. 28, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled "CCP Score Significantly Predicts PSA Failure After EBRT," was presented on Wednesday, November 28th, 2012 at the Annual Meeting of the Society of Ur
Read more →MYGNMyriad Genetics to Present at the Piper Jaffray Healthcare Conference
SALT LAKE CITY, Nov. 15, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the Piper Jaffray Healthcare Conference, at 4:00 p.m. Eastern Time on Tuesday, November 27, 2012. The confere
Read more →MYGNMyriad Genetics Reports First Quarter Fiscal Year 2013 Results
SALT LAKE CITY, Nov. 5, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its first fiscal quarter ended September 30, 2012. Revenue for the first fiscal quarter increased 21 percent over the same period in the prior year to $133.4 million.
Read more →MYGNMyriad Genetics to Present at the 2012 Credit Suisse Annual Healthcare Conference
SALT LAKE CITY, Nov. 1, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the 2012 Credit Suisse Annual Healthcare Conference, at 9:30 a.m. Mountain Time on Thursday, November 15, 2012
Read more →MYGNMyriad Genetics to Announce First Fiscal Quarter 2013 Results on Monday, November 5, 2012
SALT LAKE CITY, Oct. 15, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the first fiscal quarter 2013 following the close of market on Monday, November 5, 2012. The Company will also host a conference call on
Read more →MYGNMyriad's HRD Score Detects Loss of DNA Repair Function in Ovarian Cancer
SALT LAKE CITY, Oct. 10, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a study published in the British Journal of Cancer demonstrated the ability of the Company's Homologous Recombination Deficiency (HRD) Assay to detect loss of DNA repair in
Read more →MYGNMyriad Genetics Sponsors Cancer Awareness Initiatives in Support of National Hereditary Breast and Ovarian Cancer Week
SALT LAKE CITY, Oct. 3, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that, in support of National Hereditary Breast and Ovarian Cancer (HBOC) Week and National Previvor Day, it has launched an online quiz to help people assess their risk for heredi
Read more →MYGNMyriad Genetics Reports Fourth Quarter and Fiscal Year 2012 Results
SALT LAKE CITY, Aug. 14, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its fourth quarter and fiscal year ending June 30, 2012. Revenue for the fourth fiscal quarter increased 24 percent over the same period in the prior year to $133.0 m
Read more →MYGNMyriad Genetics and Pharma Mar Enter Into Companion Diagnostic Agreement
SALT LAKE CITY, July 26, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has signed an agreement with Pharma Mar, a leader in the development of marine-derived drugs. Under the agreement, Myriad will conduct BRCA 1 and BRCA 2 testing on patien
Read more →MYGNMyriad Genetics to Announce Fiscal Fourth Quarter and Fiscal Year 2012 Results on Tuesday, August 14, 2012
SALT LAKE CITY, July 24, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the fourth fiscal quarter and fiscal year 2012 following the close of market on Tuesday, August 14, 2012. The Company will also host a c
Read more →MYGNMyriad Genetics Receives the Charles R. Smart Visionary Award From the American Cancer Society(R)
SALT LAKE CITY, June 6, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics announced today that the Company is the honorable recipient of the 2012 Charles R. Smart Visionary Award from the American Cancer Society's Salt Lake City office, a part of the Great West Division. This award is pre
Read more →MYGNMyriad's Lung Cancer Prognosis Test Shown to Significantly Predict Survival in Early Stage Lung Cancer Patients
SALT LAKE CITY, June 4, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled "Use of a Proliferation-Based mRNA Signature to Predict Outcome in Early-Stage Non-Small Cell Lung Adenocarcinoma," was presented on Sunday, June 3, 2
Read more →MYGNMyriad Genetics to Present at Upcoming Investor Conferences in June
SALT LAKE CITY, May 22, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that the Company is scheduled to present at two upcoming investor conferences: Jefferies 2012 Global Healthcare Conference in New York City, New York on June 5th at 8:30 a.m. Eas
Read more →MYGNMyriad Genetics Announces Presentation of Lung Cancer Study at American Society for Clinical Oncology Annual Meeting
SALT LAKE CITY, May 16, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today the presentation of a study at the American Society of Clinical Oncology (ASCO) Annual Meeting, including the complete results from a study titled, "Use of a proliferation-based m
Read more →MYGNMyriad Genetics to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
SALT LAKE CITY, May 2, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the Bank of America Merrill Lynch 2012 Health Care Conference, at 4:20 p.m. Pacific Time on Wednesday, May 16,
Read more →MYGNMyriad Genetics Reports Record Third Fiscal Quarter 2012 Results
SALT LAKE CITY, May 1, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its third fiscal quarter and nine months ending March 31, 2012. Revenue for the third fiscal quarter was $129.8 million, an increase of 27 percent over the $102.4 milli
Read more →MYGNMyriad Genetics to Announce Fiscal 2012 Third Quarter Results on Tuesday, May 1, 2012
SALT LAKE CITY, April 10, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the third fiscal quarter following the close of market on Tuesday, May 1, 2012. The Company will also host a conference call on Tuesday
Read more →MYGNMyriad Study Finds High Prevalence of Mutations in the PMS2 Gene
SALT LAKE CITY, March 29, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled, "Representation of PMS2 mutations in patients seeking genetic testing for Lynch syndrome," was presented at the 2012 American College of Medical Ge
Read more →MYGNMyriad and Cephalon Enter Into Companion Diagnostic Agreement
SALT LAKE CITY, March 28, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has signed an agreement with Cephalon Inc., a subsidiary of Teva Pharmaceutical Industries Ltd Company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enr
Read more →MYGNMyriad's Prolaris(R) Test Shown to Significantly Predict Prostate Cancer Outcome in Needle Biopsy Tissue
SALT LAKE CITY, Feb. 24, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a study published in the British Journal of Cancer demonstrated the prognostic ability of the Company's Prolaris test in needle biopsy material. The study entitled, "Prognos
Read more →MYGNMyriad Genetics to Present at the Cowen and Company 32nd Annual Health Care Conference
SALT LAKE CITY, Feb. 22, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, President, Myriad Genetic Laboratories, Inc., is scheduled to present at the Cowen and Company 32nd Annual Health Care Conference, at 8:00 a.m. Eastern Time on
Read more →MYGNMyriad Genetics to Present at the Leerink Swann 2012 Global Healthcare Conference
SALT LAKE CITY, Feb. 6, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Jim Evans, Chief Financial Officer, is scheduled to present at the Leerink Swann 2012 Global Healthcare Conference, at 11:00 a.m. Eastern Time on Thursday, February 16, 2012.
Read more →MYGNMyriad's Prolaris(R) Test Shown to Significantly Predict Biochemical Recurrence Risk After Prostatectomy
SALT LAKE CITY, Feb. 2, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled, "Validation of a panel of cell-cycle progression genes for improved risk-stratification in a contemporary radical prostatectomy cohort," was presente
Read more →MYGNMyriad Genetics Reports Second Quarter Fiscal Year 2012 Results
SALT LAKE CITY, Jan. 31, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its second fiscal quarter and six months ending December 31, 2011. Revenue for the second fiscal quarter was $122.8 million, an increase of 22 percent over the $100.4
Read more →MYGNMyriad Genetics Acquires Exclusive Rights to RAD51C Gene
SALT LAKE CITY, Jan. 18, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it has obtained an exclusive license to intellectual property covering the analysis of the RAD51C gene for risk of hereditary breast and ovarian cancer. In several studies, mutat
Read more →MYGNMyriad Genetics to Announce Fiscal 2012 Second Quarter Results on Tuesday, January 31, 2012
SALT LAKE CITY, Jan. 17, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the second fiscal quarter following the close of market on Tuesday, January 31, 2012. The Company will also host a conference call on Tu
Read more →MYGNMyriad Genetics to Present at the 30th Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Dec. 28, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference, at 1:30 p.m. Pacific Time on Wednesday, January 11, 2012.
Read more →MYGNMyriad Genetics Presents BRACAnalysis(R) Cost-Effectiveness Study at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium
SALT LAKE CITY, Dec. 9, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled "Cost Effectiveness Analysis of Genetic Testing for Breast and Ovarian Cancer Susceptibility Genes (BRCA1/BRCA2)," was presented on Thursday, December
Read more →MYGNMyriad Genetics to Present at the 22nd Annual Oppenheimer Healthcare Conference
SALT LAKE CITY, Dec. 1, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, President, Myriad Genetic Laboratories, Inc., is scheduled to present at the Oppenheimer Healthcare Conference, at 9:40 a.m. Eastern Time on Wednesday, December
Read more →MYGNMyriad Genetics to Attend the 23rd Annual Piper Jaffray Health Care Conference
SALT LAKE CITY, Nov. 21, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it will meet with investors at the 23rd Annual Piper Jaffray Health Care Conference on Tuesday, November 29, 2011. The conference is being held at The New York Palace Hotel
Read more →MYGNMyriad Genetics Reports First Quarter Fiscal Year 2012 Results
SALT LAKE CITY, Nov. 1, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its first fiscal quarter ending September 30, 2011. Revenue for the first fiscal quarter was $110.5 million, an increase of 20 percent over the $91.9 million reported
Read more →MYGNMyriad Genetics to Announce Fiscal 2012 First Quarter Results on Tuesday, November 1, 2011
SALT LAKE CITY, Oct. 11, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the first fiscal quarter following the close of market on Tuesday, November 1, 2011. The Company will also host a conference call on Tue
Read more →MYGNMyriad Genetics Makes Strategic Debt Investment With Exclusive Option to Acquire Crescendo Bioscience
SALT LAKE CITY, Sept. 8, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (Nasdaq:MYGN) today announced that it has made a $25 million strategic debt investment in Crescendo Bioscience of South San Francisco, CA and secured an exclusive, three-year option to acquire the company. The
Read more →MYGNMyriad Announces New $200 Million Share Repurchase Program
SALT LAKE CITY, Aug. 15, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that its Board of Directors has authorized a new $200 million stock repurchase program. "This announcement is the result of our commitment to a balanced capital deployment appro
Read more →MYGNMyriad Genetics Reports Fourth Quarter and Fiscal Year 2011 Results
SALT LAKE CITY, Aug. 9, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its fourth fiscal quarter and fiscal year ending June 30, 2011. Revenue for the fourth fiscal quarter increased 14 percent over the same period in the prior year to $1
Read more →MYGNMyriad Applauds the Court of Appeals' Decision to Uphold Gene Patenting
SALT LAKE CITY, July 29, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) reported today that the United States Court of Appeals for the Federal Circuit declared that the composition of matter claims covering isolated DNA and cDNA of the BRCA1 and BRCA2 genes are pate
Read more →MYGNMyriad Genetics to Announce Fiscal Fourth Quarter and Fiscal Year 2011 Results on Tuesday, August 9, 2011
SALT LAKE CITY, July 19, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the fiscal fourth quarter and fiscal year 2011 following the close of market on Tuesday, August 9, 2011. The Company will also host a co
Read more →MYGNMyriad's PROLARIS(R) Test Shown to Significantly Predict Prostate Cancer Outcome From Needle Biopsy Tissue
SALT LAKE CITY, June 6, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled "Prognostic value of a 46-gene cell cycle progression (CCP) RNA signature for prostate cancer death in a conservatively managed watchful waiting needl
Read more →MYGNMyriad Genetics Completes Acquisition of Rules-Based Medicine
SALT LAKE CITY and AUSTIN, Texas, June 1, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has completed the previously announced acquisition of Rules-Based Medicine (RBM) for approximately $80 million in cash. Rules-Based Medicine is a leader
Read more →MYGNMyriad Genetics to Present at the Jefferies Global Healthcare Conference
SALT LAKE CITY, May 24, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, President, Myriad Genetic Laboratories, Inc., is scheduled to present at the Jefferies Global Healthcare Conference, at 8:00 a.m. Eastern Time on June 7, 2011, a
Read more →MYGNMyriad Genetics Announces Presentation of Prostate Cancer Study at American Society for Clinical Oncology Annual Meeting
SALT LAKE CITY, May 18, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today the presentation of a study at the American Society of Clinical Oncology (ASCO) Annual Meeting, including the complete results from a study titled, "Prognostic value of a 46-gene
Read more →MYGNMyriad Genetics Licenses Novel Technology From Chronix Biomedical
SALT LAKE CITY, May 10, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has signed an agreement to license proprietary technology for the early detection of cancer from Chronix Biomedical of San Jose, California. Under the agreement, Myriad ha
Read more →MYGNMyriad Genetics Reports Fiscal 2011 Third Quarter Results
SALT LAKE CITY, May 3, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its third fiscal quarter and nine months ending March 31, 2011. Revenue for the third fiscal quarter was $102.4 million, an increase of 13 percent over the $90.8 millio
Read more →MYGNMyriad Genetics Announces Agreement to Acquire Rules-Based Medicine
SALT LAKE CITY and AUSTIN, Texas, April 27, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (Nasdaq:MYGN) today announced that it has entered into a definitive merger agreement to acquire privately-held Rules-Based Medicine (RBM) of Austin, Texas for $80 million in cash. The deal e
Read more →MYGNMyriad Genetics and BioMarin Pharmaceutical Inc. Enter Into Agreement
SALT LAKE CITY, April 6, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has signed an agreement with BioMarin Pharmaceutical Inc., a leading biopharmaceutical company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in
Read more →MYGNMyriad Genetics to Announce Fiscal Third Quarter Financial Results on Tuesday, May 3, 2011
SALT LAKE CITY, April 5, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the third fiscal quarter following the close of market on Tuesday, May 3, 2011. The Company will also host a conference call on Tuesday,
Read more →MYGNMyriad Announces New $100 Million Share Repurchase Program
SALT LAKE CITY, March 1, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that its Board of Directors has authorized a third $100 million stock repurchase program. In connection with this stock repurchase authorization, the Company has entered into an
Read more →MYGNMyriad Genetics to Present at the Citi Global Healthcare Conference
SALT LAKE CITY, Feb. 16, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the Citi Global Healthcare Conference, at 10:00 a.m. Eastern Time on March 2, 2011, at The Hilton New York Ho
Read more →MYGNMyriad's PROLARIS(TM) Test Shown to Significantly Predict Prostate Cancer Outcome
SALT LAKE CITY, Feb. 9, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a study published in Lancet Oncology shows the Company's 46-gene PROLARIS molecular diagnostic test significantly predicts prostate cancer outcome. The study demonstrated tha
Read more →MYGNMyriad Genetics Reports Fiscal 2011 Second Quarter Results
SALT LAKE CITY, Jan. 27, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its second fiscal quarter ending December 31, 2010. Revenue for the second fiscal quarter was $100.4 million, an increase of 8 percent over the $92.8 million reported
Read more →MYGNMyriad Genetics to Report Fiscal 2011 Second Quarter Financial Results on January 27
SALT LAKE CITY, Jan. 10, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will release its financial results for its second fiscal quarter ended December 31, 2010, at the close of market on Thursday, January 27, 2011. The Company will host a c
Read more →MYGNMyriad Genetics to Present at the 29th Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Dec. 22, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference, at 4:00 p.m. Pacific on January 12, 2011, at the Westin St
Read more →MYGNMyriad Genetics Launches PANEXIA, New Predictive Test for Hereditary Pancreatic and Related Cancers
SALT LAKE CITY, Dec. 20, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the launch of PANEXIA , a predictive medicine product for hereditary pancreatic and related cancers. PANEXIA is a comprehensive analysis of the PALB2 and BRCA2 genes for assessin
Read more →MYGNMyriad Acquires Novel Technology From Melanoma Diagnostics
SALT LAKE CITY, Dec. 8, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has signed an agreement to acquire proprietary technology for the diagnosis and prognosis of malignant melanoma using highly validated genetic markers from Melanoma Diagno
Read more →MYGNMyriad Genetics Applauds Major Health Economic Study That Supports Broad Application of Genetic Testing for Hereditary Colon Cancer
SALT LAKE CITY, Nov. 29, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today said results from a major health economics study in Cancer Prevention Research, a journal of the American Association for Cancer Research (AACR), found that screening for inherited gene mu
Read more →MYGNMyriad Genetics to Present at The Lazard Capital Markets 7th Annual Healthcare Conference and The Stephens Fall Investment Conference
SALT LAKE CITY, Nov. 4, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the Lazard Capital Markets 7th Annual Healthcare Conference, at 3:10 p.m. Eastern on November 16, 2010, at the
Read more →MYGNMyriad Genetics Reports Fiscal 2011 First Quarter Financial Results
SALT LAKE CITY, Nov. 2, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN), a leading molecular diagnostic company, today reported financial results for its first fiscal quarter ended September 30, 2010. Revenues increased 7.9% to $91.9 million for the three-month peri
Read more →MYGNMyriad and Abbott Enter Into Cooperative Agreement
SALT LAKE CITY, Oct. 26, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has signed an agreement with Abbott Laboratories, a global health care company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase III mult
Read more →MYGNMyriad Genetics to Present at Morningstar's 5th Annual Stocks Forum
SALT LAKE CITY, Oct. 21, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at Morningstar's 5th Annual Stocks Forum, at 1:40 p.m. Central on November 4, 2010, at the Palmer House Hilton H
Read more →MYGNMyriad Genetics to Present Prostate Cancer Data at the ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer
SALT LAKE CITY, Oct. 14, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Steve Stone, Ph.D., Vice President of Cancer Genomics, is scheduled to present data on PROLARIS , Myriad's prognostic medicine product for prostate cancer, at the ASCO-NCI-E
Read more →MYGNMyriad Genetics to Report Fiscal 2011 First Quarter Financial Results on November 2
SALT LAKE CITY, Oct. 12, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will release its fiscal 2011 first quarter financial results at the close of market on Tuesday, November 2, 2010. The Company will host a conference call on Tuesday, Nov
Read more →MYGNMyriad Genetics' PROLARIS Test Accurately Predicts Survival With Prostate Cancer
SALT LAKE CITY, Oct. 11, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that based on recent clinical validation, its newest molecular diagnostic product, PROLARIS , accurately predicts survival with prostate cancer. The findings were presented at th
Read more →MYGNMyriad Genetics to Present at the UBS Global Life Sciences Conference and the Fifth Annual JMP Securities Healthcare Conference
SALT LAKE CITY, Aug. 31, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark C. Capone, President of Myriad Genetic Laboratories, Inc., is scheduled to present at the UBS Global Life Sciences Conference, at 1:30 p.m. Eastern on September 21, 201
Read more →MYGNMyriad Announces Additional Stock Repurchase Program
SALT LAKE CITY, Aug. 31, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that its Board of Directors has authorized the repurchase of an additional $100 million of the Company's outstanding common stock, following the completion of its previously auth
Read more →MYGNMyriad Genetics to Present at the Morgan Stanley Global Healthcare Conference and the Stifel Nicolaus Healthcare Conference
SALT LAKE CITY, Aug. 24, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the Morgan Stanley Global Healthcare Conference, at 9:45 a.m. Eastern on September 14, 2010, at the Grand Hya
Read more →MYGNMyriad Genetics Reports Fiscal 2010 Financial Results
SALT LAKE CITY, Aug. 10, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today reported financial results for its fourth quarter and fiscal year ended June 30, 2010. Financial Results - Fiscal Fourth Quarter 2010 Revenues increased 9% to $93.9 million in the fourth
Read more →MYGNMyriad Genetics Establishes Charitable Program to Give Back to Salt Lake Community
SALT LAKE CITY, Aug. 3, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has established a Charitable Giving Program. The Program aims to enrich the lives of people living along the Wasatch Front in Utah by supporting and fostering local cultur
Read more →MYGNMyriad Genetics to Report Fiscal 2010 Fourth Quarter and Year-End Financial Results on August 10
SALT LAKE CITY, July 20, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will release its fiscal 2010 fourth quarter and year-end financial results at the close of market on Tuesday, August 10, 2010. The Company will host a conference call on
Read more →MYGNMyriad Genetics Announces New Executive Vice President of International Operations
SALT LAKE CITY, July 8, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Gary A. King has joined the Company in the newly created position of Executive Vice President of International Operations. "It is with a great deal of pleasure that I welcom
Read more →MYGNMyriad Pharmaceuticals Formally Adopts Its Name Change to Myrexis, Inc. Effective July 1, 2010
SALT LAKE CITY, June 30, 2010 (GLOBE NEWSWIRE) -- Effective July 1, Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) will change its name to Myrexis, Inc. The name change was previously approved by the Company's shareholders at a special meeting held on April 22, 2010. The Company's Co
Read more →MYGNMyriad Genetics Elects Former Roche Molecular Systems CEO Heiner Dreismann to Its Board of Directors
SALT LAKE CITY, June 10, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has elected Heiner Dreismann, Ph.D. to its Board of Directors, effective immediately, increasing the size of the Company's board from seven members to eight. "I am extre
Read more →MYGNMyriad Genetics to Present at the Goldman Sachs 31st Annual Global Healthcare Conference
SALT LAKE CITY, June 1, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the Goldman Sachs 31st Annual Global Healthcare Conference, at 3:40 p.m. Pacific on June 15, 2010, at the Hyat
Read more →MYGNMyriad Genetics to Present at the William Blair & Company 30th Annual Growth Stock Conference
SALT LAKE CITY, June 1, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark C. Capone, President of Myriad Genetic Laboratories, Inc., is scheduled to present at the William Blair & Company 30th Annual Growth Stock Conference, at 11:30 a.m. Cent
Read more →MYGNMyriad Genetics to Present at the GARP Research and Securities Company Investor Conference
SALT LAKE CITY, May 26, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the GARP Research and Securities Company Investor Conference, at 9:30 a.m. Eastern on June 9, 2010, at the Mar
Read more →MYGNMyriad Pharmaceuticals Reports Third Quarter FY' 2010 Financial Results
SALT LAKE CITY, May 17, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today reported financial results for its third fiscal quarter ended March 31, 2010. The Company ended the quarter with $148.4 million in cash, cash equivalents and marketable securities an
Read more →MYGNMyriad Genetics to Present at the Citi 2010 Global Health Care Conference
SALT LAKE CITY, May 13, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark C. Capone, President of Myriad Genetic Laboratories, Inc., is scheduled to present at the Citi 2010 Global Health Care Conference, at 10:30 a.m. Eastern on May 27, 2010,
Read more →MYGNMyriad Announces Stock Repurchase Program
SALT LAKE CITY, May 4, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that its Board of Directors has authorized the repurchase of $100 million of the Company's outstanding common stock. In connection with this stock repurchase authorization, the Co
Read more →MYGNMyriad Genetics Reports Financial Results for Fiscal 2010 Third Quarter
SALT LAKE CITY, May 4, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today reported financial results for the third fiscal quarter and the nine-month period ended March 31, 2010. Third Fiscal Quarter Financial Results Revenues rose 5% to $90.8 million for the thr
Read more →MYGNMyriad Genetics to Present at the Ninth Annual JMP Securities Research Conference
SALT LAKE CITY, April 28, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark C. Capone, President of Myriad Genetic Laboratories, Inc., is scheduled to present at the Ninth Annual JMP Securities Research Conference, at 12:30 p.m. Pacific on May
Read more →MYGNMyriad Genetics Announces New, Convenient OnDose(TM) Sampling Kit
SALT LAKE CITY, April 27, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced a significant improvement in the sample collection kit for OnDoseTM, its 5-Fluorouracil (5-FU) dose optimization product. Patient sample handling can now be conducted at room te
Read more →MYGNMyriad Study Shows PTEN Gene is Useful in Predicting Prostate Cancer Recurrence
SALT LAKE CITY, April 19, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today said results from a recent study indicate that expression of the PTEN gene may be clinically useful in assessing a man's risk of prostate cancer recurrence after radical prostatectomy. T
Read more →MYGNMyriad Genetics to Report Fiscal 2010 Third Quarter Financial Results On May 4
SALT LAKE CITY, April 13, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will release its fiscal 2010 third quarter financial results at the close of market on Tuesday, May 4, 2010. The Company will host a conference call on Tuesday, May 4,
Read more →MYGNMyriad Genetics, Inc. (MYGN) President and CEO to Ring the NASDAQ Stock Market Opening Bell
ADVISORY, March 2, 2010 (GLOBE NEWSWIRE) -- Peter Meldrum, President and CEO of Myriad Genetics, Inc. (MYGN), will visit NASDAQ MarketSite in Times Square and preside over the NASDAQ Opening Bell. NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio Wednesda
Read more →MYGNMyriad Genetics Launches PROLARIS(TM): First Diagnostic Test to Predict Prostate Cancer Recurrence
SALT LAKE CITY, March 2, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the launch of PROLARIS , a 46-gene prognostic test which quantitatively determines the risk of recurrence in patients who have undergone prostatectomy surgery. For the first time
Read more →MYGNMyriad Genetics to Present at the Cowen and Company 30th Annual Health Care Conference
SALT LAKE CITY, Feb. 23, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the Cowen and Company 30th Annual Health Care Conference at 11:05 a.m. Eastern on March 9, 2010, at the Bosto
Read more →MYGNMyriad Genetics to Host Investor Day in New York
SALT LAKE CITY, Feb. 17, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today said it will host an Investor Day from 11:00 a.m. to 2:00 p.m. Eastern on March 3, 2010, at the NASDAQ MarketSite in New York City. That same day, Myriad executives will open the NASDAQ St
Read more →MYGNMyriad Pharmaceuticals Reports Second Quarter FY' 2010 Financial Results
SALT LAKE CITY, Feb. 16, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today reported financial results for its second fiscal quarter ended December 31, 2009. "We are pleased with the progress we have made over the past seven months," said Adrian N. Hobden
Read more →MYGNMyriad Genetics to Present at the RBC Capital Markets' Healthcare Conference
SALT LAKE CITY, Feb. 16, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the RBC Capital Markets' Healthcare Conference, at 2:35 p.m. Eastern on March 2, 2010, at the New York Palace
Read more →MYGNMyriad Genetics Reports Financial Results for Fiscal 2010 Second Quarter
SALT LAKE CITY, Feb. 2, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today reported financial results for its second fiscal quarter and the six-month period ended December 31, 2009. Second Fiscal Quarter Financial Results Revenues rose 11% to $92.8 million for t
Read more →MYGNMyriad Study Reveals Patients Receive Suboptimal Dosing With Chemotherapy Regimens of FOLFOX6 and FOLFOX6 Plus Avastin
SALT LAKE CITY, Jan. 25, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced that a presentation entitled: "Extensive 5-FU Inter-Patient Pharmacokinetic Variability May Result in Suboptimal 5-FU Dosing of Metastatic and Adjuvant Colon Cancer Patients on FOLFOX
Read more →MYGNMyriad Genetics to Present at the Seventh Annual Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO)
SALT LAKE CITY, Jan. 14, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that the Company is scheduled to give a presentation entitled: "Extensive 5-FU Inter-Patient Pharmacokinetic Variability May Result in Suboptimal 5-FU Dosing of Metastatic and Ad
Read more →MYGNMyriad Genetics to Report Fiscal 2010 Second Quarter Financial Results on February 2
SALT LAKE CITY, Jan. 12, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will release its fiscal 2010 second quarter financial results at the close of market on Tuesday, February 2, 2010. The Company will host a conference call on Tuesday, Fe
Read more →MYGNMyriad Genetics Partners With Mammography Reporting Systems to Increase Identification of High Risk Breast Cancer Patients
SALT LAKE CITY, Jan. 6, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today it has entered into an agreement with Mammography Reporting System, Inc. (MRS) to help increase the identification of patients at high risk for hereditary breast cancer. Under th
Read more →MYGNMyriad Genetics to Present at the 28th Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Dec. 17, 2009 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present an overview of the Company at the 28th Annual J.P. Morgan Healthcare Conference, at 10:30 a.m. Pacific on Januar
Read more →MYGNMyriad Pharmaceuticals Initiates Phase 2b Study of MPC-4326 in a Genetically-Identified Responder Population
SALT LAKE CITY, Dec. 1, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced the initiation of a Phase 2b study of MPC-4326, a first-in-class, small molecule inhibitor of HIV-1 maturation. This multicenter, randomized, open-label study is designed t
Read more →MYGNMyriad Genetics to Present at the 21st Annual Piper Jaffray Health Care Conference
SALT LAKE CITY, Nov. 17, 2009 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present an overview of the Company at the 21st Annual Piper Jaffray Health Care Conference, at 9:30 a.m. Eastern on Dece
Read more →MYGNMyriad Pharmaceuticals Reports First Quarter FY' 2010 Financial Results
SALT LAKE CITY, Nov. 12, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today reported financial results for its first fiscal quarter ended September 30, 2009. "We are pleased to be able to report the results of our first quarter as an independent publicly-t
Read more →MYGNMyriad Genetics to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
SALT LAKE CITY, Nov. 4, 2009 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Gregory C. Critchfield, M.D., President of Myriad Genetic Laboratories, Inc., is scheduled to present an overview of the Company at the Lazard Capital Markets Sixth Annual He
Read more →MYGNMyriad Genetics Reports First Quarter Fiscal 2010 Financial Results
SALT LAKE CITY, Nov. 3, 2009 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today reported financial results for its fiscal first quarter ended September 30, 2009. Molecular diagnostic revenue increased 22% to $85.1 million in the fiscal first quarter ended September 30
Read more →MYGNMyriad Genetics Acquires Exclusive Rights to Pancreatic Cancer Gene Patents From Johns Hopkins
SALT LAKE CITY, Oct. 15, 2009 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it has obtained from Johns Hopkins University a world-wide, exclusive license to patents covering mutations in the PALB2 gene that increase an individual's risk for developing pa
Read more →MYGNMyriad Genetics to Report Fiscal 2010 First Quarter Financial Results On November 3
SALT LAKE CITY, Oct. 13, 2009 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will release its fiscal 2010 first quarter financial results at the close of market on Tuesday, November 3, 2009. The Company will host a conference call on Tuesday, Nov
Read more →MYGNMyriad Genetics to Present At the Fourth Annual JMP Securities Healthcare Focus Conference
SALT LAKE CITY, Sept. 22, 2009 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present an overview of the Company at The Fourth Annual JMP Securities Healthcare Focus Conference, at 9:00 a.m. Easter
Read more →MYGNMyriad Genetics Elects Louise Phanstiel and Lawrence Best to Its Board of Directors
SALT LAKE CITY, Sept. 21, 2009 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has elected Louise Phanstiel and Lawrence Best to its Board of Directors, effective September 16, 2009, increasing the size of the Company's board from eight members to
Read more →MYGNMyriad Pharmaceutical's Tablet Formulation of MPC-4326 Reduces Viral Load in HIV-1 Patients
SALT LAKE CITY, Sept. 14, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced the presentation of two abstracts detailing positive data for MPC-4326, its novel maturation inhibitor for the treatment of HIV infection. The two abstracts, which were p
Read more →MYGNMyriad Genetics to Present At the UBS Global Life Sciences Conference
SALT LAKE CITY, Sept. 8, 2009 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present an overview of the Company at the UBS Global Life Sciences Conference, at 12:30 p.m. Eastern on September 22, 20
Read more →MYGNMyriad Genetics to Present At The Morgan Stanley Global Healthcare Conference
SALT LAKE CITY, Aug. 31, 2009 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present an overview of the Company at The Morgan Stanley Global Healthcare Conference, at 10:20 a.m. Eastern on Septembe
Read more →MYGNMyriad Genetics Reports Fiscal 2009 Financial Results
SALT LAKE CITY, Aug. 25, 2009 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today reported financial results for its fourth quarter and fiscal year ended June 30, 2009. It should be noted that as a result of the successful spin off of the Company's pharmaceutical and re
Read more →MYGNMyriad Genetics to Report Fiscal 2009 Fourth Quarter and Year-End Financial Results On August 25
SALT LAKE CITY, Aug. 3, 2009 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will release its fiscal 2009 fourth quarter and year-end financial results at the close of market on Tuesday, August 25, 2009. The company will host a conference call on
Read more →MYGNMyriad Genetics Announces Completion of Spin Off of Its Research and Pharmaceutical Business
SALT LAKE CITY, July 1, 2009 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today the successful completion of the spin off of Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX), and that Myriad Genetics has received a Private Letter Ruling from the Internal Revenue Se
Read more →MYGNMyriad Pharmaceuticals, Inc. Established as an Independent Pharmaceutical Development Company
Company Will Advance Three Clinical Development Programs in Oncology and Infectious Disease Conference Call Scheduled for 10:00 AM EDT On July 1, 2009 SALT LAKE CITY, July 1, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (MPI) today announced that it has completed its
Read more →MYGNMyriad Pharmaceuticals, Inc. to Host Initial Public Conference Call On July 1, 2009
SALT LAKE CITY, June 29, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRXV) today announced that it will hold a live webcast on Wednesday, July 1, 2009 at 10:00 AM EDT. Adrian Hobden, Ph.D., the Company's President and Chief Executive Officer will provide an ove
Read more →MYGNMyriad Genetics Files IND For Drug Candidate From Compound Family Licensed From Maxim Pharmaceuiticals
STOCKHOLM, Sweden and SAN DIEGO, Dec. 9, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals, Inc. (Nasdaq:MAXM) (SSE:MAXM) today reported that Myriad Genetics, Inc., filed an Investigational New Drug (IND) application with the FDA for a Phase 1 clinical study of MPC-6827, a pro-apoptotic
Read more →Competitive Position
How MYGN ranks across every disease it competes inCompetitive Position is a premium feature
See how MYGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial